

## **Identification and Interaction Analysis of Molecular Markers in Pancreatic Ductal Adenocarcinoma by Integrated Bioinformatics Analysis and Molecular Docking Experiments**

Basavaraj Vastrad<sup>1</sup>, Chanabasayya Vastrad<sup>\*2</sup>, Anandkumar Tengli<sup>3</sup>

1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India.
2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad, Karnataka 580001, India.
3. Department of Pharmaceutical Chemistry, JSS College of Pharmacy, Mysuru and JSS Academy of Higher Education & Research, Mysuru- 570015, Karnataka, India.

\* Chanabasayya Vastrad

channu.vastrad@gmail.com

Ph: +919480073398

Chanabasava Nilaya, Bharthinagar,

Dharwad 580001, Karnataka, India

## Abstract

The current investigation aimed to mine therapeutic molecular targets that play a key part in the advancement of pancreatic ductal adenocarcinoma (PDAC). The expression profiling by high throughput sequencing dataset profile GSE133684 dataset was downloaded from the Gene Expression Omnibus (GEO) database. Limma package of R was used to identify differentially expressed genes (DEGs). Functional enrichment analysis of DEGs were performed. Protein-protein interaction (PPI) networks of the DEGs were constructed. An integrated gene regulatory network was built including DEGs, microRNAs (miRNAs), and transcription factors. Furthermore, consistent hub genes were further validated. Molecular docking experiment was conducted. A total of 463 DEGs (232 up regulated and 231 down regulated genes) were identified between very early PDAC and normal control samples. The results of Functional enrichment analysis revealed that the DEGs were significantly enriched in vesicle organization, secretory vesicle, protein dimerization activity, lymphocyte activation, cell surface, transferase activity, transferring phosphorus-containing groups, hemostasis and adaptive immune system. The PPI network and gene regulatory network of up regulated genes and down regulated genes were established, and hub genes were identified. The expression of hub genes (CCNB1, FHL2, HLA-DPA1 and TUBB1) were also validated to be differentially expressed among PDAC and normal control samples. Molecular docking experiment predicted the novel inhibitory molecules for CCNB1 and FHL2. The identification of hub genes in PDAC enhances our understanding of the molecular mechanisms underlying the progression of this disease. These genes may be potential diagnostic biomarkers and/or therapeutic molecular targets in patients with PDAC.

**Keywords:** pancreatic ductal adenocarcinoma; bioinformatics analysis; biomarker; enrichment analysis; differentially expressed genes

## **Introduction**

Pancreatic ductal adenocarcinoma (PDAC) is one of the most prevalent cancers in the world and primary tumor of the pancreas [1]. PDAC is a global burden ranking 15th in terms of incidence and fourth in terms of mortality [2]. Despite new developments in multimodal therapy its overall 5-year survival rate remains less than 8% [3]. PDAC treatment commonly includes surgery, radiation, chemotherapy and immunotherapy [4]. However, PDAC remains common and malignant due to recurrence and metastasis, and ultimately key cause of PDAC associated death [5]. Therefore, there is a vital need to advance new diagnostic strategies and therapeutic agents to upgrade the prognosis of patients with PDAC.

The molecular mechanisms of PDAC tumorigenesis and development remain imprecise. It is therefore key to identify novel genes and pathways that are linked with PDAC tumorigenesis and patient prognosis, which may not only help to illuminate the underlying molecular mechanisms involved, but also to disclose novel diagnostic markers and therapeutic targets. Oji et al [6] demonstrated that the over expression of WT1 is linked with prognosis in patients with PDAC. A previous investigation reported that phosphoinositide 3-kinase signaling pathway is linked with development of PDAC [7]. Expression profiling by high throughput sequencing can promptly uncover gene expression on a global basis and are specially useful in identifying for differentially expressed genes (DEGs) [8]. A huge amount of data has been generated through the use of microarrays and the majority of such data has been deposited and saved in public databases. Previous investigations concerning PDAC gene expression profiling have diagnosed hundreds of DEGs [9].

The aim of this investigation was to identify hub genes and pathways in PDAC using bioinformatics methods. Our investigation contributes predictable biomarkers for early detection and prognosis, as well as effective drug targets for treating PDAC.

## **Materials and methods**

### **Sequencing data**

PDAC expression profiling by high throughput sequencing dataset in this investigation was downloaded from the GEO database (<https://www.ncbi.nlm.nih.gov/gds/>) [10]. The DEGs were considered by 1 independent PDAC dataset, GSE133684 [11] with 284 PDAC and 117 normal samples. The GSE133684 expression profiling by high throughput sequencing data was based on the GPL20795 HiSeq X Ten (Homo sapiens) platform.

### **Identification of DEGs**

The Limma package of R language were used to normalize and convert the raw data to expression profiles [12]. The limma package of R language was used for DEGs between PDAC and normal control samples [12]. The P-value was adjusted by the Benjamini-Hochberg method [13]. An adjusted P-value  $<0.05$  and  $|\log_2$  fold change (FC)  $| >1$  were considered as threshold values for DEGs identification. The ggplot2 package and gplots package of R language was used to generate volcano plot and heat map. The identified DEGs were preserved for further bioinformatics analysis.

### **GO analysis and pathway enrichment analysis of DEGs**

The GO repository (<http://geneontology.org/>) [14] consists of a massive set of annotation terms and is generally used for annotating genes and identifying the distinctive biological aspects for expression profiling by high throughput sequencing data. The REACTOME database (<https://reactome.org/>) [15] contains data on known genes and their biochemical functions and is used for identifying functional and metabolic pathways. By performing the GO and REACTOME enrichment analysis at the functional level, we can boost a better understanding of the roles of these DEGs in the induction and in the advancement of PDAC. The ToppGene (ToppFun) (<https://toppgene.cchmc.org/enrichment.jsp>) [16] is an online resource that add tools for functional annotation and bioinformatics analysis. Both GO categories and REACTOME pathway enrichment analysis were implemented using ToppGene to inform the functions of these DEGs.  $P < 0.05$  was considered to indicate a statistically significant difference.

### **Protein-protein interaction (PPI) network construction and module analysis**

The online database IID interactome (<http://iid.ophid.utoronto.ca/>) [17] was used to construct a PPI network of the proteins encoded by DEGs. Then, Cytoscape software (Version 3.8.1) [18] was applied to perform protein interaction association network analysis and analyze the interaction correlation of the candidate proteins encoded by the DEGs in PDAC. Next, the Network Analyzer Cytoscape plug-in was applied to calculate node degree [19], betweenness centrality [20], stress centrality [21], closeness centrality [22]. Finally, the PEWCC1 (<http://apps.cytoscape.org/apps/PEWCC1>) [23] module for Cytoscape was used to collect the significant modules in the PPI network complex.

### **Construction of miRNA-DEG regulatory network**

The miRNet database (<https://www.mirnet.ca/>) [24] is a database, containing miRNAs involved in various diseases. The miRNAs related to PDAC were searched from miRNet database. Through getting the intersection of the miRNAs and the DEGs, the miRNA-DEG regulatory relationships were selected. Finally, miRNA-DEG regulatory network was built using Cytoscape software.

### **Construction of TF-DEG regulatory network**

The NetworkAnalyst database (<https://www.networkanalyst.ca/>) [25] is a database, containing TFs involved in various diseases. The TFs related to PDAC were searched from TF database. Through getting the intersection of the TFs and the DEGs, the TF-DEG regulatory relationships were selected. Finally, TFs -DEG regulatory network was built using Cytoscape software.

### **Hub genes validation**

After hub genes identified from expression profiling by high throughput sequencing dataset, UALCAN (<http://ualcan.path.uab.edu/analysis.html>) [26] was used to validate the selected up regulated and down regulated hub genes. UALCAN is an online tool for gene expression analysis between PDAC and normal data from The Cancer Genome Atlas (TCGA). It adds data such as gene expression, tumor staging, and survival period for PDAC. cBioPortal is an online platform (<http://www.cbioportal.org>) [27] for gene alteration of hub genes analysis from TCGA. Human protein atlas is an online database (HPA, [www.proteinatlas.org](http://www.proteinatlas.org)) [28] for protein expression analysis between PDAC and

normal data from TCGA. TIMER is an online platform (<https://cistrome.shinyapps.io/timer/>) [29] for immune infiltration analysis from TCGA. To explore diagnostic biomarkers of PDAC, we used the above hub genes as candidates to find their diagnostic value based on generalized linear model (GLM) [30]. The pROC in R was used for Receiver operating characteristic (ROC) curve analysis [30]. In brief, half of the samples (PDAC = 142, controls = 59) were aimlessly distributed as the training set and remaining data were used as the test set, which were used to set up a model. An ROC curve analysis was tested to calculate the specificity and sensitivity of the GLM prediction model. The area under the curve (AUC) was figure out to determine the diagnostic efficiency of the classifier.

### **RT-PCR analysis**

TRI Reagent® (Sigma, USA) was used to extract total RNA from the culture cells of PDAC (CRL-2549™) and normal (CRL-2989™) according to the manufacturer's protocol. Reverse transcription cDNA kit (Thermo Fisher Scientific, Waltham, MA, USA) and random primers were used to synthesize cDNA. Quantitative real-time PCR (qRT-PCR) was conducted on the 7 Flex real-time PCR system (Thermo Fisher Scientific, Waltham, MA, USA). The reaction guideline included a denaturation program (5 min at 95 °C), followed by an amplification and quantification program over 40 cycles (15 s at 95°C and 45 s at 65°C). Each sample was tested in triplicates. Table 1 depicts the primer sequences of hub genes. The expression level was resolved as a ratio between the hub genes and the internal control  $\beta$ -actin in the same mRNA sample, and determined by the comparative CT method [31]. Levels of CCNB1, FHL2, HLA-DPA1 and TUBB1 expression were determined by the  $2^{-\Delta\Delta Ct}$  method.

### **Molecular docking experiment**

The module SYBYL-X 2.0 perpetual software were used for Surflex-Docking of the designed molecules. The molecules were sketched by using ChemDraw Software and imported and saved in sdf. format using openbabel free software. The protein structures of CyclinB1 (CCNB1) its co-crystallisedprotein of PDB code 4Y72, 5H0V and Four and half LIM domains 2 (FHL2) its NMR structure of proteins 2D8Z and 2EHE was retrieved from Protein Data Bank [32-34]. Together

with the TRIPOS force field, GasteigerHuckel (GH) charges were added to all designed derivatives for the structure optimization process. In addition, energy minimization was carried out using MMFF94s and MMFF94 algorithm process. Protein processing was carried out after the incorporation of protein. The co-crystallized ligand and all water molecules were removed from the crystal structure; more hydrogens were added and the side chain was set. TRIPOS force field was used for the minimization of structure. The compounds' interaction efficiency with the receptor was represented by the Surflex-Dock score in kcal / mol units. The interaction between the protein and the ligand, the best pose was incorporated into the molecular area. The visualisation of ligand interaction with receptor is done by using discovery studio visualizer.

## Results

### Identification of DEGs

We analyzed the DEGs of GSE133684 by using the limma package. We used  $p < 0.05$  and  $|\log FC| \geq 1$  as the cutoff criteria. We screened 463 DEGs, including 232 up regulated genes and 231 down regulated genes in PDAC samples compared with normal control samples and are listed in Table 2. We identified all the DEGs which were shown in the above volcano map according to the value of  $|\log FC|$  is shown in Fig. 1 and then displayed the DEGs on a heatmap is shown in Fig. 2.

### GO analysis and pathway enrichment analysis of DEGs

To symbolize the function of the DEGs and to identify important candidate pathways, GO functional enrichment analysis and REACTOME pathway enrichment analysis were performed. The results of GO categories analysis including biological processes (BP), cellular components (CC) and molecular functions (MF) are listed in Table 3. Firstly, the up regulated genes were annotated with the BP category, including vesicle organization and secretion, whereas the down regulated genes were annotated with the GO terms, including lymphocyte activation and regulation of cell death. Secondly, the up regulated genes were annotated with the GO terms of the CC category, namely secretory vesicle and whole membrane, whereas the down regulated genes were annotated with the GO terms, including cell surface and intrinsic component of plasma membrane.

Thirdly, the up regulated genes were annotated with the GO terms of the MF category, such as protein dimerization activity and signaling receptor binding, whereas the down regulated genes were annotated with the GO terms, including transferase activity, transferring phosphorus-containing groups and drug binding. As shown in Table 4, the significantly enriched REACTOME pathways of the up regulated genes with  $P < 0.05$  were hemostasis and cell cycle, whereas down regulated genes with  $P < 0.05$  were adaptive immune system and transmembrane transport of small molecules.

### **Protein-protein interaction (PPI) network construction and module analysis**

After all the DEGs were uploaded to the online IID interactome database, the PPI network with 6188 nodes and 13153 edges was constructed using the Cytoscape software (Fig. 3A). Hub DEGs with the node degree, betweenness centrality, stress centrality and closeness centrality were obtained and are listed in Table 5. Among them, CCNB1 and FHL2 were the major up regulated genes, while HLA-DPA1 and TUBB1 were the major down regulated genes. Then, two significant module that fulfilled the cut-off criteria, namely, PEWCC1 scores  $> 3$  and number of nodes  $> 5$ , was screened (Fig. 3B and Fig. 3C). The FGB, FGA, FGG, EEF1A1, RPL13A, ITGA4, RPL27A, RPL23A and RPL10 genes were identified in these modules. GO analysis of these genes showed that they were annotated with vesicle organization, regulation of cell death and lymphocyte activation. In addition, the REACTOME enrichment analysis suggested that these genes were mainly involved in hemostasis, innate immune system, disease and adaptive immune system.

### **Construction of miRNA-DEG regulatory network**

The regulatory network of miRNA-DEG and predicted targets is presented in Fig. 4A. Notably, MAP1B targeted 202 miRNAs, including hsa-mir-4461; CCNB1 targeted 94 miRNAs, including hsa-mir-3928-3p; AHNAK targeted 256 miRNAs, including hsa-mir-2682-5p; KMT2D targeted 209 miRNAs, including hsa-mir-1202 and top 20 are listed in Table 6. As a group, a total of 257 of the 463 DEGs were contained in the miRNA-DEG regulatory network.

### **Construction of TF-DEG regulatory network**



The regulatory network of TF-DEG and predicted targets is presented in Fig. 4B. Notably, EZH2 targeted 45 TFs, including SOX2; TPM1 targeted 40 TFs, including MYC; AHNAK targeted 58 TFs, including KLF4, TXNIP targeted 51 TFs, including TP63 and top 20 are listed in Table 6. As a group, a total of 259 of the 463 DEGs were contained in the TF-DEG regulatory network.

### **Hub genes validation**

All of the hub genes were validated in TCGA data. Hub genes contributed to the survival period in patients with PDAC, we analyzed the overall survival (OS) for each hub gene by UALCAN (Fig. 5). The results showed that the high expression of CCNB1 and FHL2 mRNA level were associated with the worse OS in patients with PDAC, while low expression of HLA-DPA1 and TUBB1 mRNA level were associated with the worse OS in patients with PDAC. As shown in Fig. 6, the expression of the up regulated hub genes CCNB1 and FHL2 in PDAC were significantly elevated compared with normal, while expression of the down regulated hub genes HLA-DPA1 and TUBB1 in PDAC were significantly decreased compared with normal. The expression of each hub gene in PDAC patients was analyzed according to the individual cancer stage. As shown in Fig. 7, the expression of CCNB1 and FHL2 were higher in patients with all individual cancer stages than that in normal, which revealed that these up regulated hub genes might be associated with tumor progression positively, where as the expression of HLA-DPA1 and TUBB1 were lower in patients with all individual cancer stages than that in normal, which revealed that these down regulated hub genes might be associated with tumor progression positively. We used cBioportal tool to explore the specific mutation of hub genes in PDAC dataset with 184 samples. From the OncoPrint, percentages of alterations in CCNB1, FHL2, HLA-DPA1 and TUBB1 genes among lung cancer ranged from 0% to 2.3% in individual genes (CCNB1, 0%; FHL2, 0.6%; HLA-DPA1, 2.3%; TUBB1, 2.3%) and is shown in Fig. 8. In addition, we used the 'HPA' to examine the protein expression levels of CCNB1 and FHL2, and observed that the protein expression levels of the these hub genes were noticeably up regulated in PDAC compared with normal tissues, whereas protein expression levels of HLA-DPA1 and TUBB1, and observed that the protein expression levels of the these hub genes were noticeably down regulated in PDAC compared with normal tissues (Fig. 9). The association of CCNB1, FHL2, HLA-DPA1 and TUBB1 expression level with immune infiltration abundance in PDAC

was evaluated using TIMER database. CCNB1 and FHL2 expression were negatively correlated with infiltration degree of B cells, CD8+ T cells, macrophage, neutrophil, and dendritic cells, where as HLA-DPA1 and TUBB1 were positively correlated with infiltration degree of B cells, CD8+ T cells, macrophage, neutrophil, and dendritic cells and is shown in Fig. 10. As these 4 genes are prominently expressed in PDAC, we performed a ROC curve analysis to evaluate their sensitivity and specificity for the diagnosis of PDAC. As shown in Fig. 11, CCNB1, FHL2, HLA-DPA1 and TUBB1 achieved an AUC value of >0.70, demonstrating that these genes have high sensitivity and specificity for PDAC diagnosis. The results suggested that CCNB1, FHL2, HLA-DPA1 and TUBB1 can be used as biomarkers for the diagnosis of PDAC.

### **RT-PCR analysis**

Next, in order to verify the results of previous bioinformatics analysis, the gene expression levels of CCNB1, FHL2, HLA-DPA1 and TUBB1 were detected by RT-PCR. As shown in Fig 12, CCNB1 and FHL2 mRNA expression levels were significantly up regulated in the PDAC compared to normal, and HLA-DPA1 and TUBB1 mRNA level were down regulated compared to normal, which was consistent with the results of bioinformatics analysis.

### **Molecular docking experiment**

The docking simulation was performed in the present study to recognize the active site conformation and significant interactions, which are responsible for complex stability with ligand receptor. Novel molecules containing alkylating group and purine heterocyclic ring were designed and performed docking studies using Sybyl X 2.1 drug design software. Molecules containing alkylating group is designed due to non-specific alkylation of physiologically important groupings and purine heterocyclic ring is incorporated due to structural similarity of purine derivatives and to compete for the synthesis of proteins. The proteins which are over expressed in pancreatic duct adenocarcinoma are selected for docking studies. The two proteins of each over expressed cyclin B1 (CCNB1) its co-crystallised protein of PDB code 4Y72, 5H0V and Four and half LIM domains 2 (FHL2) of NMR structure of proteins 2D8Z and 2EHE were selected for docking. The investigation of designed molecules was performed to identify the potential molecule. The most

of the designed molecules obtained C-score greater than 5 and are active having the c-score greater than 5 are said to be an active, among total of 48 designed molecules few molecules have excellent good binding energy (C-score) greater than 8 respectively. Few of the designed molecules IM 11 & PU 42, shown good binding score of 7.83 & 8.57 and the molecules IM 13, TZ 23, TZ 27, TZ 37, PU 41, PU 43 & PU 49 have good binding score 8.013, 8.523, 8.235, 8.800, 10.338, 10.891 & 9.411 with CCNB1 PDB code 1H0V and 4Y72 respectively and are shown in Fig. 13. Molecules of IM 09, IM 10, IM & 18 shown good binding score of 7.14, 7.75 & 7.80 and the molecules IM 8 and TZ 24 with binding score 6.24 and 6.32 with FHL2 of PDB code 2D8Z and 2EQQ respectively, the values are depicted in Table 7. The molecule IM 8 has highest binding score its interaction with protein 1H0V and hydrogen bonding and other bonding interactions with amino acids are depicted by 3D and 2D shown in Fig. 14 and Fig. 15.

## Discussion

Due to the high heterogeneity of PDAC, PDAC was still a disease with high rates of pervasiveness and fatality. With surgery as the main, the other treatments including radiotherapy, chemotherapy, targeted therapy, and gene therapy as a additive to the finite treatment measures of PDAC, the 5-year survival rate was still less than 8% [35]. Therefore, the early diagnosis and effective treatment of PDAC is crucially required, which may be achieved via the identification of the DEGs between PDAC and normal control, and by considerate the underlying molecular mechanism. Microarray and high throughput sequencing analysis can screen a massive number of genes in the human genome for farther functional analysis, and can be extensively used to screen biomarkers for early diagnosis and unique therapeutic targets. Therefore, they may help the diagnosis of PDAC in the early stages and the advancement of targeted treatment, thus developing prognosis.

The current investigation systematically applied integrated bioinformatics methods to identify novel biomarkers that serve roles in the advancement PDAC. The data extracted from the GEO dataset contained 31 pairs of lung cancer and normal samples. A total of 232 up regulated and 231 down regulated genes in PDAC, when compared with normal control samples, were identified using bioinformatics analysis, indicating that the incidence and advancement of PDAC. The results of the DEGs may provide potential biomarkers for the diagnosis of

PDAC. DAP (death associated protein) [36], KRT8 [37], IGFBP2 [38], KRT19 [39], CD44 [40], AHNAK (AHNAK nucleoprotein) [41] and BTG1 [42] are a noticeable factors in the PDAC progression. Wang et al [43] reported that KIF2C induces proliferation, migration, and invasion in gastric cancer patients through the MAPK signaling pathway, but this gene might be associated with development of PDAC. DBN1 expression was significantly increased in breast cancer [44], but this gene might be liable for development of PDAC. MAP1B was reported to lung cancer progression [45], but this gene may be key for advancement of PDAC. BNIP3L down regulation was required to develop breast and ovarian cancer [46], but this down regulation of gene might be involved in progression of PDAC. Yen et al [47] reported that ITGA4 was expressed in oral cancer, but this gene might be novel biomarker for PDAC. Tomsic et al. [48] showed that mutation in SRRM2 was associated with progression of thyroid carcinoma, but alteration in this gene might be key factor for advancement of PDAC. Recent studies have shown that down regulation of IL7R is associated with progression of esophageal squamous cell carcinoma [49], but this gene might be involved in pathogenesis of PDAC. Lee et al [50] found that reduced expression of the HLA-DRA is key factor for development of colorectal cancer, but this gene might be linked with advancement of PDAC. Liu et al. [51] reported that the absence of SESN3 linked with development of hepatocellular carcinoma, but this gene might be associated with progression of PDAC.

Then, GO and REACTOME pathway analyses were used to investigate the interactions of these DEGs. Increasing evidence shows that LAPTM4B [52], CEACAM6 [53], SERPINE2 [54] and VNN1 [55], SPHK1 [56], HRG (histidine rich glycoprotein) [57], VEGFC (vascular endothelial growth factor C) [58], ANXA3 [59], APOA2 [60], LCN2 [61], TIMP1 [62], CD63 [63], CD151 [64], MAL2 [65], ARNTL2 [66], PKD2 [67], E2F1 [68], MMP1 [69], CCR7 [70], NOTCH2 [71], BTLA (B and T lymphocyte associated) [72], TFRC (transferrin receptor) [73], CD4 [74], ATM (ATM serine/threonine kinase) [75], LEF1 [76], CSF1R [77], CTSB (cathepsin B) [78], DUSP2 [79] and NR4A1 [80] are closely associated with progression of PDAC. PTGER3 [81] and MAGI2 [82] are linked with angiogenesis, chemoresistance, cell proliferation and migration in ovary cancer, but these genes might be liable for growth PDAC. Hoagland et al [83] demonstrated that HP (haptoglobin) expression was responsible for progression of

lung cancer, but this gene might be involved in PDAC progression. FGA (fibrinogen alpha chain) was demonstrated to be a lung cancer susceptibility gene through activation of integrin–AKT signaling pathway [84], but this gene might be liable for progression of PDAC. Repetto et al [85] investigated the importance of FGB (fibrinogen beta chain) in the pathogenesis of gastric carcinoma, but this gene might be responsible for progression of PDAC. PLA2G4A [86], FGG (fibrinogen gamma chain) [87] and TYMS (thymidylatesynthetase) [88] have been demonstrated to be up regulated in cancer, but these genes might be liable for progression of PDAC. RAB32 [89], SEPTIN4 [90], TPM2 [91], ACOT7 [92], PRTFDC1 [93], CABLES1 [94], HLA-DMB [95], PTPRC (protein tyrosine phosphatase receptor type C) [96], CD5 [97], CD6 [97], MS4A1 [98], CD22 [99], CD27 [100], MRC2 [101], CLEC2D [102], EEF1A1 [103] and APOB (apolipoprotein B) [104] played a predominant role in the cancer progression, but these genes might be associated with development of PDAC. Jung et al [105] found that SMPD1 stimulates the drug resistance in colorectal cancer, but this gene might be linked with development of PDAC. Liu et al. [106], Yang et al [107], Song et al [108], Seachrist et al [109], Zhu et al [110], Wu et al [111], Wang et al [112], Yi et al [113], Lan et al [114] and Appert-Collin et al [115] revealed that PADI4, MAOB (monoamine oxidase B), TRPC6, BCL11A, CXCR5, TCF7, POU2F2, SLC4A1, STK17B and LRP1 were associated with cancer cell invasion, but these genes might be liable for progression of PDAC. Kairouz et al [116], Diez-Bello et al [117], Xue et al [118], Abo-Elfadl et al [119], Li et al [120] and Zhao et al [121] reported that GRB14, TRPC6, ZFPM2, TNFRSF13B, ADAM19 and PIK3IP1 enhance the cancer cell proliferation, but this gene might be involved in advancement of PDAC. Leite et al [122], Feng et al [123], Wang et al [124], Zhong et al [125], Yokoyama-Mashima et al [126], Guo et al [127], Lawson et al [128] and Wang et al [129] demonstrated that low levels of HLA-DPA1, FGL2, CBLB (Cbl proto-oncogene B), NCKAP1L, DYRK2, OGT (O-linked N-acetylglucosamine (GlcNAc) transferase), CAMK1D and RNF213 are linked with progression of cancer, but these genes might be essential for progression of PDAC. Polymorphic genes such as RORA (RAR related orphan receptor A) [130], IGF2R [131] and ZBTB20 [132] are contribute to progression of cancer, but these genes might be crucial for advancement of PDAC. Hope et al. [133] identified that the VCAN (versican) was central role in immune cell infiltration in cancer, but this gene may be associated with immune cell infiltration in PDAC.

Construction of PPI network and modules of DEGs may be helpful for understanding the relationship of developmental PDAC. Bai et al [134] reported that CCNB1 plays a positive role in proliferation of cancer cells, but this gene might be involved in development of PDAC. FHL2 [135] and RPL10 [136] are associated with progression of PDAC. Further investigation is required in order to clarify the underlying biological mechanisms of novel biomarkers HLA-DPA1, TUBB1, RPL13A, RPL27A and RPL23A on PDAC.

The miRNA-DEG regulatory network and TF-DEG regulatory network were constructed to explore the molecular mechanism of PDAC. The EZH2 [137], KMT2D [138], TXNIP (thioredoxin interacting protein) [139], TP63 [140], SOX2 [141], MYC [142] and KLF4 [143] genes are associated with PDAC. TPM1 [144] and hsa-mir-1202 [145] have been associated with cancer risk, but these genes and miRNAs might be responsible for progression of PDAC. Hsa-mir-4461, hsa-mir-3928-3p and hsa-mir-2682-5p might be considered as novel biomarkers for progression of PDAC.

In conclusion, we aim to identify DEGs by bioinformatics analysis to find the potential biomarkers which may be involved in the advancement of PDAC. The investigation contributes a set of useful DEGs for future studies into molecular mechanisms and biomarkers of PDAC. And the application of data mining and integration is accessible for prediction of PDAC advancement. Nevertheless, further molecular biological analyses are recommended to certify the function of the DEGs in PDAC.

### **Conflict of interest**

The authors declare that they have no conflict of interest.

### **Ethical approval**

This article does not contain any studies with human participants or animals performed by any of the authors.

### **Informed consent**

No informed consent because this study does not contain human or animals participants.

## Availability of data and materials

The datasets supporting the conclusions of this article are available in the GEO (Gene Expression Omnibus) (<https://www.ncbi.nlm.nih.gov/geo/>) repository. [(GSE133684) (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE133684>)]

## Consent for publication

Not applicable.

## Competing interests

The authors declare that they have no competing interests.

## Authors

Basavaraj Vastrad ORCID ID: [0000-0003-2202-7637](https://orcid.org/0000-0003-2202-7637)

Chanabasayya Vastrad ORCID ID: [0000-0003-3615-4450](https://orcid.org/0000-0003-3615-4450)

Anandkumar Tengli ORCID ID: [0000-0001-8076-928X](https://orcid.org/0000-0001-8076-928X)

## Acknowledgement

I thank Shenglin Huang, Fudan University, Shanghai, China, very much, the author who deposited their microarray dataset, GSE133684, into the public GEO database.

## Author Contributions

Basavaraj Vastrad - Writing original draft, and review and editing

Anandkumar Tengli - Writing original draft and investigation

Chanabasayya Vastrad - Software and investigation

## References

1. Thiruvengadam, S.S.; Chuang, J.; Huang, R.; Girotra, M.; Park, W.G. Chronic pancreatitis changes in high-risk individuals for pancreatic ductal adenocarcinoma. *Gastrointest. Endosc* **2019**, *89*, 842-851.e1. doi:[10.1016/j.gie.2018.08.029](https://doi.org/10.1016/j.gie.2018.08.029)

2. Al-Hawary, M.M.; Kaza, R.K.; Azar, S.F.; Ruma, J.A.; Francis, I.R. Mimics of pancreatic ductal adenocarcinoma. *Cancer. Imaging* **2013**,13,342-349. doi:[10.1102/1470-7330.2013.9012](https://doi.org/10.1102/1470-7330.2013.9012)
3. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2018. *CA. Cancer. J. Clin* **2018**,68,7-30. doi:[10.3322/caac.21442](https://doi.org/10.3322/caac.21442)
4. Adamska, A.; Domenichini, A.; Falasca, M. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. *Int. J. Mol. Sci* **2017**,18,1338. doi:[10.3390/ijms18071338](https://doi.org/10.3390/ijms18071338)
5. Tsuchiya, N.; Matsuyama, R.; Murakami, T.; Yabushita, Y.; Sawada, Y.U, Kumamoto, T.; Endo, I. Risk Factors Associated With Early Recurrence of Borderline Resectable Pancreatic Ductal Adenocarcinoma After Neoadjuvant Chemoradiation Therapy and Curative Resection. *Anticancer. Res* **2019**,39,4431-4440. doi:[10.21873/anticancer.13615](https://doi.org/10.21873/anticancer.13615)
6. Oji, Y.; Nakamori, S.; Fujikawa, M.; Nakatsuka, S.; Yokota, A.; Tatsumi, N.; Abeno, S.; Ikeba, A.; Takashima, S.; Tsujie, M.; et al. Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma. *Cancer. Sci.* **2004**,95,583-587. doi:[10.1111/j.1349-7006.2004.tb02490.x](https://doi.org/10.1111/j.1349-7006.2004.tb02490.x)
7. Murthy, D.; Attri, K.S.; Singh, P.K. Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics. *Front. Physiol* **2018**,9,335. doi:[10.3389/fphys.2018.00335](https://doi.org/10.3389/fphys.2018.00335)
8. Reddy, R.R.S, Ramanujam, M.V. High Throughput Sequencing-Based Approaches for Gene Expression Analysis. *Methods. Mol. Biol* **2018**,1783,299-323. doi:[10.1007/978-1-4939-7834-2\\_15](https://doi.org/10.1007/978-1-4939-7834-2_15)
9. Gu, Y.; Feng, Q.; Liu, H.; Zhou, Q.; Hu, A.; Yamaguchi, T.; Xia, S.; Kobayashi, H. Bioinformatic evidences and analysis of putative biomarkers in pancreatic ductal adenocarcinoma. *Heliyon* **2019**,5,e02378. doi:[10.1016/j.heliyon.2019.e02378](https://doi.org/10.1016/j.heliyon.2019.e02378)
10. Clough, E.; Barrett, T. The Gene Expression Omnibus Database. *Methods. Mol. Biol* **2016**,1418,93-110. doi:[10.1007/978-1-4939-3578-9\\_5](https://doi.org/10.1007/978-1-4939-3578-9_5)
11. Yu, S.; Li, Y.; Liao, Z.; Wang, Z.; Wang, Z.; Li, Y.; Qian, L.; Zhao, J.; Zong, H.; Kang, B.; et al. Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma. *Gut* **2020**,69,540-550. doi:[10.1136/gutjnl-2019-318860](https://doi.org/10.1136/gutjnl-2019-318860)



12. Ritchie, M.E.; Phipson, B.; Wu, D.; Hu, Y.; Law, C.W.; Shi, W.; Smyth, G.K. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic. Acids. Res* **2015**,43,e47. doi:[10.1093/nar/gkv007](https://doi.org/10.1093/nar/gkv007)
13. Ferreira, J.A. The Benjamini-Hochberg method in the case of discrete test statistics. *Int. J. Biostat* **2007**,3. doi:[10.2202/1557-4679.1065](https://doi.org/10.2202/1557-4679.1065)
14. Thomas, P.D. The Gene Ontology and the Meaning of Biological Function. *Methods. Mol. Biol* **2017**,1446,15–24. doi:[10.1007/978-1-4939-3743-1\\_2](https://doi.org/10.1007/978-1-4939-3743-1_2)
15. Fabregat, A.; Jupe, S.; Matthews, L.; Sidiropoulos, K.; Gillespie, M.; Garapati, P.; Haw, R.; Jassal, B.; Korninger, F.; May, B.; et al. The Reactome Pathway Knowledgebase. *Nucleic. Acids. Res* **2018**,46,D649–D655. doi:[10.1093/nar/gkx1132](https://doi.org/10.1093/nar/gkx1132)
16. Chen, J.; Bardes, E.E.; Aronow, B.J.; Jegga, A.G. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. *Nucleic. Acids. Res* **2009**,37,W305-W311. doi:[10.1093/nar/gkp427](https://doi.org/10.1093/nar/gkp427)
17. Kotlyar, M.; Pastrello, C.; Malik, Z.; Jurisica, I. IID 2018 update: context-specific physical protein-protein interactions in human, model organisms and domesticated species. *Nucleic. Acids. Res* **2019**,47,D581-D589. doi:[10.1093/nar/gky1037](https://doi.org/10.1093/nar/gky1037)
18. Shannon, P.; Markiel, A.; Ozier, O.; Baliga, N.S, Wang, J.T.; Ramage, D.; Amin, N.; Schwikowski, B.; Ideker, T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome. Res* **2003**,13(2498-2504. doi:[10.1101/gr.1239303](https://doi.org/10.1101/gr.1239303)
19. Przulj, N.; Wigle, D.A.; Jurisica, I. Functional topology in a network of protein interactions. *Bioinformatics* **2004**,20,340–348. doi:[10.1093/bioinformatics/btg415](https://doi.org/10.1093/bioinformatics/btg415)
20. Nguyen, T.P.; Liu, W.C.; Jordán, F. Inferring pleiotropy by network analysis: linked diseases in the human PPI network. *BMC. Syst. Biol* **2011**,5,179. doi:[10.1186/1752-0509-5-179](https://doi.org/10.1186/1752-0509-5-179)
21. Shi, Z.; Zhang, B. Fast network centrality analysis using GPUs. *BMC. Bioinformatics* **2011**,12,149. doi:[10.1186/1471-2105-12-149](https://doi.org/10.1186/1471-2105-12-149)
22. Fadhil, E.; Gamiendien, J.; Mwambene, E.C. Protein interaction networks as metric spaces: a novel perspective on distribution of hubs. *BMC. Syst. Biol* **2014**,8,6. doi:[10.1186/1752-0509-8-6](https://doi.org/10.1186/1752-0509-8-6)

23. Zaki, N.; Efimov, D.; Berenguères, J. Protein complex detection using interaction reliability assessment and weighted clustering coefficient. *BMC Bioinformatics* **2013**,14,163. doi:[10.1186/1471-2105-14-163](https://doi.org/10.1186/1471-2105-14-163)
24. Fan, Y.; Xia, J. miRNet-Functional Analysis and Visual Exploration of miRNA-Target Interactions in a Network Context. *Methods. Mol. Biol* **2018**,1819,215-233. doi:[10.1007/978-1-4939-8618-7\\_10](https://doi.org/10.1007/978-1-4939-8618-7_10)
25. Zhou, G.; Soufan, O.; Ewald, J.; Hancock, R.E.W.; Basu, N.; Xia, J. NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis. *Nucleic. Acids. Res* **2019**,47,W234-W241. doi:[10.1093/nar/gkz240](https://doi.org/10.1093/nar/gkz240)
26. Chandrashekar, D.S.; Bashel, B.; Balasubramanya, S.A.H.; Creighton, C.J.; Ponce-Rodriguez, I.; Chakravarthi, B.V.S.K.; Varambally, S. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. *Neoplasia* **2017**,19,649-658. doi:[10.1016/j.neo.2017.05.002](https://doi.org/10.1016/j.neo.2017.05.002)
27. Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha R.; Larsson E.; et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci Signal*. **2013**,6,pl1. doi:[10.1126/scisignal.2004088](https://doi.org/10.1126/scisignal.2004088)
28. Uhlen, M.; Oksvold, P.; Fagerberg, L.; Lundberg, E.; Jonasson, K.; Forsberg, M.; Zwahlen, M.; Kampf, C.; Wester, K.; Hober, S.; et al. Towards a knowledge-based Human Protein Atlas. *Nat. Biotechnol* **2010**,28,1248-1250. doi:[10.1038/nbt1210-1248](https://doi.org/10.1038/nbt1210-1248)
29. Li, T.; Fan, J.; Wang, B.; Traugh, N.; Chen Q.; Liu J.S.; Li B.; Liu X.S. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. *Cancer. Res* **2017**,77,e108–e110. doi:[10.1158/0008-5472.CAN-17-0307](https://doi.org/10.1158/0008-5472.CAN-17-0307)
30. Robin, X.; Turck, N.; Hainard, A.; Tiberti, N.; Lisacek, F.; Sanchez, J.C.; Müller, M. pROC: an open-source package for R and S+ to analyze and compare ROC curves. *BMC. Bioinformatics* **2011**,12,77. doi:[10.1186/1471-2105-12-77](https://doi.org/10.1186/1471-2105-12-77)
31. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* **2001**,25,402–408. doi:[10.1006/meth.2001.1262](https://doi.org/10.1006/meth.2001.1262)
32. El-Saadi M.W.; Williams-Hart T.; Salvatore B.A.; Mahdavian E. Use of in-silico assays to characterize the ADMET profile and identify potential

- therapeutic targets of fusarochromanone, a novel anti-cancer agent. *In Silico. Pharmacol* **2015**,3,6. doi:[10.1186/s40203-015-0010-5](https://doi.org/10.1186/s40203-015-0010-5)
- 33.Li, J.; Ma, X.; Liu, C.; Li, H.; Zhuang, J.; Gao, C.; Zhou, C.; Liu, L.; Wang, K.; Sun C. Exploring the Mechanism of Danshen against Myelofibrosis by Network Pharmacology and Molecular Docking. *Evid. Based. Complement. Alternat. Med.* **2018**,2018,8363295. doi:[10.1155/2018/8363295](https://doi.org/10.1155/2018/8363295)
- 34.Ruddaraju, R.R.; Murugulla, A.C.; Kotla, R.; Tirumalasetty, M.C.B.; Wudayagiri, R.; Donthabakthuni, S.; Maraju, R. Design, synthesis, anticancer activity and docking studies of theophylline containing 1,2,3-triazoles with variant amide derivatives. *Medchemcomm* **2016**,8,176-183. doi:[10.1039/c6md00479b](https://doi.org/10.1039/c6md00479b)
- 35.Moffitt, R.A.; Marayati, R.; Flate, E.L.; Volmar, K.E.; Loeza, S.G.; Hoadley, K.A.; Rashid, N.U.; Williams, L.A.; Eaton, S.C.; Chung, A.H.; et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. *Nat. Genet* **2015**,47,1168-1178. doi:[10.1038/ng.3398](https://doi.org/10.1038/ng.3398)
- 36.Dansranjav, T.; Möbius, C.; Tannapfel, A.; Bartels, M.; Wittekind, C.; Hauss, J.; Witzigmann, H. E-cadherin and DAP kinase in pancreatic adenocarcinoma and corresponding lymph node metastases. *Oncol. Rep* **2006**,15,1125-1131.
- 37.Treiber, M.; Schulz, H.U.; Landt, O.; Drenth, J.P.; Castellani, C.; Real, F.X.; Akar, N.; Ammann, R.W.; Bargetzi, M.; Bhatia, E.; et al. Keratin 8 sequence variants in patients with pancreatitis and pancreatic cancer. *J. Mol. Med (Berl)* **2006**,84,1015-1022. doi:[10.1007/s00109-006-0096-7](https://doi.org/10.1007/s00109-006-0096-7)
- 38.Liu, H.; Li, L.; Chen, H.; Kong, R.; Pan, S.; Hu, J.; Wang, Y.; Li, Y.; Sun B. Silencing IGFBP-2 decreases pancreatic cancer metastasis and enhances chemotherapeutic sensitivity. *Oncotarget* **2017**,8,61674-61686. doi:[10.18632/oncotarget.18669](https://doi.org/10.18632/oncotarget.18669)
- 39.Yao, H.; Yang, Z.; Liu, Z.; Miao, X.; Yang, L.; Li, D.; Zou, Q.; Yuan, Y. Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma. *Cancer. Biomark* **2016**,17,397-404. doi:[10.3233/CBM-160655](https://doi.org/10.3233/CBM-160655)
- 40.Huynh, D.L.; Koh, H.; Chandimali, N.; Zhang, J.J.; Kim, N.; Kang, T.Y.; Ghosh, M.; Gera, M.; Park, Y.H.; Kwon, T.; et al. BRM270 Inhibits the Proliferation of CD44 Positive Pancreatic Ductal Adenocarcinoma Cells via

- Downregulation of Sonic Hedgehog Signaling. *Evid. Based. Complement Alternat. Med.* **2019**,2019,8620469. doi:[10.1155/2019/8620469](https://doi.org/10.1155/2019/8620469)
- 41.Zhang, Z.; Liu, X.; Huang, R.; Liu, X.; Liang, Z.; Liu, T. Upregulation of nucleoprotein AHNAK is associated with poor outcome of pancreatic ductal adenocarcinoma prognosis via mediating epithelial-mesenchymal transition. *J. Cancer* **2019**,10,3860-3870. doi:[10.7150/jca.31291](https://doi.org/10.7150/jca.31291)
- 42.Huang, Y.; Zheng, J.; Tan, T.; Song, L.; Huang, S.; Zhang, Y.; Lin, L.; Liu, J.; Zheng P.; Chen X.; et al. BTG1 low expression in pancreatic ductal adenocarcinoma is associated with a poorer prognosis. *Int. J. Biol. Markers.* **2018**,33,189-194. doi:[10.5301/ijbm.5000310](https://doi.org/10.5301/ijbm.5000310)
- 43.Wang, P.B.; Chen, Y.; Ding, G.R.; Du, H.W.; Fan, H.Y. Keratin 18 induces proliferation, migration, and invasion in gastric cancer via the MAPK signalling pathway. *Clin. Exp. Pharmacol. Physiol.* **2020**,10.1111/1440-1681.13401. doi:[10.1111/1440-1681.13401](https://doi.org/10.1111/1440-1681.13401)
- 44.Alfarsi, L.H.; El Ansari, R.; Masisi, B.K.; Parks, R.; Mohammed, O.J.; Ellis, I.O.; Rakha, E.A.; Green, A.R. Integrated Analysis of Key Differentially Expressed Genes Identifies DBN1 as a Predictive Marker of Response to Endocrine Therapy in Luminal Breast Cancer. *Cancers. (Basel).* **2020**,12,1549. doi:[10.3390/cancers12061549](https://doi.org/10.3390/cancers12061549)
- 45.Tessema, M.; Yingling, C.M.; Picchi, M.A.; Wu, G.; Liu, Y.; Weissfeld, J.L.; Siegfried, J.M.; Tesfaigzi, Y.; Belinsky, S.A. Epigenetic Repression of CCDC37 and MAP1B Links Chronic Obstructive Pulmonary Disease to Lung Cancer. *J. Thorac. Oncol* **2015**,10,1181-1188. doi:[10.1097/JTO.0000000000000592](https://doi.org/10.1097/JTO.0000000000000592)
- 46.Lai, J.; Flanagan, J.; Phillips, W.A.; Chenevix-Trench, G.; Arnold, J. Analysis of the candidate 8p21 tumour suppressor, BNIP3L, in breast and ovarian cancer. *Br. J. Cancer* **2003**,88,270-276. doi:[10.1038/sj.bjc.6600674](https://doi.org/10.1038/sj.bjc.6600674)
- 47.Yen, C.Y.; Huang, C.Y.; Hou, M.F.; Yang, Y.H.; Chang, C.H.; Huang, H.W.; Chen, C.H.; Chang, H.W. Evaluating the performance of fibronectin 1 (FN1), integrin  $\alpha4\beta1$  (ITGA4), syndecan-2 (SDC2), and glycoprotein CD44 as the potential biomarkers of oral squamous cell carcinoma (OSCC). *Biomarkers* **2013**,18,63-72. doi:[10.3109/1354750X.2012.737025](https://doi.org/10.3109/1354750X.2012.737025)
- 48.Tomsic, J.; He, H.; Akagi, K.; Liyanarachchi, S.; Pan, Q.; Bertani, B.; Nagy, R.; Symer, D.E.; Blencowe, B.J.; de la Chapelle, A. A germline mutation in

- SRRM2, a splicing factor gene, is implicated in papillary thyroid carcinoma predisposition. *Sci. Rep* **2015**,5,10566. doi:[10.1038/srep10566](https://doi.org/10.1038/srep10566)
49. Kim, M.J.; Choi, S.K.; Hong, S.H.; Eun, J.W.; Nam, S.W.; Han, J.W.; You, J.S. Oncogenic IL7R is downregulated by histone deacetylase inhibitor in esophageal squamous cell carcinoma via modulation of acetylated FOXO1. *Int. J. Oncol* **2018**,53,395-403. doi:[10.3892/ijo.2018.4392](https://doi.org/10.3892/ijo.2018.4392)
50. Lee, J.; Li, L.; Gretz, N.; Gebert, J.; Dihlmann, S. Absent in Melanoma 2 (AIM2) is an important mediator of interferon-dependent and -independent HLA-DRA and HLA-DRB gene expression in colorectal cancers. *Oncogene* **2012**,31,1242-1253. doi:[10.1038/onc.2011.320](https://doi.org/10.1038/onc.2011.320)
51. Liu, Y.; Kim, H.G.; Dong, E.; Dong, C.; Huang, M.; Liu, Y.; Liangpunsakul, S, Dong, X.C. Sesn3 deficiency promotes carcinogen-induced hepatocellular carcinoma via regulation of the hedgehog pathway. *Biochim. Biophys. Acta. Mol. Basis. Dis* **2019**,1865,2685-2693. doi:[10.1016/j.bbadis.2019.07.011](https://doi.org/10.1016/j.bbadis.2019.07.011)
52. Yang, Z.; Senninger, N.; Flammang, I.; Ye, Q.; Dhayat, S.A. Clinical impact of circulating LAPTM4B-35 in pancreatic ductal adenocarcinoma. *J. Cancer. Res. Clin. Oncol* **2019**,145,1165-1178. doi:[10.1007/s00432-019-02863-w](https://doi.org/10.1007/s00432-019-02863-w)
53. Pandey, R.; Zhou, M.; Islam, S.; Chen, B.; Barker, N.K.; Langlais, P.; Srivastava, A.; Luo, M.; Cooke, L.S.; Weterings, E.; et al. Carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) in Pancreatic Ductal Adenocarcinoma (PDA): An integrative analysis of a novel therapeutic target. *Sci. Rep* **2019**,9,18347. doi:[10.1038/s41598-019-54545-9](https://doi.org/10.1038/s41598-019-54545-9)
54. Neesse, A.; Wagner, M.; Ellenrieder, V.; Bachem, M.; Gress, T.M.; Buchholz, M. Pancreatic stellate cells potentiate proinvasive effects of SERPINE2 expression in pancreatic cancer xenograft tumors. *Pancreatology* **2007**,7,380-385. doi:[10.1159/000107400](https://doi.org/10.1159/000107400)
55. Kang, M.; Qin, W.; Buya, M.; Dong, X.; Zheng, W.; Lu, W.; Chen, J.; Guo, Q.; Wu, Y. VNN1, a potential biomarker for pancreatic cancer-associated new-onset diabetes, aggravates paraneoplastic islet dysfunction by increasing oxidative stress. *Cancer. Lett* **2016**,373,241-250. doi:[10.1016/j.canlet.2015.12.031](https://doi.org/10.1016/j.canlet.2015.12.031)
56. Li, J.; Wu, H.; Li, W.; Yin, L.; Guo, S.; Xu, X.; Ouyang, Y.; Zhao, Z.; Liu, S.; Tian, Y.; et al Downregulated miR-506 expression facilitates pancreatic

- cancer progression and chemoresistance via SPHK1/Akt/NF- $\kappa$ B signaling. *Oncogene* **2016**,35,5501-5514. doi:[10.1038/onc.2016.90](https://doi.org/10.1038/onc.2016.90)
57. Chen, X.L.; Xie, K.X.; Yang, Z.L.; Yuan, L.W. Expression of FXR and HRG and their clinicopathological significance in benign and malignant pancreatic lesions. *Int. J. Clin. Exp. Pathol* **2019**,12,2111-2120.
58. Guo, J.; Lou, W.; Ji, Y.; Zhang, S. Effect of CCR7, CXCR4 and VEGF-C on the lymph node metastasis of human pancreatic ductal adenocarcinoma. *Oncol. Lett* **2013**,5,1572-1578. doi:[10.3892/ol.2013.1261](https://doi.org/10.3892/ol.2013.1261)
59. Wan, Y.C.E.; Liu, J.; Zhu, L.; Kang, T.Z.E.; Zhu, X.; Lis, J.; Ishibashi, T.; Danko, C.G.; Wang, X.; Chan, K.M. The H2BG53D oncohistone directly upregulates ANXA3 transcription and enhances cell migration in pancreatic ductal adenocarcinoma. *Signal. Transduct. Target. Ther* **2020**,5,106. doi:[10.1038/s41392-020-00219-2](https://doi.org/10.1038/s41392-020-00219-2)
60. Sato, Y.; Kobayashi, T.; Nishiumi, S.; Okada, A.; Fujita, T.; Sanuki, T.; Kobayashi, M.; Asahara, M.; Adachi, M.; Sakai, A.; et al. Prospective Study Using Plasma Apolipoprotein A2-Isoforms to Screen for High-Risk Status of Pancreatic Cancer. *Cancers (Basel)* **2020**,12,E2625. doi:[10.3390/cancers12092625](https://doi.org/10.3390/cancers12092625)
61. Gumper, K.; Dangel, A.W.; Pita-Grisanti, V.; Krishna, S.G.; Lara, L.F.; Mace, T.; Papachristou, G.I.; Conwell, D.L.; Hart, P.A.; Cruz-Monserrate, Z. Lipocalin-2 expression and function in pancreatic diseases. *Pancreatology* **2020**,20,419-424. doi:[10.1016/j.pan.2020.01.002](https://doi.org/10.1016/j.pan.2020.01.002)
62. D'Costa, Z.; Jones, K.; Azad, A.; van Stiphout, R.; Lim, S.Y.; Gomes, A.L.; Kinchesh, P.; Smart, S.C.; Gillies McKenna, W.; Buffa, F.M.; et al. Gemcitabine-Induced TIMP1 Attenuates Therapy Response and Promotes Tumor Growth and Liver Metastasis in Pancreatic Cancer. *Cancer. Res.* **2017**,77,5952-5962. doi:[10.1158/0008-5472.CAN-16-2833](https://doi.org/10.1158/0008-5472.CAN-16-2833)
63. Buscail, E.; Chauvet, A.; Quincy, P.; Degrandi, O.; Buscail, C.; Lamrissi, I.; Moranvillier, I.; Caumont, C.; Verdon, S.; Brisson, A.; et al. CD63-GPC1-Positive Exosomes Coupled with CA19-9 Offer Good Diagnostic Potential for Resectable Pancreatic Ductal Adenocarcinoma. *Transl. Oncol* **2019**,12,1395-1403. doi:[10.1016/j.tranon.2019.07.009](https://doi.org/10.1016/j.tranon.2019.07.009)
64. Zhu, G.H.; Huang, C.; Qiu, Z.J.; Liu, J.; Zhang, Z.H.; Zhao, N.; Feng, Z.Z.; Lv, X.H. Expression and prognostic significance of CD151, c-Met, and

- integrin alpha3/alpha6 in pancreatic ductal adenocarcinoma. *Dig. Dis. Sci* **2011**,56,1090-1098. doi:[10.1007/s10620-010-1416-x](https://doi.org/10.1007/s10620-010-1416-x)
65. Eguchi, D.; Ohuchida, K.; Kozono, S.; Ikenaga, N.; Shindo, K.; Cui, L.; Fujiwara, K.; Akagawa, S.; Ohtsuka, T.; Takahata, S.; et al. MAL2 expression predicts distant metastasis and short survival in pancreatic cancer. *Surgery* **2013**,154,573-582. doi:[10.1016/j.surg.2013.03.010](https://doi.org/10.1016/j.surg.2013.03.010)
66. Wang, Z.; Liu, T.; Xue, W.; Fang, Y.; Chen, X.; Xu, L.; Zhang, L.; Guan, K.; Pan, J.; Zheng, L.; et al. ARNTL2 promotes pancreatic ductal adenocarcinoma progression through TGF/BETA pathway and is regulated by miR-26a-5p. *Cell. Death. Dis* **2020**,11,692. doi:[10.1038/s41419-020-02839-6](https://doi.org/10.1038/s41419-020-02839-6)
67. Yuan, J.; Rozengurt, E. PKD, PKD2, and p38 MAPK mediate Hsp27 serine-82 phosphorylation induced by neurotensin in pancreatic cancer PANC-1 cells. *J. Cell. Biochem* **2008**,103,648-662. doi:[10.1002/jcb.21439](https://doi.org/10.1002/jcb.21439)
68. Schild, C.; Wirth, M.; Reichert, M.; Schmid, R.M.; Saur, D.; Schneider, G.; PI3K signaling maintains c-myc expression to regulate transcription of E2F1 in pancreatic cancer cells. *Mol. Carcinog* **2009**,48,1149-1158. doi:[10.1002/mc.2056](https://doi.org/10.1002/mc.2056)
69. Chen, Y.; Peng, S.; Cen, H.; Lin, Y.; Huang, C.; Chen, Y.; Shan, H.; Su, Y.; Zeng, L. MicroRNA hsa-miR-623 directly suppresses MMP1 and attenuates IL-8-induced metastasis in pancreatic cancer. *Int. J. Oncol* **2019**,55,142-156. doi:[10.3892/ijo.2019.4803](https://doi.org/10.3892/ijo.2019.4803)
70. Wang, L.; Zhao, X.Y.; Zhu, J.S.; Chen, N.W.; Fan, H.N.; Yang, W.; Guo, J.H. CCR7 regulates ANO6 to promote migration of pancreatic ductal adenocarcinoma cells via the ERK signaling pathway. *Oncol. Lett* **2018**,16,2599-2605. doi:[10.3892/ol.2018.8962](https://doi.org/10.3892/ol.2018.8962)
71. Mazur, P.K.; Einwächter, H.; Lee, M.; Sipos, B.; Nakhai, H.; Rad, R.; Zimmer-Strobl, U.; Strobl, L.J.; Radtke, F.; Klöppel, G.; et al. Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. *Proc. Natl. Acad. Sci. U. S. A.* **2010**,107,13438-13443. doi:[10.1073/pnas.1002423107](https://doi.org/10.1073/pnas.1002423107)
72. Bian, B.; Fanale, D.; Dusetti, N.; Roque, J.; Pastor, S.; Chretien, A.S.; Incorvaia, L.; Russo, A.; Olive, D.; Iovanna, J.; et al. Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients

- with pancreatic adenocarcinoma. *Oncoimmunology* **2019**,8,e1561120. doi:[10.1080/2162402X.2018.1561120](https://doi.org/10.1080/2162402X.2018.1561120)
- 73.Ryschich, E.; Huszty, G.; Knaebel, H.P.; Hartel, M.; Büchler, M.W.; Schmidt, J. Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas. *Eur. J. Cancer* **2004**,40,1418-1422. doi:[10.1016/j.ejca.2004.01.036](https://doi.org/10.1016/j.ejca.2004.01.036)
- 74.Sonntag, K.; Hashimoto, H.; Eyrich, M.; Menzel, M.; Schubach, M.; Döcker, D.; Battke, F.; Courage, C.; Lambertz, H.; Handgretinger, R.; et al. Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multi-peptide vaccines: a case report. *J. Transl. Med* **2018**,16,23. doi:[10.1186/s12967-018-1382-1](https://doi.org/10.1186/s12967-018-1382-1)
- 75.Hutchings, D.; Jiang, Z.; Skaro, M.; Weiss, M.J.; Wolfgang, C.L.; Makary, M.A.; He, J.; Cameron, J.L.; Zheng, L.; Klimstra, D.S.; et al. Histomorphology of pancreatic cancer in patients with inherited ATM serine/threonine kinase pathogenic variants. *Mod. Pathol* **2019**,32,1806-1813. doi:[10.1038/s41379-019-0317-6](https://doi.org/10.1038/s41379-019-0317-6)
- 76.Singhi, A.D.; Lilo, M.; Hruban, R.H.; Cressman, K.L.; Fuhrer, K.; Seethala, R.R. Overexpression of lymphoid enhancer-binding factor 1 (LEF1) in solid-pseudopapillary neoplasms of the pancreas. *Mod. Pathol* **2014**,27,1355-1363. doi:[10.1038/modpathol.2014.40](https://doi.org/10.1038/modpathol.2014.40)
- 77.Zhu, Y.; Knolhoff, B.L.; Meyer, M.A.; Nywening, T.M.; West, B.L.; Luo, J.; Wang-Gillam, A.; Goedegebuure, S.P.; Linehan, D.C.; DeNardo, D.G. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. *Cancer. Res* **2014**,74,5057-5069. doi:[10.1158/0008-5472.CAN-13-3723](https://doi.org/10.1158/0008-5472.CAN-13-3723)
- 78.Dumartin, L.; Whiteman, H.J.; Weeks, M.E.; Hariharan, D.; Dmitrovic, B.; Iacobuzio-Donahue, C.A.; Brentnall, T.A.; Bronner, M.P.; Feakins, R.M.; Timms, J.F.; et al. AGR2 is a novel surface antigen that promotes the dissemination of pancreatic cancer cells through regulation of cathepsins B and D. *Cancer. Res* **2011**,71,7091-7102. doi:[10.1158/0008-5472.CAN-11-1367](https://doi.org/10.1158/0008-5472.CAN-11-1367)
- 79.Wang, C.A.; Chang, I.H.; Hou, P.C.; Tai, Y.J.; Li, W.N.; Hsu, P.L.; Wu, S.R.; Chiu, W.T.; Li, C.F.; Shan, Y.S.; et al. DUSP2 regulates extracellular



- vesicle-VEGF-C secretion and pancreatic cancer early dissemination. *J. Extracell. Vesicles* **2020**,9,1746529. doi:[10.1080/20013078.2020.1746529](https://doi.org/10.1080/20013078.2020.1746529)
80. Yoon, K.; Lee, S.O.; Cho, S.D.; Kim, K.; Khan, S.; Safe, S. Activation of nuclear TR3 (NR4A1) by a diindolylmethane analog induces apoptosis and proapoptotic genes in pancreatic cancer cells and tumors. *Carcinogenesis* **2011**,32,836-842. doi:[10.1093/carcin/bgr040](https://doi.org/10.1093/carcin/bgr040)
81. Rodriguez-Aguayo, C.; Bayraktar, E.; Ivan, C.; Aslan, B.; Mai, J.; He, G.; Mangala, L.S.; Jiang, D.; Nagaraja, A.S.; Ozpolat, B.; et al. PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. *EBioMedicine* **2019**,40,290-304. doi:[10.1016/j.ebiom.2018.11.045](https://doi.org/10.1016/j.ebiom.2018.11.045)
82. Chang, H.; Zhang, X.; Li, B.; Meng, X. MAGI2-AS3 suppresses MYC signaling to inhibit cell proliferation and migration in ovarian cancer through targeting miR-525-5p/MXD1 axis. *Cancer. Med* **2020**,9,6377-6386. doi:[10.1002/cam4.3126](https://doi.org/10.1002/cam4.3126)
83. Hoagland, L.F.; Campa, M.J.; Gottlin, E.B.; Herndon, J.E.; Patz, E.F. Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer. *Cancer* **2007**,110,2260-2268. doi:[10.1002/cncr.23049](https://doi.org/10.1002/cncr.23049)
84. Wang, M.; Zhang, G.; Zhang, Y.; Cui, X.; Wang, S.; Gao, S.; Wang, Y.; Liu, Y.; Bae, J.H.; Yang, W.H.; et al. Fibrinogen Alpha Chain Knockout Promotes Tumor Growth and Metastasis through Integrin-AKT Signaling Pathway in Lung Cancer. *Mol. Cancer. Res* **2020**,18,943-954. doi:[10.1158/1541-7786.MCR-19-1033](https://doi.org/10.1158/1541-7786.MCR-19-1033)
85. Repetto, O.; Maiero, S.; Magris, R.; Miolo, G.; Cozzi, M.R.; Steffan, A.; Canzonieri, V.; Cannizzaro, R.; De Re, V. Quantitative Proteomic Approach Targeted to Fibrinogen  $\beta$  Chain in Tissue Gastric Carcinoma. *Int. J. Mol. Sci* **2018**,19,759. doi:[10.3390/ijms19030759](https://doi.org/10.3390/ijms19030759)
86. Bazhan, D.; Khaniani, M.S. Supplementation with omega fatty acids increases the mRNA expression level of PLA2G4A in patients with gastric cancer. *J. Gastrointest. Oncol* **2018**,9,1176-1183. doi:[10.21037/jgo.2018.08.12](https://doi.org/10.21037/jgo.2018.08.12)
87. Duan, S.; Gong, B.; Wang, P.; Huang, H.; Luo, L.; Liu, F. Novel prognostic biomarkers of gastric cancer based on gene expression microarray:

- COL12A1, GSTA3, FGA and FGG. *Mol. Med. Rep* **2018**,18,3727-3736.  
doi:[10.3892/mmr.2018.9368](https://doi.org/10.3892/mmr.2018.9368)
- 88.Lee, S.W.; Chen, T.J.; Lin, L.C.; Li, C.F.; Chen, L.T.; Hsing, C.H.; Hsu, H.P.; Tsai, C.J.; Huang, H.Y.; Shiue, Y.L. Overexpression of thymidylate synthetase confers an independent prognostic indicator in nasopharyngeal carcinoma. *Exp. Mol. Pathol* **2013**,95,83-90.  
doi:[10.1016/j.yexmp.2013.05.006](https://doi.org/10.1016/j.yexmp.2013.05.006)
- 89.Shibata, D.; Mori, Y.; Cai, K.; Zhang, L.; Yin, J.; Elahi, A.; Hamelin, R.; Wong, Y.F.; Lo, W.K.; Chung T.K.; et al. RAB32 hypermethylation and microsatellite instability in gastric and endometrial adenocarcinomas. *Int. J. Cancer* **2006**,119,801-806. doi:[10.1002/ijc.21912](https://doi.org/10.1002/ijc.21912)
- 90.Zhao, X.; Feng, H.; Wang, Y.; Wu, Y.; Guo, Q.; Feng, Y.; Ma, M.; Guo, W.; Song, X.; Zhang, Y.; et al. Septin4 promotes cell death in human colon cancer cells by interacting with BAX. *Int. J. Biol. Sci* **2020**,16,1917-1928.  
doi:[10.7150/ijbs.44429](https://doi.org/10.7150/ijbs.44429)
- 91.Zhang, J.; Zhang, J.; Xu, S.; Zhang, X.; Wang, P.; Wu, H.; Xia, B.; Zhang, G.; Lei, B.; Wan, L.; et al. Hypoxia-Induced TPM2 Methylation is Associated with Chemoresistance and Poor Prognosis in Breast Cancer. *Cell. Physiol. Biochem* **2018**,45,692-705. doi:[10.1159/000487162](https://doi.org/10.1159/000487162)
- 92.Feng, H.; Liu, X. Interaction between ACOT7 and LncRNA NMRAL2P via Methylation Regulates Gastric Cancer Progression. *Yonsei. Med. J* **2020**,61,471-481. doi:[10.3349/ymj.2020.61.6.471](https://doi.org/10.3349/ymj.2020.61.6.471)
- 93.Suzuki, E.; Imoto, I.; Pimkhaokham, A.; Nakagawa, T.; Kamata, N.; Kozaki, K.I.; Amagasa, T.; Inazawa, J. PRTFDC1, a possible tumor-suppressor gene, is frequently silenced in oral squamous-cell carcinomas by aberrant promoter hypermethylation. *Oncogene* **2007**,26,7921-7932.  
doi:[10.1038/sj.onc.1210589](https://doi.org/10.1038/sj.onc.1210589)
- 94.Sakamoto, H.; Friel, A.M.; Wood, A.W.; Guo, L.; Ilic, A.; Seiden, M.V.; Chung, D.C.; Lynch, M.P.; Serikawa, T.; Munro, E.; et al. Mechanisms of Cables 1 gene inactivation in human ovarian cancer development. *Cancer. Biol. Ther* **2008**,7,180-188. doi:[10.4161/cbt.7.2.5253](https://doi.org/10.4161/cbt.7.2.5253)
- 95.Callahan, M.J.; Nagymanyoki, Z.; Bonome, T.; Johnson, M.E.; Litkouhi, B.; Sullivan, E.H.; Hirsch, M.S.; Matulonis, U.A.; Liu, J.; Birrer, M.J.; et al. Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous

- ovarian cancer. *Clin. Cancer. Res* **2008**,14,7667-7673. doi:[10.1158/1078-0432.CCR-08-0479](https://doi.org/10.1158/1078-0432.CCR-08-0479)
96. Wu, Y.; Han, J.; Vladimirovna, K.E.; Zhang, S.; Lv, W.; Zhang, Y.; Jamaspishvili, E.; Sun, J.; Fang, Q.; Meng, J.; et al. Upregulation Of Protein Tyrosine Phosphatase Receptor Type C Associates To The Combination Of Hashimoto's Thyroiditis And Papillary Thyroid Carcinoma And Is Predictive Of A Poor Prognosis. *Oncotargets. Ther* **2019**,12,8479-8489. doi:[10.2147/OTT.S226426](https://doi.org/10.2147/OTT.S226426)
97. Moreno-Manuel, A.; Jantus-Lewintre, E.; Simões, I.; Aranda, F.; Calabuig-Fariñas, S.; Carreras, E.; Zúñiga, S.; Saenger, Y.; Rosell, R.; Camps, C.; et al. CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer. *Transl. Lung. Cancer. Res* **2020**,9,1074-1083. doi:[10.21037/tlcr-19-445](https://doi.org/10.21037/tlcr-19-445)
98. Wright, C.M.; Savarimuthu Francis, S.M.; Tan, M.E.; Martins, M.U.; Winterford, C.; Davidson, M.R.; Duhig, E.E.; Clarke, B.E.; Hayward, N.K.; et al. MS4A1 dysregulation in asbestos-related lung squamous cell carcinoma is due to CD20 stromal lymphocyte expression. *PLoS. One* **2012**,7,e34943. doi:[10.1371/journal.pone.0034943](https://doi.org/10.1371/journal.pone.0034943)
99. Tuscano, J.M.; Kato, J.; Pearson, D.; Xiong, C.; Newell, L.; Ma, Y.; Gandara, D.R.; O'Donnell, R.T. CD22 antigen is broadly expressed on lung cancer cells and is a target for antibody-based therapy. *Cancer. Res* **2012**,72,5556-5565. doi:[10.1158/0008-5472.CAN-12-0173](https://doi.org/10.1158/0008-5472.CAN-12-0173)
100. Nielsen, J.S.; Sahota, R.A.; Milne, K.; Kost, S.E.; Nesslinger, N.J.; Watson, P.H.; Nelson, B.H. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. *Clin. Cancer. Res* **2012**,18,3281-3292. doi:[10.1158/1078-0432.CCR-12-0234](https://doi.org/10.1158/1078-0432.CCR-12-0234)
101. Gai, X.; Tu, K.; Lu, Z.; Zheng, X. MRC2 expression correlates with TGFβ1 and survival in hepatocellular carcinoma. *Int. J. Mol. Sci* **2014**,15,15011-15025. doi:[10.3390/ijms150915011](https://doi.org/10.3390/ijms150915011)
102. Mathew, S.O.; Chaudhary, P.; Powers, S.B.; Vishwanatha, J.K.; Mathew, P.A. Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer cells inhibits NK cell-mediated killing through LLT1-NKRP1A (CD161) interaction. *Oncotarget* **2016**,7,68650-68661. doi:[10.18632/oncotarget.11896](https://doi.org/10.18632/oncotarget.11896)

103. Joung, E.K.; Kim, J.; Yoon, N.; Maeng, L.S.; Kim, J.H.; Park, S.; Kang, K.; Kim, J.S.; Ahn, Y.H.; Ko, Y.H.; et al. Expression of EEF1A1 Is Associated with Prognosis of Patients with Colon Adenocarcinoma. *J. Clin. Med* **2019**,8,1903. doi:[10.3390/jcm8111903](https://doi.org/10.3390/jcm8111903)
104. Yang, D.D.; Chen, Z.H.; Wang, D.S.; Yu, H.E.; Lu, J.H.; Xu, R.H.; Zeng, Z.L. Prognostic value of the serum apolipoprotein B to apolipoprotein A-I ratio in metastatic colorectal cancer patients. *J. Cancer* **2020**,11,1063-1074. doi:[10.7150/jca.3565](https://doi.org/10.7150/jca.3565)
105. Jung, J.H.; Taniguchi, K.; Lee, H.M.; Lee, M.Y.; Bandu, R.; Komura, K.; Lee, K.Y.; Akao, Y.; Kim, K.P. Comparative lipidomics of 5-Fluorouracil-sensitive and -resistant colorectal cancer cells reveals altered sphingomyelin and ceramide controlled by acid sphingomyelinase (SMPD1). *Sci. Rep* **2020**,10,6124. doi:[10.1038/s41598-020-62823-0](https://doi.org/10.1038/s41598-020-62823-0)
106. Liu, M.; Qu, Y.; Teng, X.; Xing, Y.; Li, D.; Li, C.; Cai, L.; PADI4-mediated epithelial-mesenchymal transition in lung cancer cells. *Mol. Med. Rep* **2019**,19,3087-3094. doi:[10.3892/mmr.2019.9968](https://doi.org/10.3892/mmr.2019.9968)
107. Yang, Y.C.; Chien, M.H.; Lai, T.C.; Su, C.Y.; Jan, Y.H.; Hsiao, M.; Chen, C.L. Monoamine Oxidase B Expression Correlates with a Poor Prognosis in Colorectal Cancer Patients and Is Significantly Associated with Epithelial-to-Mesenchymal Transition-Related Gene Signatures. *Int. J. Mol. Sci* **2020**,21,2813. doi:[10.3390/ijms21082813](https://doi.org/10.3390/ijms21082813)
108. Song, Y.; Liu, G.; Liu, S.; Chen, R.; Wang, N.; Liu, Z.; Zhang, X.; Xiao, Z.; Liu, L. Helicobacter pylori upregulates TRPC6 via Wnt/ $\beta$ -catenin signaling to promote gastric cancer migration and invasion. *Onco. Targets. Ther* **2019**,12,5269-5279. doi:[10.2147/OTT.S201025](https://doi.org/10.2147/OTT.S201025)
109. Seachrist, D.D.; Hannigan, M.M.; Ingles, N.N.; Webb, B.M.; Weber-Bonk, K.L.; Yu, P.; Bebek, G.; Singh, S.; Sizemore, S.T.; Varadan, V.; et al. The transcriptional repressor BCL11A promotes breast cancer metastasis. *J. Biol. Chem* **2020**,295,11707-11719. doi:[10.1074/jbc.RA120.014018](https://doi.org/10.1074/jbc.RA120.014018)
110. Zhu, Z.; Zhang, X.; Guo, H.; Fu, L.; Pan, G.; Sun, Y. CXCL13-CXCR5 axis promotes the growth and invasion of colon cancer cells via PI3K/AKT pathway. *Mol. Cell. Biochem* **2015**,400,287-295. doi:[10.1007/s11010-014-2285-y](https://doi.org/10.1007/s11010-014-2285-y)
111. Wu, B.; Chen, M.; Gao, M.; Cong, Y.; Jiang, L.; Wei, J.; Huang, J. Down-regulation of lncTCF7 inhibits cell migration and invasion in

- colorectal cancer via inhibiting TCF7 expression. *Hum. Cell* **2019**,32,31-40. doi:[10.1007/s13577-018-0217-y](https://doi.org/10.1007/s13577-018-0217-y)
112. Wang, S.M.; Tie, J.; Wang, W.L.; Hu, S.J.; Yin, J.P.; Yi, X.F.; Tian, Z.H.; Zhang, X.Y.; Li, M.B.; Li, Z.S.; et al. POU2F2-oriented network promotes human gastric cancer metastasis. *Gut* **2016**,65,1427-1438. doi:[10.1136/gutjnl-2014-308932](https://doi.org/10.1136/gutjnl-2014-308932)
113. Yi, T.; Zhou, X.; Sang, K.; Huang, X.; Zhou, J.; Ge, L. Activation of lncRNA lnc-SLC4A1-1 induced by H3K27 acetylation promotes the development of breast cancer via activating CXCL8 and NF- $\kappa$ B pathway. *Artif. Cells. Nanomed. Biotechnol* **2019**,47,3765-3773. doi:[10.1080/21691401.2019.1664559](https://doi.org/10.1080/21691401.2019.1664559)
114. Lan, Y.; Han, J.; Wang, Y.; Wang, J.; Yang, G.; Li, K.; Song, R.; Zheng, T.; Liang, Y.; Pan, S.; et al. STK17B promotes carcinogenesis and metastasis via AKT/GSK-3 $\beta$ /Snail signaling in hepatocellular carcinoma. *Cell. Death. Dis* **2018**,9,236. doi:[10.1038/s41419-018-0262-1](https://doi.org/10.1038/s41419-018-0262-1)
115. Appert-Collin, A.; Bennisroune, A.; Jeannesson, P.; Terryn, C.; Fuhrmann, G.; Morjani, H.; Dedieu, S. Role of LRP-1 in cancer cell migration in 3-dimensional collagen matrix. *Cell. Adh. Migr* **2017**,11,316-326. doi:[10.1080/19336918.2016.1215788](https://doi.org/10.1080/19336918.2016.1215788)
116. Kairouz, R.; Parmar, J.; Lyons, R.J.; Swarbrick, A.; Musgrove, E.A.; Daly, R.J. Hormonal regulation of the Grb14 signal modulator and its role in cell cycle progression of MCF-7 human breast cancer cells. *J. Cell. Physiol* **2005**,203,85-93. doi:[10.1002/jcp.20199](https://doi.org/10.1002/jcp.20199)
117. Diez-Bello, R.; Jardin, I.; Lopez, J.J.; El Haouari, M.; Ortega-Vidal, J.; Altarejos, J.; Salido, G.M.; Salido, S.; Rosado, J.A. (-)-Oleocanthal inhibits proliferation and migration by modulating Ca<sup>2+</sup> entry through TRPC6 in breast cancer cells. *Biochim. Biophys. Acta. Mol. Cell. Res.* **2019**,1866,474-485. doi:[10.1016/j.bbamcr.2018.10.010](https://doi.org/10.1016/j.bbamcr.2018.10.010)
118. Xue, M.; Tao, W.; Yu, S.; Yan, Z.; Peng, Q.; Jiang, F.; Gao, X. lncRNA ZFPM2-AS1 promotes proliferation via miR-18b-5p/VMA21 axis in lung adenocarcinoma. *J. Cell. Biochem* **2020**,121,313-321. doi:[10.1002/jcb.29176](https://doi.org/10.1002/jcb.29176)
119. Abo-Elfadl, M.T.; Gamal-Eldeen, A.M.; Ismail, M.F.; Shahin, N.N. Silencing of the cytokine receptor TNFRSF13B: A new therapeutic target

- for triple-negative breast cancer. *Cytokine* **2020**,125,154790. doi:[10.1016/j.cyto.2019.154790](https://doi.org/10.1016/j.cyto.2019.154790)
120. Li, J.; Xu, X.; Wei, C.; Liu, L.; Wang, T. Long noncoding RNA NORAD regulates lung cancer cell proliferation, apoptosis, migration, and invasion by the miR-30a-5p/ADAM19 axis. *Int. J. Clin. Exp. Pathol* **2020**,13,1-13.
121. Zhao, J.; Cheng, L. Long non-coding RNA CCAT1/miR-148a axis promotes osteosarcoma proliferation and migration through regulating PIK3IP1. *Acta. Biochim. Biophys. Sin (Shanghai)* **2017**,49,503-512. doi:[10.1093/abbs/gmx041](https://doi.org/10.1093/abbs/gmx041)
122. Leite, F.A.; Lira, R.C.; Fedatto, P.F.; Antonini, S.R.; Martinelli, C.E. ; de Castro, M.; Neder, L.; Ramalho, L.N.; Tucci, S.; Mastelaro, M.J.; et al. Low expression of HLA-DRA, HLA-DPA1, and HLA-DPB1 is associated with poor prognosis in pediatric adrenocortical tumors (ACT). *Pediatr. Blood. Cancer* **2014**,61,1940-1948. doi:[10.1002/pbc.25118](https://doi.org/10.1002/pbc.25118)
123. Feng, Y.; Guo, C.; Wang, H.; Zhao, L.; Wang, W.; Wang, T.; Feng, Y.; Yuan, K.; Huang, G. Fibrinogen-Like Protein 2 (FGL2) is a Novel Biomarker for Clinical Prediction of Human Breast Cancer. *Med. Sci. Monit* **2020**,26,e923531. doi:[10.12659/MSM.923531](https://doi.org/10.12659/MSM.923531)
124. Wang, S.; Xu, L.; Che, X.; Li, C.; Xu, L.; Hou, K.; Fan, Y.; Wen, T.; Qu, X.; Liu, Y. E3 ubiquitin ligases Cbl-b and c-Cbl downregulate PD-L1 in EGFR wild-type non-small cell lung cancer. *FEBS. Lett* **2018**,592,621-630. doi:[10.1002/1873-3468.12985](https://doi.org/10.1002/1873-3468.12985)
125. Zhong, X.P.; Kan, A.; Ling, Y.H.; Lu, L.H.; Mei, J.; Wei, W.; Li, S.H.; Guo, R.P. NCKAP1 improves patient outcome and inhibits cell growth by enhancing Rb1/p53 activation in hepatocellular carcinoma. *Cell. Death. Dis* **2019**,10,369.. doi:[10.1038/s41419-019-1603-4](https://doi.org/10.1038/s41419-019-1603-4)
126. Yokoyama-Mashima, S.; Yogosawa, S.; Kanegae, Y.; Hirooka, S.; Yoshida, S.; Horiuchi, T.; Ohashi, T.; Yanaga, K.; Saruta, M.; Oikawa, T.; et al. Forced expression of DYRK2 exerts anti-tumor effects via apoptotic induction in liver cancer. *Cancer. Lett* **2019**,451,100-109. doi:[10.1016/j.canlet.2019.02.046](https://doi.org/10.1016/j.canlet.2019.02.046)
127. Guo, H.; Zhang, B.; Nairn, A.V.; Nagy, T.; Moremen, K.W.; Buckhaults, P.; Pierce, M. O-Linked N-Acetylglucosamine (O-GlcNAc) Expression Levels Epigenetically Regulate Colon Cancer Tumorigenesis by

- Affecting the Cancer Stem Cell Compartment via Modulating Expression of Transcriptional Factor MYBL1. *J. Biol. Chem* **2017**,292,4123-4137. doi:[10.1074/jbc.M116.763201](https://doi.org/10.1074/jbc.M116.763201)
128. Lawson, J.; Dickman, C.; MacLellan, S.; Towle, R.; Jabalee, J.; Lam, S.; Garnis, C. Selective secretion of microRNAs from lung cancer cells via extracellular vesicles promotes CAMK1D-mediated tube formation in endothelial cells. *Oncotarget* **2017**,8,83913-83924. doi:[10.18632/oncotarget.19996](https://doi.org/10.18632/oncotarget.19996)
129. Wang, X.; Ye, M.; Wu, M.; Fang, H.; Xiao, B.; Xie, L.; Zhu, X. RNF213 suppresses carcinogenesis in glioblastoma by affecting MAPK/JNK signaling pathway. *Clin. Transl. Oncol* **2020**,22,1506-1516. doi:[10.1007/s12094-020-02286-x](https://doi.org/10.1007/s12094-020-02286-x)
130. Taheri, M.; Omrani, M.D.; Noroozi, R.; Ghafouri-Fard, S.; Sayad, A. Retinoic acid-related orphan receptor alpha (RORA) variants and risk of breast cancer. *Breast. Dis* **2017**,37,21-25. doi:[10.3233/BD-160248](https://doi.org/10.3233/BD-160248)
131. Hoyo, C.; Murphy, S.K.; Schildkraut, J.M.; Vidal, A.C.; Skaar, D.; Millikan, R.C.; Galanko, J.; Sandler R.S.; Jirtle R.; Keku T. IGF2R genetic variants, circulating IGF2 concentrations and colon cancer risk in African Americans and Whites. *Dis. Markers* **2012**,32,133-141. doi:[10.3233/DMA-2011-0865](https://doi.org/10.3233/DMA-2011-0865)
132. Bai, F.; Xiao, K. Prediction of gastric cancer risk: association between ZBTB20 genetic variance and gastric cancer risk in Chinese Han population. *Biosci. Rep* **2020**,40,BSR20202102. doi:[10.1042/BSR20202102](https://doi.org/10.1042/BSR20202102)
133. Hope, C.; Emmerich, P.B, Papadas, A.; Pagenkopf, A.; Matkowskyj, K.A.; Van De Hey, D.R.; Payne, S.N.; Clipson, L.; Callander, N.S.; Hematti, P.; et al. Versican-Derived Matrikines Regulate Batf3-Dendritic Cell Differentiation and Promote T Cell Infiltration in Colorectal Cancer. *J. Immunol* **2017**,199,1933-1941. doi:[10.4049/jimmunol.1700529](https://doi.org/10.4049/jimmunol.1700529)
134. Bai, X.; Wang, W.; Zhao, P.; Wen, J.; Guo, X.; Shen, T.; Shen, J.; Yang, X. LncRNA CRNDE acts as an oncogene in cervical cancer through sponging miR-183 to regulate CCNB1 expression. *Carcinogenesis* **2020**,41,111-121. doi:[10.1093/carcin/bgz166](https://doi.org/10.1093/carcin/bgz166)
135. Zienert, E.; Eke, I.; Aust, D.; Cordes, N. LIM-only protein FHL2 critically determines survival and radioresistance of pancreatic cancer cells. *Cancer. Lett* **2015**,364,17-24. doi:[10.1016/j.canlet.2015.04.019](https://doi.org/10.1016/j.canlet.2015.04.019)

136. Yang, J.; Chen, Z.; Liu, N.; Chen, Y. Ribosomal protein L10 in mitochondria serves as a regulator for ROS level in pancreatic cancer cells. *Redox Biol* **2018**,19,158-165. doi:[10.1016/j.redox.2018.08.016](https://doi.org/10.1016/j.redox.2018.08.016)
137. Xie, F.; Huang, Q.; Wang, C.; Chen, S.; Liu, C.; Lin, X.; Lv, X.; Wang, C. Downregulation of long noncoding RNA SNHG14 suppresses cell proliferation and invasion by regulating EZH2 in pancreatic ductal adenocarcinoma (PDAC). *Cancer. Biomark* **2020**,27,357-364. doi:[10.3233/CBM-190908](https://doi.org/10.3233/CBM-190908)
138. Li, S.S.; Jiang, W.L.; Xiao, W.Q.; Li, K.; Zhang, Y.F.; Guo, X.Y.; Dai, Y.Q.; Zhao, Q.Y.; Jiang, M.J.; Lu, Z.J.; et al. KMT2D deficiency enhances the anti-cancer activity of L48H37 in pancreatic ductal adenocarcinoma. *World. J. Gastrointest. Oncol* **2019**,11,599-621. doi:[10.4251/wjgo.v11.i8.599](https://doi.org/10.4251/wjgo.v11.i8.599)
139. Zhu, G.; Zhou, L.; Liu, H.; Shan, Y.; Zhang, X. MicroRNA-224 Promotes Pancreatic Cancer Cell Proliferation and Migration by Targeting the TXNIP-Mediated HIF1 $\alpha$  Pathway. *Cell. Physiol. Biochem* **2018**,48,1735-1746. doi:[10.1159/000492309](https://doi.org/10.1159/000492309)
140. Zhang, K.D.; Hu, B.; Cen, G.; Yang, Y.H.; Chen, W.W.; Guo, Z.Y.; Wang, X.F.; Zhao, Q.; Qiu, Z.J. MiR-301a transcriptionally activated by HIF-2 $\alpha$  promotes hypoxia-induced epithelial-mesenchymal transition by targeting TP63 in pancreatic cancer. *World. J. Gastroenterol* **2020**,26,2349-2373. doi:[10.3748/wjg.v26.i19.2349](https://doi.org/10.3748/wjg.v26.i19.2349)
141. Wuebben, E.L.; Wilder, P.J.; Cox, J.L.; Grunkemeyer, J.A.; Caffrey, T.; Hollingsworth, M.A.; Rizzino, A. SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells. *Oncotarget* **2016**,7,34890-34906. doi:[10.18632/oncotarget.8994](https://doi.org/10.18632/oncotarget.8994)
142. Muthalagu, N.; Monteverde, T.; Raffo-Iraolagoitia, X.; Wiesheu, R.; Whyte, D.; Hedley, A.; Laing, S.; Kruspig, B.; Upstill-Goddard R.; Shaw R.; et al. Repression of the Type I Interferon Pathway Underlies MYC- and KRAS-Dependent Evasion of NK and B Cells in Pancreatic Ductal Adenocarcinoma. *Cancer. Discov* **2020**,10,872-887. doi:[10.1158/2159-8290.CD-19-0620](https://doi.org/10.1158/2159-8290.CD-19-0620)
143. Wang, Z.; Chen, Y.; Lin, Y.; Wang, X.; Cui, X.; Zhang, Z.; Xian, G.; Qin, C. Novel crosstalk between KLF4 and ZEB1 regulates gemcitabine



resistance in pancreatic ductal adenocarcinoma. *Int. J. Oncol* **2017**,51,1239-1248. doi:[10.3892/ijo.2017.4099](https://doi.org/10.3892/ijo.2017.4099)

144. Hu, L.; Fang, L.; Zhang, Z.P.; Yan, Z.L. TPM1 is a Novel Predictive Biomarker for Gastric Cancer Diagnosis and Prognosis. *Clin Lab.* **2020**,66,10.7754/Clin.Lab.2019.190235. doi:[10.7754/Clin.Lab.2019.190235](https://doi.org/10.7754/Clin.Lab.2019.190235)

145. Chen, H.; Fan, Y.; Xu, W.; Chen, J.; Meng, Y.; Fang, D.; Wang, J. Exploration of miR-1202 and miR-196a in human endometrial cancer based on high throughout gene screening analysis. *Oncol. Rep* **2017**,37,3493-3501. doi:[10.3892/or.2017.5596](https://doi.org/10.3892/or.2017.5596)

## Tables

**Table 1** The sequences of primers for quantitative RT-PCR

| Genes    | Primers   | Length of target fragment, bp |
|----------|---|-------------------------------|
| CCNB1    | <b>F:</b> AATAAGGCGAAGATCAACATGGC<br><b>R:</b> TTTGTTACCAATGTCCCAAGAG | 23                            |
| FHL2     | <b>F:</b> GTACAGACTGCTATTCCAACGAG<br><b>R:</b> GCACTGCATGGCATGTTGTT   | 23                            |
| HLA-DPA1 | <b>F:</b> ATGCGCCTGAAGACAGAATG<br><b>R:</b> ACACATGGTCCGCCTTGATG      | 21                            |
| TUBB1    | <b>F:</b> AACACGGGATCGACTTGGC<br><b>R:</b> CTCGGGGCACATATTCCTAC       | 21                            |

**F: Forward Primers**      **R: Reverse Primers**

**Table 2** The statistical metrics for key differentially expressed genes (DEGs)

| Gene Symbol | logFC    | p Value  | adj.P.Val | t value  | Regulation | Gene Name   |
|-------------|----------|----------|-----------|----------|------------|---|
| DAP         | 0.729809 | 3.54E-14 | 2.59E-11  | 7.862623 | Up         | death associated protein                              |
| MTRNR2L2    | 1.55786  | 4.87E-14 | 3.22E-11  | 7.816552 | Up         | MT-RNR2 like 2  |
| ICA1        | 1.027176 | 1.66E-13 | 9E-11     | 7.636838 | Up         | islet cell autoantigen 1                              |
| KRT8        | 1.61503  | 6.94E-13 | 3.01E-10  | 7.423576 | Up         | keratin 8   |
| MAP1LC3B2   | 1.050642 | 1.03E-11 | 3.21E-09  | 7.008711 | Up         | microtubule associated protein 1 light chain 3 beta 2 |
| KRT18       | 1.317775 | 1.21E-11 | 3.67E-09  | 6.984018 | Up         | keratin 18  |
| DBN1        | 0.680188 | 1.71E-11 | 4.78E-09  | 6.928904 | Up         | drebrin 1   |
| MAP1B       | 0.804673 | 2.02E-11 | 5.5E-09   | 6.902127 | Up         | microtubule associated protein 1B                     |
| IGFBP2      | 1.26743  | 2.04E-11 | 5.5E-09   | 6.900692 | Up         | insulin like growth factor binding protein 2          |
| KRT19       | 1.682062 | 3.2E-11  | 8.32E-09  | 6.828975 | Up         | keratin 19  |
| ARNTL2      | 1.064741 | 3.25E-11 | 8.42E-09  | 6.826429 | Up         | aryl hydrocarbon receptor nuclear translocator like 2 |
| MND1        | 1.050388 | 6.48E-11 | 1.51E-08  | 6.714983 | Up         | meiotic nuclear divisions 1                           |
| LCN2        | 1.195504 | 1.23E-10 | 2.65E-08  | 6.610378 | Up         | lipocalin 2   |
| HP          | 1.105468 | 1.98E-10 | 4.01E-08  | 6.531824 | Up         | haptoglobin   |
| GOLIM4      | 0.730931 | 1.99E-10 | 4.01E-08  | 6.531295 | Up         | golgi integral membrane protein 4                     |

|              |          |          |          |          |    |  |
|--------------|----------|----------|----------|----------|----|--|
| FGB          | 1.281458 | 2.04E-10 | 4.09E-08 | 6.526862 | Up | fibrinogen beta chain                              |
| TCEAL3       | 0.698058 | 2.11E-10 | 4.19E-08 | 6.521292 | Up | transcription elongation factor A like 3           |
| H3P47        | 0.806164 | 3.14E-10 | 5.88E-08 | 6.455108 | Up | H3 histone pseudogene 47                           |
| CD27-AS1     | 1.127104 | 3.53E-10 | 6.52E-08 | 6.435648 | Up | CD27 antisense RNA 1                               |
| LSMEM1       | 1.300595 | 3.94E-10 | 7.16E-08 | 6.417125 | Up | leucine rich single-pass membrane protein 1        |
| CD63         | 0.638758 | 4.97E-10 | 8.71E-08 | 6.378004 | Up | CD63 molecule                                      |
| MAOB         | 1.081308 | 7.82E-10 | 1.29E-07 | 6.301015 | Up | monoamine oxidase B                                |
| FGG          | 1.037158 | 8.4E-10  | 1.36E-07 | 6.288927 | Up | fibrinogen gamma chain                             |
| LOC105370027 | 1.046446 | 1.06E-09 | 1.66E-07 | 6.248715 | Up | uncharacterized LOC105370027                       |
| H2BC17       | 0.973199 | 1.13E-09 | 1.75E-07 | 6.237457 | Up | H2B clustered histone 17                           |
| ZFPM2        | 1.167509 | 1.26E-09 | 1.93E-07 | 6.218913 | Up | zinc finger protein, FOG family member 2           |
| UBE2Q2P1     | 0.75226  | 2.34E-09 | 3.3E-07  | 6.111953 | Up | ubiquitin conjugating enzyme E2 Q2 pseudogene 1    |
| GTF3C6       | 0.66658  | 2.41E-09 | 3.36E-07 | 6.107154 | Up | general transcription factor IIIC subunit 6        |
| FGA          | 1.058162 | 2.56E-09 | 3.52E-07 | 6.096366 | Up | fibrinogen alpha chain                             |
| H4C15        | 0.646131 | 3.44E-09 | 4.5E-07  | 6.044383 | Up | H4 clustered histone 15                            |
| TAX1BP3      | 0.761452 | 3.74E-09 | 4.85E-07 | 6.029641 | Up | Tax1 binding protein 3                             |
| RET          | 0.748469 | 4.44E-09 | 5.62E-07 | 5.999495 | Up | ret proto-oncogene                                 |
| HTATIP2      | 0.696367 | 4.69E-09 | 5.87E-07 | 5.989713 | Up | HIV-1 Tat interactive protein 2                    |
| MCEMP1       | 1.055887 | 7.5E-09  | 8.94E-07 | 5.906144 | Up | mast cell expressed membrane protein 1             |
| APOB         | 0.984349 | 8.66E-09 | 1.02E-06 | 5.88037  | Up | apolipoprotein B                                   |
| TPM2         | 0.808631 | 9.37E-09 | 1.09E-06 | 5.866037 | Up | tropomyosin 2                                      |
| MYL6B        | 0.735111 | 9.66E-09 | 1.12E-06 | 5.860685 | Up | myosin light chain 6B                              |
| PRELID2      | 1.007003 | 1.01E-08 | 1.16E-06 | 5.851789 | Up | PRELI domain containing 2                          |
| STAC         | 0.70663  | 1.08E-08 | 1.24E-06 | 5.839882 | Up | SH3 and cysteine rich domain                       |
| H4C14        | 0.640786 | 1.16E-08 | 1.32E-06 | 5.826872 | Up | H4 clustered histone 14                            |
| KLHDC8B      | 0.931058 | 1.17E-08 | 1.32E-06 | 5.825909 | Up | kelch domain containing 8B                         |
| HRG          | 1.25373  | 1.49E-08 | 1.63E-06 | 5.782449 | Up | histidine rich glycoprotein                        |
| DDAH1        | 0.960624 | 2.46E-08 | 2.46E-06 | 5.689878 | Up | dimethylargininedimethylaminohydrolase 1           |
| C19orf33     | 1.048033 | 2.73E-08 | 2.69E-06 | 5.670561 | Up | chromosome 19 open reading frame 33                |
| FAH          | 0.995091 | 3.02E-08 | 2.92E-06 | 5.651858 | Up | fumarylacetoacetate hydrolase                      |
| DCBLD2       | 0.939546 | 3.06E-08 | 2.96E-06 | 5.649534 | Up | discoidin, CUB and LCCL domain containing 2        |
| IFI27L2      | 0.822377 | 3.76E-08 | 3.53E-06 | 5.611483 | Up | interferon alpha inducible protein 27 like 2       |
| PTGES3L      | 0.989667 | 3.95E-08 | 3.7E-06  | 5.602037 | Up | prostaglandin E synthase 3 like                    |
| TIMP1        | 0.829195 | 4.17E-08 | 3.89E-06 | 5.591888 | Up | TIMP metalloproteinase inhibitor 1                 |
| SNURF        | 0.743535 | 4.2E-08  | 3.91E-06 | 5.590685 | Up | SNRNP upstream reading frame                       |
| CMTM2        | 0.918208 | 4.76E-08 | 4.36E-06 | 5.567227 | Up | CKLF like MARVEL transmembrane domain containing 2 |
| MDK          | 0.797135 | 6.31E-08 | 5.6E-06  | 5.513868 | Up | midkine  |
| BCAP31       | 0.771229 | 6.77E-08 | 5.93E-06 | 5.500637 | Up | B cell receptor associated protein 31              |
| RAB32        | 0.725327 | 7.54E-08 | 6.49E-06 | 5.480174 | Up | RAB32, member RAS oncogene family                  |
| PCP2         | 0.848727 | 7.79E-08 | 6.64E-06 | 5.474068 | Up | Purkinje cell protein 2                            |
| AOPEP        | 0.665257 | 9.03E-08 | 7.61E-06 | 5.445854 | Up | aminopeptidase O (putative)                        |

|              |          |          |          |          |    |   |
|--------------|----------|----------|----------|----------|----|---|
| FKBP1B       | 1.079675 | 9.08E-08 | 7.64E-06 | 5.444649 | Up | FKBP prolylisomerase 1B   |
| UBE2C        | 0.919203 | 9.19E-08 | 7.7E-06  | 5.442432 | Up | ubiquitin conjugating enzyme E2 C   |
| CETN2        | 0.907963 | 9.64E-08 | 7.99E-06 | 5.433373 | Up | centrin 2   |
| TREML3P      | 0.736245 | 1.04E-07 | 8.51E-06 | 5.418563 | Up | triggering receptor expressed on myeloid cells like 3, pseudogene             |
| CLMAT3       | 0.914772 | 1.09E-07 | 8.91E-06 | 5.409301 | Up | colorectal liver metastasis associated transcript 3                           |
| TOM1L1       | 1.010788 | 1.25E-07 | 1E-05    | 5.382976 | Up | target of myb1 like 1 membrane trafficking protein                            |
| RABAC1       | 0.685861 | 1.28E-07 | 1.02E-05 | 5.378165 | Up | Rab acceptor 1  |
| PTPRN        | 0.756419 | 1.8E-07  | 1.35E-05 | 5.312969 | Up | protein tyrosine phosphatase receptor type N                                  |
| CCDC9B       | 0.764226 | 1.89E-07 | 1.42E-05 | 5.302684 | Up | coiled-coil domain containing 9B  |
| UNC13B       | 0.669902 | 2.49E-07 | 1.8E-05  | 5.248667 | Up | unc-13 homolog B  |
| APOH         | 0.937929 | 2.62E-07 | 1.88E-05 | 5.238638 | Up | apolipoprotein H  |
| MCM10        | 0.778282 | 2.66E-07 | 1.9E-05  | 5.236183 | Up | minichromosome maintenance 10 replication initiation factor                   |
| H2BC11       | 0.672283 | 2.8E-07  | 1.98E-05 | 5.226015 | Up | H2B clustered histone 11  |
| EZH2         | 0.665264 | 3E-07    | 2.1E-05  | 5.211928 | Up | enhancer of zeste 2 polycomb repressive complex 2 subunit                     |
| H2AC13       | 0.672944 | 3.06E-07 | 2.14E-05 | 5.208195 | Up | H2A clustered histone 13  |
| NCBP2L       | 0.690397 | 3.18E-07 | 2.2E-05  | 5.200769 | Up | nuclear cap binding protein subunit 2 like                                    |
| CCNB1        | 0.69638  | 3.18E-07 | 2.2E-05  | 5.200386 | Up | cyclin B1   |
| PKD2         | 0.747713 | 3.28E-07 | 2.25E-05 | 5.194336 | Up | polycystin 2, transient receptor potential cation channel                     |
| LOC100130357 | 0.908199 | 3.58E-07 | 2.43E-05 | 5.176869 | Up | uncharacterized LOC100130357  |
| ORM1         | 0.845653 | 4.18E-07 | 2.79E-05 | 5.145905 | Up | orosomucoid 1   |
| CDR2L        | 0.75789  | 4.37E-07 | 2.89E-05 | 5.137166 | Up | cerebellar degeneration related protein 2 like                                |
| H2AJ         | 0.700133 | 4.63E-07 | 3.02E-05 | 5.125431 | Up | H2A.J histone   |
| TPM1         | 0.669813 | 4.65E-07 | 3.03E-05 | 5.124861 | Up | tropomyosin 1   |
| ACOT7        | 0.80117  | 5.34E-07 | 3.4E-05  | 5.097055 | Up | acyl-CoA thioesterase 7   |
| AP1M2        | 0.962099 | 5.68E-07 | 3.57E-05 | 5.084413 | Up | adaptor related protein complex 1 subunit mu 2                                |
| AVEN         | 0.668545 | 6.52E-07 | 4.05E-05 | 5.056569 | Up | apoptosis and caspase activation inhibitor                                    |
| DNAH2        | 0.732007 | 6.75E-07 | 4.17E-05 | 5.049466 | Up | dynein axonemal heavy chain 2   |
| TRPC2        | 0.85544  | 7.09E-07 | 4.35E-05 | 5.039399 | Up | transient receptor potential cation channel subfamily C member 2 (pseudogene) |
| RND3         | 0.841233 | 7.53E-07 | 4.58E-05 | 5.027115 | Up | Rho family GTPase 3   |
| PPP1R14A     | 0.745833 | 7.86E-07 | 4.75E-05 | 5.018397 | Up | protein phosphatase 1 regulatory inhibitor subunit 14A                        |
| TGFB3        | 0.835809 | 7.9E-07  | 4.76E-05 | 5.01733  | Up | transforming growth factor beta 3   |
| TPST1        | 0.819069 | 8.34E-07 | 4.99E-05 | 5.006228 | Up | tyrosylproteinsulfotransferase 1  |
| VNN1         | 0.865209 | 1.1E-06  | 6.32E-05 | 4.949468 | Up | vanin 1   |
| MIR1282      | 1.063689 | 1.12E-06 | 6.41E-05 | 4.945828 | Up | microRNA 1282   |
| APOA2        | 0.724038 | 1.23E-06 | 6.93E-05 | 4.92633  | Up | apolipoprotein A2   |
| FAM92A       | 0.677465 | 1.25E-06 | 7.03E-05 | 4.922308 | Up | family with sequence similarity 92 member A                                   |
| MSANTD3      | 0.66954  | 1.29E-06 | 7.18E-05 | 4.916615 | Up | Myb/SANT DNA binding domain containing 3                                      |
| GRK4         | 0.900233 | 1.37E-06 | 7.55E-05 | 4.904444 | Up | G protein-coupled receptor kinase 4   |
| TSPAN15      | 0.802125 | 1.4E-06  | 7.7E-05  | 4.899117 | Up | tetraspanin 15  |

|              |          |          |          |          |    |   |
|--------------|----------|----------|----------|----------|----|---|
| PTGER3       | 0.731073 | 1.54E-06 | 8.36E-05 | 4.879106 | Up | prostaglandin E receptor 3  |
| MITF         | 0.871653 | 1.63E-06 | 8.76E-05 | 4.867297 | Up | melanocyte inducing transcription factor                                      |
| MMP1         | 0.771433 | 1.75E-06 | 9.33E-05 | 4.852725 | Up | matrix metalloproteinase 1  |
| MAL2         | 0.749667 | 1.81E-06 | 9.62E-05 | 4.845684 | Up | mal, T cell differentiation protein 2 (gene/pseudogene)                       |
| CTPS2        | 0.67219  | 1.83E-06 | 9.71E-05 | 4.843038 | Up | CTP synthase 2  |
| LOC101929538 | 0.711706 | 1.9E-06  | 9.98E-05 | 4.835864 | Up | uncharacterized LOC101929538 olfactory receptor family 2 subfamily B member 6 |
| OR2B6        | 0.909758 | 1.94E-06 | 0.000102 | 4.831266 | Up |   |
| C20orf96     | 0.740435 | 2.13E-06 | 0.000109 | 4.811175 | Up | chromosome 20 open reading frame 96   |
| MPZL3        | 0.734878 | 2.16E-06 | 0.000111 | 4.808022 | Up | myelin protein zero like 3  |
| LOC101927420 | 0.734878 | 2.29E-06 | 0.000116 | 4.79601  | Up | uncharacterized LOC101927420  |
| EPDR1        | 0.769808 | 2.47E-06 | 0.000125 | 4.779781 | Up | ependymin related 1   |
| FHL2         | 0.853097 | 2.75E-06 | 0.000137 | 4.756748 | Up | four and a half LIM domains 2   |
| LAPTM4B      | 0.92193  | 3.02E-06 | 0.000148 | 4.736673 | Up | lysosomal protein transmembrane 4 beta  |
| ARG2         | 1.000424 | 3.03E-06 | 0.000149 | 4.735971 | Up | arginase 2  |
| ADAM22       | 0.710055 | 3.12E-06 | 0.000152 | 4.729888 | Up | ADAM metalloproteinase domain 22  |
| GPC5         | 0.6499   | 3.29E-06 | 0.000159 | 4.718778 | Up | glypican 5  |
| DERA         | 0.676038 | 3.31E-06 | 0.000161 | 4.716998 | Up | deoxyribose-phosphate aldolase  |
| OXTR         | 0.917126 | 3.55E-06 | 0.00017  | 4.70246  | Up | oxytocin receptor   |
| PROK2        | 0.789874 | 3.77E-06 | 0.000179 | 4.689155 | Up | prokineticin 2  |
| CNN1         | 0.901951 | 3.81E-06 | 0.00018  | 4.686924 | Up | calponin 1  |
| KRT7         | 0.904375 | 4.03E-06 | 0.000188 | 4.674982 | Up | keratin 7   |
| CENPI        | 0.730063 | 4.07E-06 | 0.00019  | 4.672762 | Up | centromere protein I  |
| LINC01684    | 0.731662 | 4.19E-06 | 0.000195 | 4.666397 | Up | long intergenic non-protein coding RNA 1684                                   |
| KCNMB1       | 0.752736 | 4.56E-06 | 0.000209 | 4.647801 | Up | potassium calcium-activated channel subfamily M regulatory beta subunit 1     |
| LACTB2       | 0.695963 | 4.69E-06 | 0.000215 | 4.641781 | Up | lactamase beta 2  |
| BEST3        | 0.711771 | 4.73E-06 | 0.000216 | 4.640144 | Up | bestrophin 3  |
| C5orf30      | 0.731538 | 5.21E-06 | 0.000236 | 4.618767 | Up | chromosome 5 open reading frame 30  |
| SMPD1        | 0.834518 | 5.41E-06 | 0.000244 | 4.610568 | Up | sphingomyelinphosphodiesterase 1  |
| ANO10        | 0.657575 | 5.46E-06 | 0.000246 | 4.608531 | Up | anoctamin 10  |
| GINS1        | 0.706019 | 5.61E-06 | 0.000252 | 4.602785 | Up | GINS complex subunit 1  |
| TGFB1I1      | 0.782636 | 6.07E-06 | 0.000269 | 4.585606 | Up | transforming growth factor beta 1 induced transcript 1                        |
| CABLES1      | 0.659259 | 6.29E-06 | 0.000277 | 4.577514 | Up | Cdk5 and Abl enzyme substrate 1   |
| ROBO1        | 0.71818  | 7.03E-06 | 0.000304 | 4.552913 | Up | roundabout guidance receptor 1  |
| BUB1         | 0.667318 | 7.42E-06 | 0.000319 | 4.541048 | Up | BUB1 mitotic checkpoint serine/threonine kinase                               |
| FUNDC1       | 0.767386 | 7.66E-06 | 0.000328 | 4.533938 | Up | FUN14 domain containing 1   |
| CRTC3-AS1    | 0.751802 | 7.83E-06 | 0.000334 | 4.529039 | Up | CRTC3 antisense RNA 1   |
| DMC1         | 0.841001 | 7.84E-06 | 0.000334 | 4.528894 | Up | DNA meiotic recombinase 1   |
| ZSCAN16-AS1  | 0.738009 | 8.09E-06 | 0.000344 | 4.521862 | Up | ZSCAN16 antisense RNA 1   |
| SCARF1       | 0.676906 | 8.39E-06 | 0.000355 | 4.513776 | Up | scavenger receptor class F member 1   |
| ACCSL        | 0.65649  | 8.65E-06 | 0.000365 | 4.50688  | Up | 1-aminocyclopropane-1-carboxylate synthase homolog (inactive) like            |
| CXCL3        | 0.778559 | 1.03E-05 | 0.000421 | 4.468754 | Up | C-X-C motif chemokine ligand 3  |

|            |          |          |          |          |    |  |
|------------|----------|----------|----------|----------|----|--|
| LINC00892  | 0.819555 | 1.05E-05 | 0.00043  | 4.462734 | Up | long intergenic non-protein coding RNA 892                           |
| RNF208     | 0.841349 | 1.06E-05 | 0.000433 | 4.461088 | Up | ring finger protein 208  |
| EAF2       | 0.668192 | 1.15E-05 | 0.000464 | 4.443023 | Up | ELL associated factor 2  |
| LAMB2      | 0.699363 | 1.16E-05 | 0.000468 | 4.44064  | Up | laminin subunit beta 2   |
| LOXL3      | 0.736971 | 1.19E-05 | 0.000477 | 4.435804 | Up | lysyl oxidase like 3   |
| CEACAM6    | 0.828845 | 1.22E-05 | 0.000489 | 4.429132 | Up | CEA cell adhesion molecule 6   |
| HPD        | 0.801889 | 1.29E-05 | 0.00051  | 4.417691 | Up | 4-hydroxyphenylpyruvate dioxygenase                                  |
| TMEM67     | 0.706644 | 1.3E-05  | 0.000511 | 4.415933 | Up | transmembrane protein 67   |
| LINC00534  | 0.991484 | 1.3E-05  | 0.000511 | 4.415737 | Up | long intergenic non-protein coding RNA 534                           |
| TYMS       | 0.660517 | 1.31E-05 | 0.000514 | 4.413975 | Up | thymidylatesynthetase  |
| ZGLP1      | 0.781496 | 1.36E-05 | 0.000529 | 4.405803 | Up | zinc finger GATA like protein 1                                      |
| GNG8       | 0.74057  | 1.51E-05 | 0.000581 | 4.381524 | Up | G protein subunit gamma 8  |
| MT1X       | 0.78313  | 1.59E-05 | 0.000609 | 4.368771 | Up | metallothionein 1X   |
| EVA1B      | 0.700855 | 1.71E-05 | 0.000642 | 4.352699 | Up | eva-1 homolog B  |
| FRMD3      | 0.658149 | 1.91E-05 | 0.000704 | 4.326801 | Up | FERM domain containing 3   |
| ADAMTS1    | 0.710457 | 1.94E-05 | 0.000709 | 4.324203 | Up | ADAM metalloproteinase with thrombospondin type 1 motif 1            |
| ACTR3B     | 0.733415 | 2.06E-05 | 0.00075  | 4.309603 | Up | actin related protein 3B   |
| METTL22    | 0.69995  | 2.27E-05 | 0.00082  | 4.286931 | Up | methyltransferase like 22  |
| WASF1      | 0.742178 | 2.34E-05 | 0.000842 | 4.280128 | Up | WASP family member 1   |
| LINC00548  | 0.776323 | 2.51E-05 | 0.000886 | 4.264099 | Up | long intergenic non-protein coding RNA 548                           |
| DTL        | 0.641962 | 2.52E-05 | 0.00089  | 4.262623 | Up | denticleless E3 ubiquitin protein ligase homolog                     |
| NT5DC2     | 0.692809 | 2.71E-05 | 0.000939 | 4.245871 | Up | 5'-nucleotidase domain containing 2                                  |
| VEGFC      | 0.669813 | 2.88E-05 | 0.000989 | 4.231356 | Up | vascular endothelial growth factor C                                 |
| MAGI2      | 0.735314 | 2.89E-05 | 0.00099  | 4.230904 | Up | membrane associated guanylate kinase, WW and PDZ domain containing 2 |
| LINC00211  | 0.894161 | 2.93E-05 | 0.001001 | 4.227722 | Up | long intergenic non-protein coding RNA 211                           |
| SPHK1      | 0.676802 | 3.04E-05 | 0.001028 | 4.219226 | Up | sphingosine kinase 1   |
| ZNF529-AS1 | 0.661567 | 3.35E-05 | 0.001114 | 4.196168 | Up | ZNF529 antisense RNA 1   |
| ADAMTS5    | 0.660099 | 3.39E-05 | 0.001123 | 4.193506 | Up | ADAM metalloproteinase with thrombospondin type 1 motif 5            |
| DYNC1H1    | 0.795012 | 3.39E-05 | 0.001124 | 4.193181 | Up | dynein cytoplasmic 1 intermediate chain 1                            |
| CCDC3      | 0.674572 | 3.42E-05 | 0.001131 | 4.191397 | Up | coiled-coil domain containing 3                                      |
| YIF1B      | 0.743761 | 3.43E-05 | 0.001133 | 4.190185 | Up | Yip1 interacting factor homolog B, membrane trafficking protein      |
| PRKAR1B    | 0.701104 | 3.54E-05 | 0.001164 | 4.182731 | Up | protein kinase cAMP-dependent type I regulatory subunit beta         |
| NMNAT3     | 0.641441 | 4.03E-05 | 0.001305 | 4.151903 | Up | nicotinamide nucleotide adenylyltransferase 3                        |
| TSPAN13    | 0.656865 | 4.05E-05 | 0.00131  | 4.150707 | Up | tetraspanin 13   |
| POLR3G     | 0.862253 | 4.19E-05 | 0.001346 | 4.143028 | Up | RNA polymerase III subunit G   |
| TMEM158    | 0.832551 | 4.39E-05 | 0.0014   | 4.131626 | Up | transmembrane protein 158 (gene/pseudogene)                          |
| CYTOR      | 0.669042 | 4.41E-05 | 0.001403 | 4.130782 | Up | cytoskeleton regulator RNA   |
| FN3K       | 0.715739 | 4.44E-05 | 0.001411 | 4.128739 | Up | fructosamine 3 kinase  |
| CENPU      | 0.685833 | 4.48E-05 | 0.001421 | 4.126825 | Up | centromere protein U   |
| ANXA3      | 0.642891 | 4.52E-05 | 0.001431 | 4.124872 | Up | annexin A3   |

|                    |          |          |          |          |    |  |
|--------------------|----------|----------|----------|----------|----|--|
| PGLYRP1            | 0.743358 | 4.53E-05 | 0.001432 | 4.124178 | Up | peptidoglycan recognition protein 1<br>long intergenic non-protein coding RNA<br>853       |
| LINC00853          | 0.886342 | 4.73E-05 | 0.001482 | 4.113907 | Up |  |
| C21orf58           | 0.673046 | 5E-05    | 0.001552 | 4.10054  | Up | chromosome 21 open reading frame 58  |
| PHACTR3            | 0.768701 | 5.12E-05 | 0.001582 | 4.094798 | Up | phosphatase and actin regulator 3<br>cysteine rich transmembrane module<br>containing 1    |
| CYSTM1             | 0.639491 | 6.02E-05 | 0.001809 | 4.055347 | Up |  |
| E2F1               | 0.689528 | 6.28E-05 | 0.001867 | 4.045197 | Up | E2F transcription factor 1   |
| CTNS               | 0.723506 | 6.31E-05 | 0.001876 | 4.043771 | Up | cystinosin, lysosomal cystine transporter  |
| LUZP6              | 0.784849 | 6.33E-05 | 0.00188  | 4.043183 | Up | leucine zipper protein 6   |
| LY6G6F-<br>LY6G6D  | 0.697512 | 6.82E-05 | 0.002    | 4.024994 | Up | LY6G6F-LY6G6D readthrough  |
| DRC7               | 0.641026 | 6.97E-05 | 0.00203  | 4.019452 | Up | dynein regulatory complex subunit 7  |
| SPINT2             | 0.716213 | 7.44E-05 | 0.002142 | 4.003447 | Up | serine peptidase inhibitor, Kunitz type 2  |
| TST                | 0.653129 | 8.57E-05 | 0.002428 | 3.968702 | Up | thiosulfate sulfurtransferase<br>phenazine biosynthesis like protein<br>domain containing  |
| PBLD               | 0.728909 | 9.82E-05 | 0.002708 | 3.934854 | Up |  |
| COL6A3             | 0.800552 | 0.000106 | 0.002866 | 3.916014 | Up | collagen type VI alpha 3 chain   |
| SMYD3              | 0.658545 | 0.00011  | 0.002954 | 3.906774 | Up | SET and MYND domain containing 3   |
| SEPTIN4            | 0.678613 | 0.000113 | 0.003014 | 3.900217 | Up | septin 4   |
| ADAM32             | 0.660263 | 0.000114 | 0.003032 | 3.898284 | Up | ADAM metallopeptidase domain 32<br>alcohol dehydrogenase 1B (class I), beta<br>polypeptide |
| ADH1B              | 0.683312 | 0.000115 | 0.003044 | 3.896241 | Up |  |
| TTL7               | 0.772356 | 0.000116 | 0.003081 | 3.892908 | Up | tubulin tyrosine ligase like 7   |
| ME1                | 0.679181 | 0.000119 | 0.003134 | 3.887332 | Up | malic enzyme 1   |
| PADI4              | 0.638723 | 0.000119 | 0.00315  | 3.885738 | Up | peptidyl arginine deiminase 4<br>cell death inducing DFFA like effector c<br>pseudogene 1  |
| CIDECP1            | 0.65588  | 0.000123 | 0.003226 | 3.877866 | Up |  |
| CD151              | 0.680244 | 0.000133 | 0.003439 | 3.859108 | Up | CD151 molecule (Raph blood group)  |
| ETV4               | 0.762875 | 0.000137 | 0.003518 | 3.851736 | Up | ETS variant transcription factor 4   |
| MYOM1              | 0.712787 | 0.000141 | 0.003611 | 3.843573 | Up | myomesin 1   |
| MSANTD3-<br>TMEFF1 | 0.694055 | 0.000161 | 0.00403  | 3.810035 | Up | MSANTD3-TMEFF1 readthrough   |
| GLA                | 0.768164 | 0.000169 | 0.004193 | 3.797347 | Up | galactosidase alpha<br>thyrotropin releasing hormone degrading<br>enzyme                   |
| TRHDE              | 0.673175 | 0.000173 | 0.004275 | 3.791127 | Up | chaperonin containing TCP1 subunit 6<br>pseudogene 3                                       |
| CCT6P3             | 0.64622  | 0.000176 | 0.00433  | 3.786849 | Up |  |
| DNAH14             | 0.67538  | 0.000197 | 0.004737 | 3.757991 | Up | dynein axonemal heavy chain 14<br>pleckstrin homology domain containing<br>A8 pseudogene 1 |
| PLEKHA8P1          | 0.678922 | 0.000198 | 0.004758 | 3.756381 | Up |  |
| MIR646HG           | 0.725938 | 0.0002   | 0.004796 | 3.753511 | Up | MIR646 host gene   |
| TMEFF1             | 0.71416  | 0.000213 | 0.005026 | 3.73756  | Up | transmembrane protein with EGF like<br>and two follistatin like domains 1                  |
| DPY19L2            | 0.678632 | 0.000214 | 0.005044 | 3.736377 | Up | dpy-19 like 2  |
| ERC2               | 0.640215 | 0.000232 | 0.005396 | 3.715528 | Up | ELKS/RAB6-interacting/CAST family<br>member 2  |
| PLA2G4A            | 0.672732 | 0.000232 | 0.005396 | 3.715504 | Up | phospholipase A2 group IVA<br>zinc finger CCCH-type containing,<br>antiviral 1 like        |
| ZC3HAV1L           | 0.67853  | 0.000241 | 0.005556 | 3.705049 | Up |  |
| AQP10              | 0.702387 | 0.000255 | 0.005825 | 3.690433 | Up | aquaporin 10   |
| PRTFDC1            | 0.732046 | 0.000266 | 0.006032 | 3.67956  | Up | phosphoribosyltransferase domain<br>containing 1   |
| SERPINE2           | 0.708281 | 0.000278 | 0.006263 | 3.667198 | Up | serpin family E member 2   |

|              |          |          |          |          |      |   |
|--------------|----------|----------|----------|----------|------|---|
| PRR16        | 0.647548 | 0.000365 | 0.007821 | 3.594668 | Up   | proline rich 16   |
| ACER2        | 0.714054 | 0.000441 | 0.009068 | 3.543878 | Up   | alkaline ceramidase 2   |
| THEM5        | 0.68475  | 0.000632 | 0.012136 | 3.44491  | Up   | thioesterase superfamily member 5   |
| MS4A3        | 0.669703 | 0.000713 | 0.013422 | 3.41125  | Up   | membrane spanning 4-domains A3  |
| CLEC2L       | 0.667059 | 0.000745 | 0.013903 | 3.398829 | Up   | C-type lectin domain family 2 member L<br>transient receptor potential cation<br>channel subfamily C member 6 |
| TRPC6        | 0.669122 | 0.000816 | 0.014941 | 3.373194 | Up   | long intergenic non-protein coding RNA<br>1089  |
| LINC01089    | 0.641558 | 0.00098  | 0.017284 | 3.320844 | Up   | growth factor receptor bound protein 14   |
| GRB14        | 0.73252  | 0.001457 | 0.023689 | 3.205476 | Up   | myeloma overexpressed   |
| MYEOV        | 0.66784  | 0.001553 | 0.024891 | 3.186553 | Up   | troponin C2, fast skeletal type   |
| TNNC2        | 0.681795 | 0.001798 | 0.027848 | 3.142855 | Up   | phospholipase A and acyltransferase 1   |
| PLAAT1       | 0.716924 | 0.001991 | 0.030092 | 3.112202 | Up   | INKA2 antisense RNA 1   |
| INKA2-AS1    | 0.64851  | 0.002272 | 0.033302 | 3.072049 | Up   | defensin alpha 1  |
| DEFA1        | 0.710406 | 0.002482 | 0.035699 | 3.044927 | Up   | LYPLAL1 divergent transcript  |
| LYPLAL1-DT   | 0.653678 | 0.00251  | 0.035991 | 3.041436 | Up   | G0/G1 switch 2  |
| G0S2         | 0.666254 | 0.003148 | 0.04269  | 2.970966 | Up   | uncharacterized LOC105371967  |
| LOC105371967 | 0.715866 | 0.00336  | 0.044907 | 2.950485 | Up   | F-box protein 7   |
| FBXO7        | -1.02578 | 4.57E-31 | 2.47E-26 | -12.6471 | Down | CD44 molecule (Indian blood group)  |
| CD44         | -0.77354 | 1.37E-24 | 3.7E-20  | -10.9533 | Down | BCL2 interacting protein 3 like   |
| BNIP3L       | -1.11652 | 7.58E-24 | 1.37E-19 | -10.7506 | Down | integrin subunit alpha 4  |
| ITGA4        | -0.7155  | 7.16E-22 | 6.46E-18 | -10.202  | Down | serine/arginine repetitive matrix 2   |
| SRRM2        | -0.7545  | 2.82E-21 | 1.74E-17 | -10.0332 | Down | interleukin 7 receptor<br>major histocompatibility complex, class<br>II, DR alpha                             |
| IL7R         | -0.9167  | 3.22E-21 | 1.74E-17 | -10.0169 | Down | AHNAK nucleoprotein   |
| HLA-DRA      | -0.72512 | 6.41E-21 | 2.89E-17 | -9.93149 | Down | sestrin 3   |
| AHNAK        | -1.08285 | 1.37E-20 | 5.71E-17 | -9.83691 | Down | BTG anti-proliferation factor 1   |
| SESN3        | -0.83384 | 3.7E-20  | 1.34E-16 | -9.71209 | Down | transcription factor 7<br>protein tyrosine phosphatase receptor<br>type C                                     |
| BTG1         | -0.67464 | 8.57E-20 | 2.9E-16  | -9.606   | Down | serine/threonine kinase 17b   |
| TCF7         | -1.05537 | 9.82E-20 | 3.13E-16 | -9.58878 | Down | IKAROS family zinc finger 3   |
| PTPRC        | -0.79038 | 1.95E-19 | 5.55E-16 | -9.50153 | Down | O-linked N-acetylglucosamine (GlcNAc)<br>transferase  |
| STK17B       | -0.6627  | 8.27E-19 | 1.95E-15 | -9.31582 | Down | metastasis associated lung<br>adenocarcinoma transcript 1   |
| IKZF3        | -0.84512 | 4.27E-18 | 9.64E-15 | -9.10211 | Down | muscleblind like splicing regulator 3   |
| OGT          | -0.85075 | 8.43E-18 | 1.83E-14 | -9.01274 | Down | thioredoxin interacting protein   |
| MALAT1       | -1.15502 | 1.98E-17 | 4.04E-14 | -8.89988 | Down | solute carrier family 38 member 1   |
| MBNL3        | -0.85006 | 2.01E-17 | 4.04E-14 | -8.89733 | Down | NCK associated protein 1 like   |
| TXNIP        | -0.69647 | 3.04E-17 | 5.67E-14 | -8.8425  | Down | paired box 5<br>trinucleotide repeat containing adaptor<br>6B   |
| SLC38A1      | -0.674   | 7.23E-17 | 1.22E-13 | -8.72615 | Down | ATM serine/threonine kinase<br>major histocompatibility complex, class<br>II, DP alpha 1                      |
| NCKAP1L      | -0.66777 | 7.45E-17 | 1.22E-13 | -8.72221 | Down | family with sequence similarity 102   |
| PAX5         | -1.15676 | 2.44E-16 | 3.67E-13 | -8.56139 | Down |   |
| TNRC6B       | -0.80631 | 3.35E-16 | 4.86E-13 | -8.51801 | Down |   |
| ATM          | -0.65967 | 4.2E-16  | 5.83E-13 | -8.48699 | Down |   |
| HLA-DPA1     | -0.67781 | 1.41E-15 | 1.82E-12 | -8.31961 | Down |   |
| FAM102A      | -0.76298 | 1.5E-15  | 1.89E-12 | -8.31093 | Down |   |

|          |          |          |          |          |      | member A   |
|----------|----------|----------|----------|----------|------|--|
| DYRK2    | -0.69741 | 1.54E-15 | 1.89E-12 | -8.30769 | Down | dual specificity tyrosine phosphorylation regulated kinase 2 |
| STRADB   | -0.88854 | 2.32E-15 | 2.7E-12  | -8.24996 | Down | STE20 related adaptor beta                                   |
| RNF213   | -0.78696 | 2.36E-15 | 2.7E-12  | -8.2476  | Down | ring finger protein 213                                      |
| RPL10    | -0.68279 | 2.4E-15  | 2.7E-12  | -8.24564 | Down | ribosomal protein L10  |
| EEF1A1   | -0.93399 | 4.56E-15 | 4.75E-12 | -8.15527 | Down | eukaryotic translation elongation factor 1 alpha 1           |
| RPL23A   | -0.69095 | 5.13E-15 | 5.14E-12 | -8.13875 | Down | ribosomal protein L23a                                       |
| RPL37    | -0.68343 | 6.21E-15 | 5.9E-12  | -8.11176 | Down | ribosomal protein L37  |
| HBB      | -1.18457 | 1.01E-14 | 9.1E-12  | -8.04285 | Down | hemoglobin subunit beta                                      |
| CAMK4    | -1.1638  | 1.36E-14 | 1.17E-11 | -8.00017 | Down | calcium/calmodulin dependent protein kinase IV               |
| TENT5C   | -0.78619 | 1.47E-14 | 1.24E-11 | -7.98892 | Down | terminal nucleotidyltransferase 5C                           |
| BACH2    | -1.06422 | 1.5E-14  | 1.24E-11 | -7.98579 | Down | BTB domain and CNC homolog 2                                 |
| TBCEL    | -0.64594 | 1.51E-14 | 1.24E-11 | -7.98482 | Down | tubulin folding cofactor E like                              |
| WDFY4    | -0.99635 | 2.23E-14 | 1.75E-11 | -7.9292  | Down | WDFY family member 4   |
| RPL27A   | -0.6388  | 2.37E-14 | 1.83E-11 | -7.92052 | Down | ribosomal protein L27a                                       |
| AAK1     | -0.65765 | 4.11E-14 | 2.89E-11 | -7.8413  | Down | AP2 associated kinase 1                                      |
| MS4A1    | -0.95361 | 4.31E-14 | 2.96E-11 | -7.8342  | Down | membrane spanning 4-domains A1                               |
| DCAF12   | -0.7593  | 5.05E-14 | 3.3E-11  | -7.81122 | Down | DDB1 and CUL4 associated factor 12                           |
| KMT2D    | -0.87707 | 5.94E-14 | 3.83E-11 | -7.78757 | Down | lysine methyltransferase 2D                                  |
| OPA1     | -0.62121 | 6.75E-14 | 4.3E-11  | -7.76907 | Down | OPA1 mitochondrial dynamin like GTPase                       |
| CAMK1D   | -0.67422 | 1.2E-13  | 6.98E-11 | -7.68504 | Down | calcium/calmodulin dependent protein kinase ID               |
| FAM117B  | -0.73486 | 1.2E-13  | 6.98E-11 | -7.68502 | Down | family with sequence similarity 117 member B                 |
| BCL11B   | -0.71547 | 1.26E-13 | 7.28E-11 | -7.67723 | Down | BAF chromatin remodeling complex subunit BCL11B              |
| HBA1     | -1.28343 | 1.39E-13 | 7.86E-11 | -7.66283 | Down | hemoglobin subunit alpha 1                                   |
| SEC16A   | -0.63051 | 2.06E-13 | 1.07E-10 | -7.60474 | Down | SEC16 homolog A, endoplasmic reticulum export factor         |
| NOTCH2   | -1.02848 | 3.2E-13  | 1.62E-10 | -7.53985 | Down | notch receptor 2   |
| SLC25A37 | -0.97321 | 3.22E-13 | 1.62E-10 | -7.53857 | Down | solute carrier family 25 member 37                           |
| BCL9L    | -0.7821  | 3.41E-13 | 1.67E-10 | -7.53032 | Down | BCL9 like  |
| RCAN3    | -0.67723 | 3.62E-13 | 1.75E-10 | -7.52118 | Down | RCAN family member 3   |
| RALGPS2  | -0.81589 | 4.58E-13 | 2.08E-10 | -7.48622 | Down | Ral GEF with PH domain and SH3 binding motif 2               |
| SOX6     | -1.09995 | 5.44E-13 | 2.43E-10 | -7.46032 | Down | SRY-box transcription factor 6                               |
| TRANK1   | -0.70118 | 6.86E-13 | 2.99E-10 | -7.4255  | Down | tetratricopeptide repeat and ankyrin repeat containing 1     |
| IL10RA   | -0.80857 | 7.25E-13 | 3.11E-10 | -7.41713 | Down | interleukin 10 receptor subunit alpha                        |
| TCP11L2  | -0.85596 | 8.16E-13 | 3.42E-10 | -7.39924 | Down | t-complex 11 like 2  |
| TMC8     | -0.90771 | 8.95E-13 | 3.69E-10 | -7.38532 | Down | transmembrane channel like 8                                 |
| HBA2     | -1.1918  | 1.49E-12 | 5.84E-10 | -7.30802 | Down | hemoglobin subunit alpha 2                                   |
| ZBTB20   | -0.68652 | 2.37E-12 | 8.9E-10  | -7.23703 | Down | zinc finger and BTB domain containing 20                     |
| CTSB     | -0.68749 | 3.44E-12 | 1.27E-09 | -7.17953 | Down | cathepsin B  |
| NSUN3    | -0.97469 | 3.57E-12 | 1.3E-09  | -7.17397 | Down | NOP2/Sun RNA methyltransferase 3                             |
| MARCHF8  | -0.64518 | 4.02E-12 | 1.45E-09 | -7.15528 | Down | membrane associated ring-CH-type finger 8                    |



|             |          |          |          |          |      |  |
|-------------|----------|----------|----------|----------|------|--|
| BLK         | -0.93113 | 4.45E-12 | 1.6E-09  | -7.13963 | Down | BLK proto-oncogene, Src family tyrosine kinase   |
| LEF1        | -0.72094 | 5.64E-12 | 1.97E-09 | -7.10302 | Down | lymphoid enhancer binding factor 1   |
| TLCD4       | -0.94983 | 5.98E-12 | 2.04E-09 | -7.09373 | Down | TLC domain containing 4  |
| CBLB        | -0.62042 | 6.13E-12 | 2.06E-09 | -7.08996 | Down | Cbl proto-oncogene B interferon induced protein with tetratricopeptide repeats 1B                    |
| IFIT1B      | -1.14286 | 7.54E-12 | 2.43E-09 | -7.05769 | Down |  |
| NLRP1       | -0.70059 | 8.94E-12 | 2.81E-09 | -7.03094 | Down | NLR family pyrin domain containing 1   |
| SORL1       | -0.74274 | 1.46E-11 | 4.32E-09 | -6.95383 | Down | sortilin related receptor 1  |
| IGF2R       | -0.81797 | 1.48E-11 | 4.34E-09 | -6.95175 | Down | insulin like growth factor 2 receptor  |
| PLEC        | -0.76357 | 1.63E-11 | 4.68E-09 | -6.93634 | Down | plectin  |
| EEF2        | -0.65473 | 1.63E-11 | 4.68E-09 | -6.93587 | Down | eukaryotic translation elongation factor 2   |
| AFF3        | -0.87612 | 1.65E-11 | 4.71E-09 | -6.93416 | Down | AF4/FMR2 family member 3   |
| YOD1        | -0.88888 | 1.72E-11 | 4.78E-09 | -6.92773 | Down | YOD1 deubiquitinase  |
| SFT2D2      | -0.63701 | 2E-11    | 5.49E-09 | -6.90414 | Down | SFT2 domain containing 2   |
| NIBAN3      | -0.99082 | 2.03E-11 | 5.5E-09  | -6.90116 | Down | niban apoptosis regulator 3  |
| POU2F2      | -0.62862 | 2.43E-11 | 6.49E-09 | -6.87264 | Down | POU class 2 homeobox 2<br>BAF chromatin remodeling complex subunit BCL11A                            |
| BCL11A      | -0.69858 | 3.3E-11  | 8.52E-09 | -6.82374 | Down |  |
| CLEC17A     | -0.81849 | 3.72E-11 | 9.42E-09 | -6.80453 | Down | C-type lectin domain containing 17A  |
| ARL4A       | -0.79887 | 3.94E-11 | 9.88E-09 | -6.79545 | Down | ADP ribosylation factor like GTPase 4A   |
| TLCD4-RWDD3 | -0.96826 | 4.03E-11 | 1E-08    | -6.79186 | Down | TLCD4-RWDD3 readthrough  |
| SCARNA21B   | -1.42152 | 4.37E-11 | 1.07E-08 | -6.77868 | Down | small Cajal body-specific RNA 21B  |
| RANBP10     | -0.73457 | 5.18E-11 | 1.22E-08 | -6.75141 | Down | RAN binding protein 10   |
| BMF         | -0.79975 | 6.24E-11 | 1.46E-08 | -6.72111 | Down | Bcl2 modifying factor  |
| CLEC2D      | -0.68117 | 9.34E-11 | 2.09E-08 | -6.65559 | Down | C-type lectin domain family 2 member D class II major histocompatibility complex transactivator      |
| CIITA       | -0.75359 | 1.01E-10 | 2.25E-08 | -6.64292 | Down |  |
| TTN         | -1.14193 | 1.17E-10 | 2.57E-08 | -6.61882 | Down | titin  |
| SLC4A1      | -1.02319 | 1.56E-10 | 3.25E-08 | -6.57166 | Down | solute carrier family 4 member 1 (Diego blood group)<br>V-set and transmembrane domain containing 2A |
| VSTM2A      | -0.78114 | 1.64E-10 | 3.41E-08 | -6.56331 | Down |  |
| FGL2        | -0.65079 | 1.81E-10 | 3.71E-08 | -6.54693 | Down | fibrinogen like 2  |
| RORA        | -0.65858 | 1.96E-10 | 3.99E-08 | -6.53369 | Down | RAR related orphan receptor A  |
| TNFRSF13C   | -0.91687 | 2.97E-10 | 5.64E-08 | -6.46456 | Down | TNF receptor superfamily member 13C  |
| EP400       | -0.66759 | 3.19E-10 | 5.96E-08 | -6.45231 | Down | E1A binding protein p400   |
| PER1        | -0.85447 | 3.87E-10 | 7.05E-08 | -6.42021 | Down | period circadian regulator 1   |
| MPEG1       | -0.67212 | 5.39E-10 | 9.42E-08 | -6.3641  | Down | macrophage expressed 1   |
| MGAT4A      | -0.65772 | 5.49E-10 | 9.55E-08 | -6.36127 | Down | alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase A                             |
| OSBPL10     | -0.76921 | 6.1E-10  | 1.04E-07 | -6.34334 | Down | oxysterol binding protein like 10  |
| SLC2A1      | -1.01788 | 6.65E-10 | 1.13E-07 | -6.32861 | Down | solute carrier family 2 member 1   |
| PLAGL2      | -0.65128 | 7.62E-10 | 1.27E-07 | -6.30558 | Down | PLAG1 like zinc finger 2   |
| WDFY2       | -0.69295 | 7.76E-10 | 1.29E-07 | -6.30233 | Down | WD repeat and FYVE domain containing 2   |
| SLC14A1     | -0.82792 | 7.81E-10 | 1.29E-07 | -6.30132 | Down | solute carrier family 14 member 1 (Kidd blood group)   |
| VIPR1       | -0.76825 | 8.51E-10 | 1.37E-07 | -6.28656 | Down | vasoactive intestinal peptide receptor 1   |

|           |          |          |          |          |      |   |
|-----------|----------|----------|----------|----------|------|---|
| TFRC      | -0.80086 | 8.7E-10  | 1.39E-07 | -6.28281 | Down | transferrin receptor  |
| AGPAT4    | -0.83329 | 9.33E-10 | 1.48E-07 | -6.27089 | Down | 1-acylglycerol-3-phosphate O-acyltransferase 4                  |
| COBLL1    | -0.72259 | 1.01E-09 | 1.59E-07 | -6.25677 | Down | cordon-bleu WH2 repeat protein like 1                           |
| SPOCK2    | -0.89285 | 1.11E-09 | 1.74E-07 | -6.24084 | Down | SPARC (osteonectin), cwcv and kazal like domains proteoglycan 2 |
| FECH      | -0.79692 | 1.35E-09 | 2.03E-07 | -6.20743 | Down | ferrochelatase  |
| HLA-DMB   | -0.71841 | 1.47E-09 | 2.19E-07 | -6.19232 | Down | major histocompatibility complex, class II, DM beta             |
| MXI1      | -0.66288 | 1.67E-09 | 2.43E-07 | -6.17102 | Down | MAX interactor 1, dimerization protein                          |
| TRAK2     | -0.99989 | 1.9E-09  | 2.73E-07 | -6.14798 | Down | trafficking kinesin protein 2                                   |
| TSPAN5    | -0.68028 | 3.29E-09 | 4.34E-07 | -6.05219 | Down | tetraspanin 5   |
| SPTA1     | -1.01751 | 4.06E-09 | 5.21E-07 | -6.01532 | Down | spectrin alpha, erythrocytic 1                                  |
| SCARNA10  | -1.16787 | 4.37E-09 | 5.55E-07 | -6.00252 | Down | small Cajal body-specific RNA 10                                |
| CXCR5     | -0.91719 | 5.95E-09 | 7.25E-07 | -5.9476  | Down | C-X-C motif chemokine receptor 5                                |
| KLK1      | -0.94232 | 6.66E-09 | 8.03E-07 | -5.92739 | Down | kallikrein 1  |
| CTC1      | -0.70188 | 8.37E-09 | 9.87E-07 | -5.88644 | Down | CST telomere replication complex component 1                    |
| ALDH5A1   | -0.71117 | 9.58E-09 | 1.11E-06 | -5.86216 | Down | aldehyde dehydrogenase 5 family member A1                       |
| YIPF4     | -0.68858 | 9.91E-09 | 1.14E-06 | -5.85599 | Down | Yip1 domain family member 4                                     |
| SZT2      | -0.73017 | 1.03E-08 | 1.18E-06 | -5.84867 | Down | SZT2 subunit of KICSTOR complex                                 |
| MIAT      | -0.63403 | 1.18E-08 | 1.33E-06 | -5.82457 | Down | myocardial infarction associated transcript                     |
| LENG8     | -0.63693 | 1.58E-08 | 1.72E-06 | -5.7713  | Down | leukocyte receptor cluster member 8                             |
| SLC7A6    | -0.77445 | 1.83E-08 | 1.94E-06 | -5.74413 | Down | solute carrier family 7 member 6                                |
| PLBD2     | -0.83269 | 1.94E-08 | 2.05E-06 | -5.73332 | Down | phospholipase B domain containing 2                             |
| RPL13A    | -0.62991 | 2.15E-08 | 2.21E-06 | -5.71499 | Down | ribosomal protein L13a  |
| TNFRSF13B | -0.94543 | 2.39E-08 | 2.41E-06 | -5.6953  | Down | TNF receptor superfamily member 13B                             |
| CD22      | -0.67168 | 2.5E-08  | 2.49E-06 | -5.68696 | Down | CD22 molecule   |
| SERINC5   | -0.73923 | 2.52E-08 | 2.5E-06  | -5.6859  | Down | serine incorporator 5   |
| GPRASP1   | -0.81967 | 2.57E-08 | 2.55E-06 | -5.68227 | Down | G protein-coupled receptor associated sorting protein 1         |
| ADA2      | -0.73878 | 2.61E-08 | 2.58E-06 | -5.67885 | Down | adenosine deaminase 2   |
| CCR7      | -0.82793 | 2.73E-08 | 2.68E-06 | -5.67111 | Down | C-C motif chemokine receptor 7                                  |
| SCARNA6   | -0.77803 | 2.88E-08 | 2.81E-06 | -5.66069 | Down | small Cajal body-specific RNA 6                                 |
| CNKSR2    | -0.75294 | 3.18E-08 | 3.06E-06 | -5.64253 | Down | connector enhancer of kinase suppressor of Ras 2                |
| VCAN      | -0.73858 | 3.74E-08 | 3.52E-06 | -5.61242 | Down | versican  |
| SLC24A4   | -0.87802 | 4.35E-08 | 4.03E-06 | -5.58396 | Down | solute carrier family 24 member 4                               |
| LINC00926 | -0.87511 | 4.52E-08 | 4.17E-06 | -5.57692 | Down | long intergenic non-protein coding RNA 926                      |
| ACSL6     | -0.82878 | 4.81E-08 | 4.39E-06 | -5.56537 | Down | acyl-CoA synthetase long chain family member 6                  |
| TTC14     | -0.89136 | 4.84E-08 | 4.41E-06 | -5.5642  | Down | tetratricopeptide repeat domain 14                              |
| FCRL1     | -0.86187 | 5.34E-08 | 4.82E-06 | -5.54543 | Down | Fc receptor like 1  |
| SLC25A39  | -0.68018 | 5.46E-08 | 4.91E-06 | -5.54135 | Down | solute carrier family 25 member 39                              |
| LY9       | -0.76456 | 5.66E-08 | 5.08E-06 | -5.53456 | Down | lymphocyte antigen 9  |
| GOLGA8A   | -0.83441 | 7.01E-08 | 6.08E-06 | -5.49414 | Down | golgin A8 family member A                                       |
| ATP2B1    | -0.62628 | 7.37E-08 | 6.37E-06 | -5.48451 | Down | ATPase plasma membrane Ca <sup>2+</sup> transporting 1          |

|           |          |          |          |          |      |  |
|-----------|----------|----------|----------|----------|------|--|
| PWAR5     | -0.75691 | 8.03E-08 | 6.79E-06 | -5.46817 | Down | PraderWilli/Angelman region RNA 5  |
| MRC2      | -0.81976 | 9.06E-08 | 7.63E-06 | -5.44524 | Down | mannose receptor C type 2  |
| SPIB      | -0.63152 | 9.37E-08 | 7.82E-06 | -5.43865 | Down | Spi-B transcription factor   |
| GRINA     | -0.65332 | 1.01E-07 | 8.28E-06 | -5.42515 | Down | glutamate ionotropic receptor NMDA type subunit associated protein 1                         |
| LRP1      | -0.84115 | 1.01E-07 | 8.28E-06 | -5.42512 | Down | LDL receptor related protein 1   |
| ADAM28    | -0.81306 | 1.11E-07 | 9.02E-06 | -5.40656 | Down | ADAM metallopeptidase domain 28  |
| TRABD2A   | -0.7573  | 1.16E-07 | 9.42E-06 | -5.39715 | Down | TraB domain containing 2A piezo type mechanosensitive ion channel component 1                |
| PIEZO1    | -0.74385 | 1.17E-07 | 9.44E-06 | -5.39644 | Down |  |
| ADAM19    | -0.68425 | 1.47E-07 | 1.15E-05 | -5.35189 | Down | ADAM metallopeptidase domain 19 poly(ADP-ribose) polymerase family member 15                 |
| PARP15    | -0.71333 | 2.02E-07 | 1.5E-05  | -5.29026 | Down |  |
| CD27      | -0.71993 | 2.07E-07 | 1.53E-05 | -5.28562 | Down | CD27 molecule  |
| NELL2     | -0.67846 | 2.21E-07 | 1.62E-05 | -5.27231 | Down | neural EGFL like 2   |
| CD79A     | -0.74535 | 2.38E-07 | 1.73E-05 | -5.2578  | Down | CD79a molecule   |
| ANKRD52   | -0.63287 | 2.6E-07  | 1.87E-05 | -5.24037 | Down | ankyrin repeat domain 52   |
| DNHD1     | -0.7211  | 2.8E-07  | 1.98E-05 | -5.22571 | Down | dynein heavy chain domain 1  |
| NEURL1    | -0.74572 | 2.93E-07 | 2.06E-05 | -5.21673 | Down | neuralized E3 ubiquitin protein ligase 1 CREB regulated transcription coactivator 1          |
| CRTC1     | -0.68306 | 3.27E-07 | 2.25E-05 | -5.1949  | Down |  |
| GOLGA8B   | -0.84973 | 3.8E-07  | 2.56E-05 | -5.16529 | Down | golgin A8 family member B  |
| ZNF860    | -0.72407 | 3.83E-07 | 2.58E-05 | -5.16356 | Down | zinc finger protein 860  |
| P2RX5     | -0.67155 | 3.84E-07 | 2.58E-05 | -5.16328 | Down | purinergic receptor P2X 5  |
| BTLA      | -0.73832 | 3.96E-07 | 2.65E-05 | -5.15708 | Down | B and T lymphocyte associated obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF |
| OBSCN     | -0.80054 | 4.42E-07 | 2.91E-05 | -5.13505 | Down | semaphorin 7A (John Milton Hagen blood group)  |
| SEMA7A    | -0.6976  | 4.47E-07 | 2.94E-05 | -5.13259 | Down |  |
| IFFO1     | -0.65589 | 4.96E-07 | 3.2E-05  | -5.11184 | Down | intermediate filament family orphan 1  |
| SLC38A5   | -0.75551 | 5.64E-07 | 3.56E-05 | -5.0858  | Down | solute carrier family 38 member 5 long intergenic non-protein coding RNA 2273                |
| LINC02273 | -0.70556 | 5.67E-07 | 3.57E-05 | -5.08477 | Down |  |
| DNAH1     | -0.7411  | 6.47E-07 | 4.02E-05 | -5.05819 | Down | dynein axonemal heavy chain 1  |
| NEU3      | -0.70715 | 7.2E-07  | 4.4E-05  | -5.03638 | Down | neuraminidase 3  |
| POLM      | -0.67693 | 7.44E-07 | 4.53E-05 | -5.02954 | Down | DNA polymerase mu  |
| RPS6KA5   | -0.67198 | 8.28E-07 | 4.96E-05 | -5.00771 | Down | ribosomal protein S6 kinase A5   |
| PDE3B     | -0.68318 | 8.73E-07 | 5.17E-05 | -4.99695 | Down | phosphodiesterase 3B   |
| COL7A1    | -0.7674  | 9.21E-07 | 5.42E-05 | -4.98585 | Down | collagen type VII alpha 1 chain  |
| HEPACAM2  | -0.65213 | 1.02E-06 | 5.93E-05 | -4.96469 | Down | HEPACAM family member 2 cadherin EGF LAG seven-pass G-type receptor 1                        |
| CELSR1    | -0.64047 | 1.12E-06 | 6.39E-05 | -4.94638 | Down | zinc finger and BTB domain containing 39   |
| ZBTB39    | -0.67388 | 1.13E-06 | 6.46E-05 | -4.94372 | Down |  |
| MOB3B     | -0.68472 | 1.25E-06 | 7.03E-05 | -4.92272 | Down | MOB kinase activator 3B  |
| RHAG      | -0.8349  | 1.26E-06 | 7.06E-05 | -4.92115 | Down | Rh associated glycoprotein   |
| CR1       | -0.65192 | 1.32E-06 | 7.32E-05 | -4.91176 | Down | complement C3b/C4b receptor 1 (Knops blood group)  |
| DBP       | -0.65426 | 1.38E-06 | 7.62E-05 | -4.90202 | Down | D-box binding PAR bZIP transcription factor  |
| TUBGCP6   | -0.66735 | 1.55E-06 | 8.4E-05  | -4.8776  | Down | tubulin gamma complex associated protein 6   |

|           |          |          |          |          |      |  |
|-----------|----------|----------|----------|----------|------|--|
| ZNF549    | -0.69296 | 1.59E-06 | 8.58E-05 | -4.87232 | Down | zinc finger protein 549  |
| CSF1R     | -0.63553 | 1.62E-06 | 8.71E-05 | -4.86868 | Down | colony stimulating factor 1 receptor                           |
| EPB42     | -0.87201 | 1.73E-06 | 9.24E-05 | -4.85526 | Down | erythrocyte membrane protein band 4.2                          |
| SCARNA7   | -0.63099 | 1.87E-06 | 9.88E-05 | -4.83874 | Down | small Cajal body-specific RNA 7                                |
| GNG7      | -0.66304 | 1.98E-06 | 0.000104 | -4.82656 | Down | G protein subunit gamma 7                                      |
| ZNF589    | -0.63146 | 2E-06    | 0.000105 | -4.82428 | Down | zinc finger protein 589  |
| GCNT2     | -0.69581 | 2.01E-06 | 0.000105 | -4.82357 | Down | glucosaminyl (N-acetyl) transferase 2 (I blood group)          |
| GPR146    | -0.72697 | 2.04E-06 | 0.000106 | -4.82048 | Down | G protein-coupled receptor 146                                 |
| QSOX2     | -0.66298 | 2.14E-06 | 0.000109 | -4.8106  | Down | quiescin sulphydryl oxidase 2                                  |
| SNORA53   | -0.92118 | 2.21E-06 | 0.000113 | -4.80308 | Down | small nucleolar RNA, H/ACA box 53                              |
| SCARNA13  | -0.77859 | 2.26E-06 | 0.000115 | -4.79894 | Down | small Cajal body-specific RNA 13                               |
| ITGB2-AS1 | -0.62011 | 3.09E-06 | 0.000151 | -4.73185 | Down | ITGB2 antisense RNA 1  |
| ESPN      | -0.78256 | 3.11E-06 | 0.000152 | -4.73085 | Down | espin  |
| NEAT1     | -0.72879 | 3.35E-06 | 0.000162 | -4.71479 | Down | nuclear paraspeckle assembly transcript 1                      |
| FHDC1     | -0.93149 | 3.52E-06 | 0.000169 | -4.70423 | Down | FH2 domain containing 1  |
| ZC3H12D   | -0.64158 | 3.53E-06 | 0.000169 | -4.70345 | Down | zinc finger CCCH-type containing 12D                           |
| ABCD2     | -0.6691  | 3.76E-06 | 0.000178 | -4.6898  | Down | ATP binding cassette subfamily D member 2                      |
| MCOLN1    | -0.69108 | 3.83E-06 | 0.000181 | -4.68576 | Down | mucolipin 1  |
| NR4A1     | -0.64016 | 4.23E-06 | 0.000196 | -4.66458 | Down | nuclear receptor subfamily 4 group A member 1                  |
| SLC25A42  | -0.63249 | 4.54E-06 | 0.000209 | -4.64904 | Down | solute carrier family 25 member 42                             |
| GYPA      | -0.73764 | 5.3E-06  | 0.000239 | -4.61504 | Down | glycophorin A (MNS blood group)                                |
| SCARNA2   | -0.67524 | 6.79E-06 | 0.000297 | -4.5607  | Down | small Cajal body-specific RNA 2                                |
| FAM167A   | -0.65735 | 7.44E-06 | 0.000319 | -4.54065 | Down | family with sequence similarity 167 member A                   |
| ALDH6A1   | -0.6308  | 8.11E-06 | 0.000345 | -4.52128 | Down | aldehyde dehydrogenase 6 family member A1                      |
| CD4       | -0.62279 | 8.14E-06 | 0.000345 | -4.52057 | Down | CD4 molecule   |
| ABCA2     | -0.6866  | 9.04E-06 | 0.000378 | -4.49716 | Down | ATP binding cassette subfamily A member 2                      |
| BEND4     | -0.64725 | 9.32E-06 | 0.000388 | -4.49036 | Down | BEN domain containing 4  |
| CENPF     | -0.7335  | 1.03E-05 | 0.000422 | -4.46818 | Down | centromere protein F   |
| CD6       | -0.65075 | 1.03E-05 | 0.000423 | -4.46737 | Down | CD6 molecule   |
| KLHL3     | -0.63143 | 1.15E-05 | 0.000465 | -4.44229 | Down | kelch like family member 3                                     |
| GYPB      | -0.73759 | 1.45E-05 | 0.00056  | -4.39099 | Down | glycophorin B (MNS blood group)                                |
| ABCC13    | -0.70835 | 1.46E-05 | 0.000566 | -4.38865 | Down | ATP binding cassette subfamily C member 13 (pseudogene)        |
| ATP13A1   | -0.61946 | 1.58E-05 | 0.000606 | -4.3702  | Down | ATPase 13A1  |
| MYO15B    | -0.6612  | 1.65E-05 | 0.000624 | -4.36062 | Down | myosin XVb   |
| CD5       | -0.65427 | 1.89E-05 | 0.000697 | -4.32962 | Down | CD5 molecule   |
| DUSP2     | -0.64467 | 1.91E-05 | 0.000702 | -4.32778 | Down | dual specificity phosphatase 2                                 |
| SCML4     | -0.63141 | 1.91E-05 | 0.000702 | -4.32734 | Down | Scmpolycomb group protein like 4                               |
| PIK3IP1   | -0.62444 | 3.82E-05 | 0.001247 | -4.16463 | Down | phosphoinositide-3-kinase interacting protein 1                |
| ALAS2     | -0.66726 | 5.72E-05 | 0.001735 | -4.06777 | Down | 5'-aminolevulinatase synthase 2                                |
| RMRP      | -0.64882 | 8.71E-05 | 0.002461 | -3.96458 | Down | RNA component of mitochondrial RNA processing endoribonuclease |
| RNF182    | -0.84789 | 0.000111 | 0.00298  | -3.90357 | Down | ring finger protein 182  |

|           |          |          |          |          |      |   |
|-----------|----------|----------|----------|----------|------|---|
| RNA5-8SN2 | -1.28453 | 0.000116 | 0.003077 | -3.89329 | Down | RNA, 5.8S ribosomal N2                      |
| SELENBP1  | -0.63971 | 0.000122 | 0.003212 | -3.87967 | Down | selenium binding protein 1                  |
| LINC01857 | -0.67006 | 0.000136 | 0.003506 | -3.85285 | Down | long intergenic non-protein coding RNA 1857 |
| SCARNA5   | -0.67276 | 0.00026  | 0.005928 | -3.68493 | Down | small Cajal body-specific RNA 5             |
| HBM       | -0.66252 | 0.001557 | 0.024934 | -3.18581 | Down | hemoglobin subunit mu                       |
| TUBB1     | -0.63203 | 0.002292 | 0.033535 | -3.06938 | Down | tubulin beta 1 class VI                     |

**Table 3** The enriched GO terms of the up and down regulated differentially expressed genes

| GO ID                     | CATEGORY | GO Name              | P Value  | FDR B&H  | FDR B&Y  | Bonferroni | Gene Count | Gene  |
|---------------------------|----------|----------------------|----------|----------|----------|------------|------------|---|
| <b>Up regulated genes</b> |          |                      |          |          |          |            |            |   |
| GO:0016050                | BP       | vesicle organization | 3.92E-07 | 8.10E-04 | 7.19E-03 | 1.58E-03   | 40         | LAPTM4B,CEACAM6,PTGER3,DEFA1,MAGI2,SERPINE2,GLA,PTPRN,HP,VNN1,SPHK1,FGA,FGB,HRG,PLA2G4A,LOXL3,FGG,RAB32,WASF1,VEGFC,UNC13B,PGLYRP1,SEPTIN4,ANXA3,GRK4,APOA2,APOB,LCN2,APOH,DERA,SCARF1,TGFB3,ORM1,TIMP1,MS4A3,CYSTM1,CD63,ERC2,CD151,MCEMP1 |
| GO:0046903                | BP       | secretion            | 5.39E-06 | 1.17E-03 | 1.04E-02 | 2.18E-02   | 38         | MYOM1,MAOB,CEACAM6,MDK,PTGER3,DEFA1,SERPINE2,GLA,PTPRN,HP,VNN1,SPHK1,FGA,FGB,HRG,PLA2G4A,FGG,FKBP1B,VEGFC,UNC13B,PGLYRP1,SEPTIN4,ANXA3,ICA1,APOA2,LCN2,APOH,DERA,ARG2,TGFB3,ORM1,OXTR,TIMP1,MS4A3,CYSTM1,CD63,ERC2,MCEMP1                   |
| GO:0099503                | CC       | secretory vesicle    | 1.01E-08 | 4.90E-06 | 3.31E-05 | 4.90E-06   | 32         | CEACAM6,DEFA1,SERPINE2,GLA,PTPRN,HP,VNN1,SPHK1,FGA,FGB,HRG,PLA2G4A,FGG,VEGFC,UNC13B,PGLYRP1,SEPTIN4,ANXA3,ICA1,RABAC1,LCN2,APOH,DERA,TGFB3,MAL2,O   |

|                             |    |                               |          |          |          |          |    |   |
|-----------------------------|----|-------------------------------|----------|----------|----------|----------|----|---|
| GO:0098805                  | CC | whole membrane                | 2.77E-03 | 3.64E-02 | 2.47E-01 | 1.00E+00 | 29 | RM1,TIMP1,MS4A3, CYSTM1,CD63,SMP D1,MCEMP1 TSPAN15,MAOB,LA PTM4B,CEACAM6,F UNDC1,PTPRN,MAP 1LC3B2,VNN1,SPHK 1,GOLIM4,HRG,RAB 32,WASF1,UNC13B,S EPTIN4,ANXA3,ICA1 ,TOM1L1,AP1M2,GR B14,APOB,RET,SCA RF1,MAL2,MS4A3,C YSTM1,CD63,CTNS, MCEMP1               |
| GO:0046983                  | MF | protein dimerization activity | 4.40E-04 | 9.54E-02 | 6.73E-01 | 2.86E-01 | 30 | TPM1,TPM2,PADI4, MYOM1,MAOB,TRP C6,ACOT7,CEACAM 6,ARNTL2,PRTFDC1, TYMS,H2AC13,H2BC 17,GLA,HP,H4C14,MI TF,PKD2,FGG,H2BC 11,TPST1,SEPTIN4,I CA1,H4C15,GRB14,E 2F1,APOA2,LCN2,TG FB3,H2AJ  |
| GO:0005102                  | MF | signaling receptor binding    | 4.71E-03 | 2.10E-01 | 1.00E+00 | 1.00E+00 | 30 | MDK,MTRNR2L2,M AGI2,SERPINE2,GLA ,PKD2,FGA,FGB,HR G,FGG,FHL2,FKBP1 B,VEGFC,PROK2,PG LYRP1,CMTM2,GRB 14,LAMB2,APOA2,A POB,ADAMTS5,CXC L3,ADAM22,CCNB1, TGFB11I,TGFB3,BC AP31,IGFBP2,TIMP1, CD151   |
| <b>Down regulated genes</b> |    |                               |          |          |          |          |    |   |
| GO:0046649                  | BP | lymphocyte activation         | 1.37E-15 | 5.40E-12 | 4.78E-11 | 5.40E-12 | 40 | HLA-DMB,HLA-DPA1,SPTA1,BCL11 A,ITGA4,FGL2,CXC R5,FCRL1,PTPRC,ZC 3H12D,FBXO7,CCR7, NOTCH2,TCF7,IKZF 3,POLM,CAMK4,PO U2F2,BTLA,CR1,CBL B,SLC4A1,TFRC,BCL 11B,CD4,CD5,CD6,M S4A1,CD22,CD27,CD 44,TNFRSF13C,TNFR SF13B,CD79A,RORA, ATM,LY9,LEF1,IL7R, NCKAP1L |
| GO:0010941                  | BP | regulation of cell death      | 9.53E-05 | 6.03E-03 | 5.34E-02 | 3.75E-01 | 40 | STK17B,OBSCN,ITG A4,NR4A1,STRADB, BNIP3L,PTPRC,BTG1 ,TMC8,FBXO7,PLAG L2,CCR7,NOTCH2,T CF7,IKZF3,OGT,CA MK1D,BMF,NLRP1, GRINA,OPA1,EEF1A 1,TXNIP,BCL11B,IGF 2R,CSF1R,CD27,NEU RL1,CD44,LRP1,AT M,HBA1,HBA2,HBB, CTSB,LEF1,RPL10,IL 7R,SORL1,NCKAP1L        |
| GO:0009986                  | CC | cell surface                  | 2.02E-09 | 3.10E-07 | 2.08E-06 | 9.30E-07 | 35 | ADAM19,HLA-DPA1,HLA-  |

|            |    |   |          |          |          |          |    |   |
|------------|----|---|----------|----------|----------|----------|----|---|
| GO:0031226 | CC | intrinsic component of plasma membrane                          | 5.35E-07 | 4.11E-05 | 2.76E-04 | 2.47E-04 | 43 | DRA,ITGA4,CXCR5, FCRL1,PTPRC,CIITA ,MRC2,CCR7,NOTCH 2,SEMA7A,BTLA,CR 1,SLC4A1,TFRC,CD4, CD5,IGF2R,CD6,CSF 1R,MS4A1,CLEC17A, CD22,CD27,GYPA,V CAN,CD44,CLEC2D, TNFRSF13C,TNFRSF 13B,CD79A,LY9,CTS B,IL7R   |
| GO:0016772 | MF | transferase activity, transferring phosphorus-containing groups | 9.72E-04 | 4.32E-02 | 3.09E-01 | 6.92E-01 | 35 | HLA-DPA1,HLA-DRA,SPTA1,SLC38A 5,ITGA4,SLC38A1,C XCR5,PTPRC,SLC24 A4,TMC8,NOTCH2,V IPR1,TRABD2A,SEM A7A,BTLA,SLC7A6, CR1,MCOLN1,SLC2 A1,TSPAN5,RHAG,S LC4A1,TFRC,CELSR 1,CD4,CD5,IGF2R,CD 6,CSF1R,P2RX5,MS4 A1,SLC14A1,CD22,C D27,GYPA,GYPB,CD 44,CLEC2D,LRP1,TN FRSF13B,ATP2B1,SO RLI,NCKAP1L |
| GO:0008144 | MF | drug binding  | 1.15E-02 | 1.55E-01 | 1.00E+00 | 1.00E+00 | 30 | ZBTB20,RPS6KA5,ST K17B,OBSCN,TENT5 C,TTN,PIK3IP1,BLK, STRADB,PTPRC,CIIT A,FBXO7,CCR7,DYR K2,OGT,CAMK1D,C TC1,POLM,CAMK4, DUSP2,AAK1,CBLB, SLC4A1,EEF1A1,RM RP,CD4,IGF2R,CSF1 R,NEURL1,CD44,LR P1,ATM,SERINC5,SO RLI,NCKAP1L   |
|            |    |   |          |          |          |          |    | ABCA2,RPS6KA5,ST K17B,OBSCN,TTN,B LK,STRADB,CIITA,A LAS2,ABCD2,DYRK 2,DNHD1,ACSL6,CA MK1D,EP400,ATP13 A1,CAMK4,AAK1,N LRP1,EEF1A1,DNAH 1,CSF1R,P2RX5,ATM ,HBA1,HBA2,HBM,H BB,ATP2B1,EPB42   |

Biological Process(BP), Cellular Component(CC) and Molecular Functions (MF)

**Table 4** The enriched pathway terms of the up and down regulated differentially expressed genes

| Pathway ID                | Pathway Name | P-value  | FDR B&H  | FDR B&Y  | Bonferroni | Gene Count | Gene  |
|---------------------------|--------------|----------|----------|----------|------------|------------|---|
| <b>Up regulated genes</b> |              |          |          |          |            |            |   |
| 1269340                   | Hemostasis   | 4.28E-06 | 7.47E-04 | 5.11E-03 | 2.24E-03   | 22         | GNG8,TRPC6,CEACAM 6,CABLES1,SERPINE2, FGA,KCNMB1,FGB,HR G,PLA2G4A,MMP1,FG G,VEGFC,GRB14,APOB ,APOH,ZFPM2,TGFB3, |

|                             |  |          |          |          |          |    |   |
|-----------------------------|--|----------|----------|----------|----------|----|---|
| 1269741                     | Cell Cycle                                 | 8.91E-04 | 2.12E-02 | 1.45E-01 | 4.67E-01 | 17 | ORM1,TIMP1,CD63,PRKAR1B<br>CETN2,MND1,MCM10,GINS1,TYMS,H2BC17,H4C14,BUB1,H2BC11,UBE2C,H4C15,CENPU,E2F1,CCNB1,DMC1,CENPI,H2AJ    |
| 1269507                     | Signaling by Rho GTPases                   | 1.14E-02 | 8.42E-02 | 5.76E-01 | 1.00E+00 | 11 | PPP1R14A,TAX1BP3,H2BC17,H4C14,BUB1,WASF1,H2BC11,H4C15,CENPU,CENPI,H2AJ  |
| 1269203                     | Innate Immune System                       | 7.89E-02 | 2.91E-01 | 1.00E+00 | 1.00E+00 | 21 | CEACAM6,DEFA1,GLA,HP,VNN1,FGA,FGB,FGG,WASF1,PGLYRP1,APOB,RET,LCN2,POLR3G,DERA,ORM1,MS4A3,CYSTM1,CD63,PRKAR1B,MCEMP1             |
| 1270001                     | Metabolism of lipids and lipoproteins      | 1.52E-01 | 3.82E-01 | 1.00E+00 | 1.00E+00 | 13 | ACER2,ACOT7,ME1,GLA,SPHK1,PLA2G4A,FHL2,PLAAT1,G0S2,THEM5,APOA2,APOB,SMPD1   |
| 1268677                     | Metabolism of proteins                     | 3.37E-01 | 5.01E-01 | 1.00E+00 | 1.00E+00 | 21 | GNG8,CETN2,FN3K,H2AC13,H2BC17,VNN1,SPHK1,H4C14,MITF,FGA,MMP1,RAB32,METTL2,DYNC1H1,H2BC11,ADAMTS1,UBE2C,H4C15,ADAMTS5,IGFBP2,AOP |
| <b>Down regulated genes</b> |  |          |          |          |          |    |   |
| 1269171                     | Adaptive Immune System                     | 1.59E-03 | 8.64E-02 | 5.87E-01 | 7.96E-01 | 20 | HLA-DMB,HLA-DPA1,HLA-DRA,TNRC6B,ITGA4,NR4A1,BLK,KLHL3,PTPRC,MRC2,FBXO7,RNF213,BTLA,CBLB,CD4,CD22,CLEC2D,CD79A,CTSB,RNF182       |
| 1269903                     | Transmembrane transport of small molecules | 1.39E-02 | 1.95E-01 | 1.00E+00 | 1.00E+00 | 15 | ABCA2,SLC38A5,SLC38A1,SLC24A4,ABCD2,GNNG7,ATP13A1,SLC7A6,MCOLN1,SLC2A1,RHAG,SLC4A1,TFRC,SLC14A1,ATP2B1                          |
| 1269203                     | Innate Immune System                       | 8.82E-02 | 4.76E-01 | 1.00E+00 | 1.00E+00 | 21 | RPS6KA5,SPTA1,TNRC6B,NR4A1,ADA2,FGL2,PTPRC,CAMK4,DUSP2,NLRP1,CNKSR2,CR1,EEF1A1,TXNIP,EEF2,CD4,IGF2R,CD44,HBB,CTSB,NCKAP1L       |
| 1269876                     | Vesicle-mediated transport                 | 1.54E-01 | 5.50E-01 | 1.00E+00 | 1.00E+00 | 11 | SPTA1,SEC16A,COL7A1,AAK1,TFRC,CD4,IGF2R,LRP1,HBA1,HBA2,HBB  |
| 1268854                     | Disease                                    | 3.21E-01 | 6.43E-01 | 1.00E+00 | 1.00E+00 | 12 | RPL23A,RPL27A,RPL37,NR4A1,NOTCH2,CNKSR2,EEF2,CD4,VCAN,NEURL1,RPL13A,RPL10   |
| 1268677                     | Metabolism of proteins                     | 5.53E-01 | 7.60E-01 | 1.00E+00 | 1.00E+00 | 19 | RPL23A,RPL27A,RPL37,SPTA1,MGAT4A,NEU3,ADA2,TUBB1,YOD1,SEC16A,GNG7,KLK1,COL7A1,OGT,EEF1A1,EEF2,RPL13A,RPL10,SORL1                |



**Table 5** Topology table for up and down regulated genes.

| Regulation | Node     | Degree | Betweenness | Stress   | Closeness |
|------------|----------|--------|-------------|----------|-----------|
| Up         | EZH2     | 350    | 0.076224    | 81130962 | 0.349924  |
| Up         | DBN1     | 256    | 0.049032    | 39941040 | 0.348151  |
| Up         | CCNB1    | 158    | 0.024471    | 43653864 | 0.313488  |
| Up         | FHL2     | 158    | 0.031673    | 16397718 | 0.336762  |
| Up         | E2F1     | 151    | 0.025971    | 16601668 | 0.333208  |
| Up         | TPM1     | 134    | 0.022043    | 16976362 | 0.329604  |
| Up         | KRT18    | 132    | 0.018793    | 17362522 | 0.338383  |
| Up         | TPM2     | 126    | 0.021531    | 17717608 | 0.323503  |
| Up         | FGB      | 115    | 0.021143    | 15804232 | 0.298889  |
| Up         | PTGER3   | 113    | 0.019531    | 25585198 | 0.284342  |
| Up         | SPINT2   | 108    | 0.023415    | 14310762 | 0.303448  |
| Up         | BUB1     | 102    | 0.018982    | 9083534  | 0.319527  |
| Up         | PTPRN    | 93     | 0.015139    | 21217898 | 0.283912  |
| Up         | BCAP31   | 91     | 0.017733    | 11925460 | 0.323825  |
| Up         | MAP1B    | 91     | 0.011535    | 22589676 | 0.310858  |
| Up         | KRT8     | 79     | 0.009251    | 9231600  | 0.332081  |
| Up         | TMEM67   | 76     | 0.014065    | 4982016  | 0.290838  |
| Up         | RABAC1   | 74     | 0.013172    | 9708740  | 0.293098  |
| Up         | APOB     | 72     | 0.011818    | 15182272 | 0.302587  |
| Up         | UBE2C    | 69     | 0.00877     | 8892764  | 0.298716  |
| Up         | SPHK1    | 68     | 0.011494    | 4951244  | 0.325666  |
| Up         | TOM1L1   | 66     | 0.00895     | 6727694  | 0.305124  |
| Up         | RET      | 66     | 0.009723    | 10964184 | 0.305199  |
| Up         | WASF1    | 65     | 0.010329    | 14175172 | 0.29873   |
| Up         | KRT19    | 64     | 0.008418    | 5490710  | 0.32224   |
| Up         | CENPU    | 61     | 0.011081    | 3633098  | 0.296468  |
| Up         | DTL      | 61     | 0.006526    | 9721978  | 0.297152  |
| Up         | CETN2    | 60     | 0.009249    | 16418248 | 0.269586  |
| Up         | MCM10    | 59     | 0.007694    | 9107150  | 0.300602  |
| Up         | DYNC11I  | 58     | 0.007347    | 6841812  | 0.299279  |
| Up         | PLA2G4A  | 57     | 0.006497    | 7102868  | 0.307673  |
| Up         | TYMS     | 55     | 0.008254    | 2898568  | 0.306378  |
| Up         | MDK      | 54     | 0.007633    | 2641060  | 0.307322  |
| Up         | GOLIM4   | 45     | 0.009056    | 6535396  | 0.299091  |
| Up         | TGFB11I  | 43     | 0.00576     | 2542056  | 0.317363  |
| Up         | PKD2     | 42     | 0.006903    | 2134988  | 0.290538  |
| Up         | FGA      | 41     | 0.004439    | 1801264  | 0.293153  |
| Up         | PRKAR1B  | 41     | 0.004763    | 4851900  | 0.299424  |
| Up         | ACOT7    | 39     | 0.00511     | 6777086  | 0.287968  |
| Up         | FGG      | 37     | 0.002736    | 1188570  | 0.282125  |
| Up         | AP1M2    | 37     | 0.007088    | 9431672  | 0.281894  |
| Up         | MITF     | 36     | 0.006067    | 5049390  | 0.308118  |
| Up         | SMYD3    | 35     | 0.006122    | 1971838  | 0.303776  |
| Up         | ACTR3B   | 35     | 0.002767    | 5762182  | 0.273907  |
| Up         | CTPS2    | 34     | 0.004516    | 1656234  | 0.297352  |
| Up         | HP       | 33     | 0.004002    | 2476788  | 0.299743  |
| Up         | MYL6B    | 33     | 0.001721    | 1494552  | 0.303835  |
| Up         | LAMB2    | 33     | 0.003266    | 3787290  | 0.283015  |
| Up         | ME1      | 32     | 0.00497     | 5458746  | 0.266142  |
| Up         | FKBP1B   | 31     | 0.002492    | 3149134  | 0.263535  |
| Up         | EAF2     | 31     | 0.003666    | 3614748  | 0.273181  |
| Up         | CD63     | 30     | 0.002963    | 1542292  | 0.278807  |
| Up         | TMEFF1   | 29     | 0.004306    | 1459454  | 0.277382  |
| Up         | PHACTR3  | 29     | 0.003235    | 6793662  | 0.273205  |
| Up         | MMP1     | 28     | 0.004131    | 1062610  | 0.285972  |
| Up         | RAB32    | 28     | 0.004125    | 3089688  | 0.273326  |
| Up         | NT5DC2   | 27     | 0.003149    | 4016356  | 0.290497  |
| Up         | LAPTM4B  | 26     | 0.003861    | 1308630  | 0.280985  |
| Up         | LCN2     | 26     | 0.003047    | 3293226  | 0.261121  |
| Up         | GRB14    | 26     | 0.001737    | 2102726  | 0.272171  |
| Up         | PRTFDC1  | 26     | 0.003559    | 2778424  | 0.248364  |
| Up         | SERPINE2 | 25     | 0.003606    | 2767974  | 0.266199  |
| Up         | APOA2    | 24     | 0.003639    | 1777538  | 0.282035  |
| Up         | CNN1     | 24     | 0.002696    | 1398988  | 0.281984  |

|      |           |     |          |          |          |
|------|-----------|-----|----------|----------|----------|
| Up   | MAGI2     | 24  | 0.003636 | 4072986  | 0.273277 |
| Up   | PADI4     | 24  | 0.001853 | 2786250  | 0.285457 |
| Up   | ARNTL2    | 23  | 0.004537 | 2736046  | 0.276156 |
| Up   | MAL2      | 23  | 0.004035 | 3057928  | 0.266555 |
| Up   | TAX1BP3   | 22  | 0.00296  | 2483404  | 0.27773  |
| Up   | APOH      | 22  | 0.002261 | 1011952  | 0.294759 |
| Up   | GLA       | 22  | 0.002185 | 2812520  | 0.25131  |
| Up   | KRT7      | 22  | 0.002247 | 3354252  | 0.283132 |
| Up   | ROBO1     | 22  | 0.002997 | 2829202  | 0.285181 |
| Up   | ADAMTS1   | 21  | 0.003523 | 2991386  | 0.249044 |
| Up   | OXTR      | 21  | 0.003005 | 1885024  | 0.254274 |
| Up   | ADAM32    | 21  | 0.002751 | 2226220  | 0.244362 |
| Up   | TSPAN15   | 20  | 0.002903 | 1636154  | 0.248684 |
| Up   | DMC1      | 20  | 0.001518 | 1667540  | 0.255218 |
| Up   | EPDR1     | 20  | 0.00263  | 955076   | 0.289735 |
| Up   | LACTB2    | 20  | 0.003285 | 3861294  | 0.241888 |
| Up   | UNC13B    | 19  | 0.003409 | 6715552  | 0.228252 |
| Up   | ERC2      | 19  | 0.002956 | 2368572  | 0.246592 |
| Up   | HRG       | 19  | 0.002437 | 1023636  | 0.273991 |
| Up   | SMPD1     | 19  | 0.00236  | 2063048  | 0.275125 |
| Up   | ZFPM2     | 19  | 0.001198 | 1822000  | 0.266153 |
| Up   | METTL22   | 19  | 0.001598 | 2257038  | 0.269023 |
| Up   | ORM1      | 18  | 0.001349 | 1072266  | 0.255461 |
| Up   | ZC3HAV1L  | 18  | 0.001054 | 1624786  | 0.281202 |
| Up   | STAC      | 18  | 0.001798 | 2388538  | 0.275578 |
| Up   | POLR3G    | 17  | 0.003237 | 9664174  | 0.229055 |
| Up   | DDAH1     | 17  | 0.003704 | 1699018  | 0.290824 |
| Up   | TIMP1     | 17  | 0.002047 | 1211820  | 0.264888 |
| Up   | DERA      | 17  | 0.001512 | 1709944  | 0.240983 |
| Up   | TGFB3     | 16  | 0.001732 | 1135010  | 0.26056  |
| Up   | ANXA3     | 16  | 0.002306 | 3218636  | 0.263928 |
| Up   | ETV4      | 16  | 0.00158  | 1430402  | 0.286767 |
| Up   | RND3      | 16  | 0.001618 | 1798784  | 0.267963 |
| Up   | FUNDC1    | 16  | 0.001881 | 5031262  | 0.246033 |
| Up   | PPP1R14A  | 16  | 0.001348 | 1468196  | 0.269398 |
| Up   | ADAM22    | 16  | 9.66E-04 | 1467492  | 0.278092 |
| Up   | TRHDE     | 16  | 0.002417 | 2718244  | 0.265571 |
| Up   | AOPEP     | 15  | 5.09E-04 | 455628   | 0.281778 |
| Up   | LOXL3     | 15  | 0.002245 | 2647672  | 0.272735 |
| Up   | TST       | 15  | 0.002644 | 2760934  | 0.24058  |
| Up   | CENPI     | 15  | 6.90E-04 | 213372   | 0.26143  |
| Up   | TRPC6     | 15  | 0.002982 | 3195972  | 0.236597 |
| Up   | MSANTD3   | 14  | 0.001423 | 599870   | 0.282602 |
| Up   | DCBLD2    | 14  | 0.001863 | 1414006  | 0.280806 |
| Up   | ICA1      | 14  | 0.001837 | 1818980  | 0.253566 |
| Up   | CABLES1   | 14  | 4.42E-04 | 448806   | 0.275222 |
| Up   | GTF3C6    | 13  | 0.001446 | 393772   | 0.300413 |
| Up   | AVEN      | 13  | 7.46E-04 | 364352   | 0.294788 |
| Up   | PBLD      | 13  | 0.001491 | 1062854  | 0.235839 |
| Up   | CD151     | 13  | 0.001883 | 1879220  | 0.264662 |
| Up   | YIF1B     | 13  | 0.001267 | 1419634  | 0.263917 |
| Up   | C5orf30   | 13  | 0.001783 | 1452154  | 0.265582 |
| Up   | FRMD3     | 11  | 8.55E-04 | 686546   | 0.235579 |
| Up   | FAH       | 11  | 0.001509 | 1294972  | 0.259587 |
| Up   | HTATIP2   | 11  | 0.00148  | 1272602  | 0.261231 |
| Up   | CYSTM1    | 11  | 0.002293 | 1438306  | 0.2152   |
| Up   | MAP1LC3B2 | 10  | 0.001139 | 1052378  | 0.240608 |
| Up   | MYEOV     | 2   | 5.45E-05 | 24642    | 0.227079 |
| Up   | DNAH14    | 1   | 0        | 0        | 0.212349 |
| Up   | MYOM1     | 1   | 0        | 0        | 0.247539 |
| Down | HEPACAM2  | 496 | 0.004088 | 4614336  | 0.259565 |
| Down | HLA-DPA1  | 443 | 0.021345 | 6656236  | 0.294395 |
| Down | DCAF12    | 359 | 0.002195 | 1838728  | 0.28738  |
| Down | POLM      | 259 | 6.45E-05 | 60748    | 0.246809 |
| Down | TUBB1     | 231 | 0.017014 | 13445244 | 0.31686  |
| Down | KMT2D     | 211 | 0.004121 | 6143304  | 0.276119 |
| Down | TNFRSF13B | 208 | 0.004558 | 7473486  | 0.25441  |
| Down | SEC16A    | 199 | 0.024345 | 23456762 | 0.332778 |
| Down | AHNAK     | 158 | 0.012868 | 12992410 | 0.339572 |
| Down | OGT       | 151 | 0.02538  | 23785672 | 0.321486 |

|      |         |     |          |          |          |
|------|---------|-----|----------|----------|----------|
| Down | TRAK2   | 148 | 0.005447 | 1889278  | 0.291359 |
| Down | PER1    | 143 | 0.007889 | 3343992  | 0.297667 |
| Down | TXNIP   | 142 | 0.005831 | 3723272  | 0.3011   |
| Down | GPRASP1 | 140 | 0.011046 | 5269570  | 0.284316 |
| Down | CTSB    | 139 | 0.011516 | 5746824  | 0.316973 |
| Down | ITGA4   | 132 | 0.110358 | 99169576 | 0.373747 |
| Down | CBLB    | 131 | 0.011859 | 9651222  | 0.31117  |
| Down | LEF1    | 111 | 0.008924 | 3863000  | 0.305275 |
| Down | PLEC    | 110 | 0.025923 | 21209448 | 0.346999 |
| Down | BNIP3L  | 110 | 0.005843 | 2394548  | 0.292184 |
| Down | CAMK1D  | 109 | 0.007993 | 5854240  | 0.294255 |
| Down | NR4A1   | 99  | 0.024611 | 10885038 | 0.333639 |
| Down | OPA1    | 94  | 0.007387 | 5152054  | 0.317804 |
| Down | EEF2    | 83  | 0.037887 | 47075150 | 0.354698 |
| Down | SEMA7A  | 82  | 0.00308  | 4153990  | 0.271146 |
| Down | RPS6KA5 | 78  | 0.010004 | 5767566  | 0.321653 |
| Down | STK17B  | 78  | 0.00446  | 1356036  | 0.284918 |
| Down | P2RX5   | 75  | 0.003754 | 3579124  | 0.255008 |
| Down | SLC2A1  | 68  | 0.003791 | 2359116  | 0.318622 |
| Down | GYPB    | 66  | 0.007619 | 6671358  | 0.262863 |
| Down | HBB     | 65  | 0.01032  | 10858208 | 0.304059 |
| Down | CD22    | 64  | 0.001809 | 1124092  | 0.279752 |
| Down | CD4     | 64  | 0.018753 | 14195846 | 0.322845 |
| Down | CD44    | 63  | 0.031474 | 16859342 | 0.344469 |
| Down | TFRC    | 63  | 0.019104 | 17774714 | 0.337221 |
| Down | PTPRC   | 62  | 0.012352 | 6796924  | 0.316681 |
| Down | CD5     | 62  | 0.00189  | 1129318  | 0.283456 |
| Down | HLA-DRA | 61  | 0.009348 | 4428892  | 0.287995 |
| Down | HLA-DMB | 60  | 0.002503 | 1238774  | 0.277344 |
| Down | CELSR1  | 60  | 0.003079 | 1745004  | 0.272928 |
| Down | MS4A1   | 58  | 0.0017   | 1236694  | 0.276378 |
| Down | SPTA1   | 55  | 0.007158 | 4511084  | 0.30275  |
| Down | IL7R    | 54  | 0.027811 | 45141856 | 0.327043 |
| Down | GYPB    | 53  | 8.14E-04 | 390278   | 0.260045 |
| Down | SLC4A1  | 53  | 0.002142 | 1341058  | 0.273169 |
| Down | EPB42   | 52  | 0.002323 | 1787000  | 0.260879 |
| Down | RHAG    | 49  | 0        | 0        | 0.214566 |
| Down | CD79A   | 49  | 0.008789 | 4491848  | 0.293056 |
| Down | CD6     | 48  | 0        | 0        | 0.220862 |
| Down | CSF1R   | 48  | 0.002723 | 5503564  | 0.281868 |
| Down | IKZF3   | 48  | 0.021447 | 15624140 | 0.316487 |
| Down | POU2F2  | 46  | 0.002814 | 4242740  | 0.262773 |
| Down | IGF2R   | 45  | 0.005336 | 8354606  | 0.300049 |
| Down | NSUN3   | 45  | 0        | 0        | 0.226647 |
| Down | BLK     | 44  | 0.009001 | 4827382  | 0.309644 |
| Down | VCAN    | 44  | 0.00605  | 2854094  | 0.288546 |
| Down | ADAM28  | 41  | 0        | 0        | 0.272076 |
| Down | RPL27A  | 41  | 0.009338 | 13186584 | 0.337921 |
| Down | RPL23A  | 39  | 0.022449 | 25286012 | 0.35326  |
| Down | EEF1A1  | 37  | 0.098882 | 1.23E+08 | 0.370457 |
| Down | RPL13A  | 37  | 0.009659 | 13645424 | 0.339386 |
| Down | RPL10   | 35  | 0.066934 | 69760500 | 0.352275 |
| Down | NOTCH2  | 35  | 0.009449 | 4095454  | 0.307291 |
| Down | ATP2B1  | 35  | 0.00508  | 5650696  | 0.303835 |
| Down | SLC38A1 | 35  | 0.008346 | 5880382  | 0.292709 |
| Down | QSOX2   | 35  | 0.00527  | 3561792  | 0.291167 |
| Down | SORL1   | 34  | 0.01017  | 6644994  | 0.299569 |
| Down | LRP1    | 34  | 0.030447 | 29146796 | 0.321269 |
| Down | SRRM2   | 34  | 0.044661 | 52105132 | 0.347662 |
| Down | ABCC13  | 34  | 0        | 0        | 0.250182 |
| Down | ATM     | 33  | 0.040568 | 31808618 | 0.330997 |
| Down | FECH    | 33  | 0.007383 | 3340210  | 0.299511 |
| Down | CD27    | 32  | 0.004882 | 2960412  | 0.278142 |
| Down | VIPR1   | 32  | 0.004948 | 5472644  | 0.278694 |
| Down | AGPAT4  | 32  | 1.70E-05 | 28760    | 0.230987 |
| Down | CIITA   | 32  | 0.003427 | 3117716  | 0.289328 |
| Down | EP400   | 31  | 0.007237 | 9601258  | 0.288196 |
| Down | RORA    | 31  | 0.004548 | 1396286  | 0.302558 |
| Down | SOX6    | 31  | 0.001788 | 1768940  | 0.255661 |
| Down | CENPF   | 30  | 0.008068 | 6644598  | 0.297681 |

|      |          |    |          |          |          |
|------|----------|----|----------|----------|----------|
| Down | FAM167A  | 29 | 0.008587 | 3540932  | 0.276168 |
| Down | MXI1     | 28 | 0.001985 | 3293278  | 0.269504 |
| Down | ALDH5A1  | 27 | 0.003494 | 4468018  | 0.270813 |
| Down | RPL37    | 27 | 0.001913 | 3460916  | 0.29617  |
| Down | TSPAN5   | 26 | 0.01221  | 9998796  | 0.2873   |
| Down | PIEZO1   | 26 | 0        | 0        | 0.223188 |
| Down | BTG1     | 25 | 0.002334 | 3106952  | 0.271777 |
| Down | SPIB     | 25 | 0.001073 | 679476   | 0.280679 |
| Down | ALDH6A1  | 25 | 0.00345  | 3839804  | 0.246053 |
| Down | COL7A1   | 25 | 0.003621 | 3830672  | 0.277705 |
| Down | PAX5     | 25 | 0.008408 | 15230588 | 0.288317 |
| Down | DUSP2    | 24 | 0.003694 | 4774362  | 0.262573 |
| Down | IFFO1    | 24 | 0.004108 | 2648480  | 0.262006 |
| Down | COBLL1   | 24 | 0.00318  | 3800612  | 0.267373 |
| Down | DBP      | 24 | 0.00207  | 2593884  | 0.258708 |
| Down | SELENBP1 | 24 | 0.011965 | 15173332 | 0.275259 |
| Down | DYRK2    | 23 | 0.00992  | 5736550  | 0.313918 |
| Down | PDE3B    | 23 | 0.005858 | 5188848  | 0.268242 |
| Down | ABCA2    | 22 | 0.002246 | 1887488  | 0.270647 |
| Down | TTN      | 22 | 0.022803 | 22179002 | 0.328956 |
| Down | AAK1     | 22 | 0.001768 | 1776702  | 0.306636 |
| Down | CAMK4    | 21 | 0.001804 | 1122842  | 0.282382 |
| Down | ANKRD52  | 21 | 0.004706 | 3610412  | 0.290251 |
| Down | OBSCN    | 21 | 0.002307 | 1424536  | 0.295125 |
| Down | YOD1     | 21 | 0.003727 | 4452540  | 0.278581 |
| Down | RNF213   | 21 | 0.003281 | 4225796  | 0.28073  |
| Down | HBM      | 21 | 0.003971 | 2893622  | 0.211891 |
| Down | FAM117B  | 20 | 0.002939 | 3060242  | 0.274465 |
| Down | RANBP10  | 20 | 0.010162 | 16110914 | 0.263344 |
| Down | RALGPS2  | 20 | 0.008034 | 10752578 | 0.280386 |
| Down | CNKSR2   | 19 | 0.003716 | 4283878  | 0.253753 |
| Down | MYO15B   | 19 | 0.001548 | 1850770  | 0.253763 |
| Down | BMF      | 18 | 0.002348 | 3575424  | 0.266842 |
| Down | WDFY2    | 18 | 0.004928 | 3808614  | 0.241237 |
| Down | LENG8    | 18 | 0.006353 | 9944066  | 0.270896 |
| Down | TUBGCP6  | 18 | 0.00405  | 3821222  | 0.278155 |
| Down | NELL2    | 17 | 0.005907 | 5985122  | 0.250435 |
| Down | YIPF4    | 17 | 0.002754 | 3249620  | 0.263928 |
| Down | OSBPL10  | 17 | 0.002471 | 663904   | 0.287727 |
| Down | BACH2    | 16 | 0.002632 | 2910574  | 0.257534 |
| Down | NLRP1    | 16 | 0.003929 | 3755972  | 0.280691 |
| Down | BCL11B   | 2  | 0.001184 | 2467486  | 0.258362 |
| Down | STRADB   | 2  | 0.001267 | 1783952  | 0.276898 |
| Down | BCL11A   | 1  | 0.004017 | 6158386  | 0.273664 |
| Down | RCAN3    | 1  | 0        | 0        | 0.233006 |
| Down | KLHL3    | 1  | 0.003155 | 2811806  | 0.280551 |
| Down | CLEC2D   | 1  | 0.015351 | 13153684 | 0.270766 |
| Down | TNRC6B   | 1  | 0.010638 | 19725384 | 0.302365 |
| Down | FBXO7    | 1  | 0.011435 | 14645282 | 0.298528 |
| Down | MOB3B    | 1  | 0        | 0        | 0.202401 |
| Down | ZNF549   | 1  | 0        | 0        | 0.230523 |
| Down | VSTM2A   | 1  | 0        | 0        | 0.220343 |
| Down | CTC1     | 1  | 0        | 0        | 0.200285 |
| Down | MRC2     | 1  | 0.002911 | 3908206  | 0.26787  |
| Down | TTC14    | 1  | 0        | 0        | 0.257985 |
| Down | ADA2     | 1  | 0        | 0        | 0.257985 |

**Table 6** miRNA - target gene and TF - target gene interaction

| Regulation | Target Genes | Degree | MicroRNA        | Regulation | Target Genes | Degree | TF     |
|------------|--------------|--------|-----------------|------------|--------------|--------|--------|
| Up         | COL1A1       | 178    | hsa-mir-4492    | Up         | IRF4         | 10     | NFATC2 |
| Up         | IRF4         | 140    | hsa-mir-4319    | Up         | LCK          | 10     | YY1    |
| Up         | MYBL2        | 83     | hsa-mir-637     | Up         | RET          | 10     | NR2C2  |
| Up         | PRKCB        | 81     | hsa-mir-1261    | Up         | MAP1LC3C     | 10     | MAX    |
| Up         | IL2RB        | 54     | hsa-mir-4300    | Up         | IL2RB        | 8      | PDX1   |
| Up         | CCR5         | 50     | hsa-mir-5193    | Up         | GRAP2        | 8      | ELK1   |
| Up         | GRAP2        | 41     | hsa-mir-3681-5p | Up         | MYBPC2       | 7      | RELA   |


|      |          |     |                   |      |        |    |        |
|------|----------|-----|-------------------|------|--------|----|--------|
| Up   | MDFI     | 41  | hsa-mir-4441      | Up   | MDFI   | 6  | TFAP2A |
| Up   | RET      | 17  | hsa-mir-129-2-3p  | Up   | MYBL2  | 6  | GATA2  |
| Up   | IKZF1    | 16  | hsa-mir-3607-3p   | Up   | CD247  | 5  | SREBF1 |
| Up   | BTK      | 13  | hsa-mir-4667-3p   | Up   | COL1A1 | 5  | NFYA   |
| Up   | LCK      | 6   | hsa-mir-210-3p    | Up   | PRKCB  | 4  | IRF2   |
| Up   | MYBPC2   | 6   | hsa-mir-214-3p    | Up   | IKZF1  | 4  | E2F6   |
| Up   | CD247    | 4   | hsa-mir-346       | Up   | BTK    | 2  | SOX5   |
| Up   | MAP1LC3C | 2   | hsa-mir-27a-3p    | Up   | CCR5   | 1  | EGR1   |
| Down | JUN      | 144 | hsa-mir-3943      | Down | ATF3   | 19 | TP53   |
| Down | EGR1     | 132 | hsa-mir-548e-3p   | Down | EGR1   | 16 | ARID3A |
| Down | ZFP36    | 130 | hsa-mir-6077      | Down | JUNB   | 15 | SRF    |
| Down | FOS      | 105 | hsa-mir-5586-5p   | Down | FOS    | 13 | CREB1  |
| Down | DUSP1    | 97  | hsa-mir-4458      | Down | PTPRO  | 12 | NR3C1  |
| Down | JUNB     | 85  | hsa-mir-3065-5p   | Down | NR0B2  | 11 | USF1   |
| Down | MME      | 54  | hsa-mir-922       | Down | MME    | 9  | BRCA1  |
| Down | NR4A2    | 50  | hsa-mir-29b-2-5p  | Down | JUN    | 9  | SP1    |
| Down | ATF3     | 48  | hsa-mir-5000-5p   | Down | DUSP1  | 9  | STAT3  |
| Down | NR4A1    | 43  | hsa-mir-107       | Down | NR4A1  | 9  | HINFP  |
| Down | PCK1     | 38  | hsa-mir-1185-1-3p | Down | NR4A2  | 7  | NR2E3  |
| Down | PTPRO    | 18  | hsa-mir-203a-3p   | Down | PCK1   | 6  | NR2F1  |
| Down | APOB     | 17  | hsa-mir-548p      | Down | ZFP36  | 5  | TFAP2C |
| Down | ALB      | 10  | hsa-mir-492       | Down | APOB   | 4  | FOXA1  |
| Down | NR0B2    | 5   | hsa-mir-141-3p    | Down | ALB    | 4  | STAT1  |

**Table 7.** Docking results of designed molecules on CCNB1 and FHL2


| Sl. No/<br>Code | CCNB1       |             |        |             |             |        | FHL2        |             |        |             |             |        |
|-----------------|-------------|-------------|--------|-------------|-------------|--------|-------------|-------------|--------|-------------|-------------|--------|
|                 | PDB: 1H0V   |             |        | PDB: 4Y72   |             |        | PDB: 2D8Z   |             |        | PDB: 2EHE   |             |        |
|                 | Total Score | Crash (-Ve) | Polar  | Total Score | Crash (-Ve) | Polar  | Total Score | Crash (-Ve) | Polar  | Total Score | Crash (-Ve) | Polar  |
| IM 1            | 7.239       | 0.5252      | 4.194  | 6.229       | 1.1758      | 1.3468 | 5.1488      | 1.0826      | 2.402  | 3.9597      | 1.1337      | 1.1388 |
| IM 2            | 3.9559      | 3.76        | 1.2296 | 7.7753      | 1.5013      | 3.1751 | 6.8491      | 0.7865      | 3.1253 | 5.3884      | 0.7304      | 3.2443 |
| IM 3            | 7.1917      | 1.469       | 4.9203 | 7.3727      | 2.1681      | 1.9271 | 5.4126      | 0.9455      | 1.6539 | 4.5339      | 0.7044      | 0.9497 |
| IM 4            | 4.1974      | 3.568       | 4.3031 | 6.8188      | 2.006       | 2.4134 | 5.6181      | 0.9326      | 1.7125 | 3.5135      | 0.7458      | 1.0505 |
| IM 5            | 4.5533      | 1.6492      | 2.0927 | 8.4227      | 0.344       | 2.1941 | 6.0708      | 0.8126      | 1.7745 | 5.5747      | 0.8468      | 3.3308 |
| IM 6            | 6.3787      | 1.9626      | 3.3289 | 9.0333      | 1.8462      | 3.2587 | 6.6937      | 0.6986      | 1.7217 | 5.1739      | 0.7641      | 3.8671 |
| IM 7            | 6.1374      | 4.1751      | 3.5386 | 9.6167      | 1.1087      | 3.9025 | 5.225       | 1.4565      | 2.041  | 4.6648      | 1.4029      | 3.3006 |
| IM 8            | 8.5712      | 2.8957      | 5.1053 | 7.0482      | 1.1147      | 1.7475 | 5.8786      | 2.3548      | 4.3253 | 6.2485      | 0.9775      | 7.501  |
| IM 9            | 7.2601      | 1.6697      | 4.5599 | 11.1159     | 3.4644      | 4.6657 | 7.1497      | 0.8496      | 2.7825 | 4.8018      | 1.1365      | 3.8469 |
| IM 10           | 7.1162      | 1.8814      | 4.5343 | 8.442       | 3.5097      | 1.9408 | 7.7546      | 3.7166      | 5.382  | 4.9785      | 0.8538      | 3.1734 |
| IM 11           | 7.8374      | 2.1808      | 5.6745 | 9.5941      | 0.7735      | 2.1344 | 5.2956      | 1.1168      | 2.1061 | 3.9556      | 1.1707      | 0.6484 |
| IM 12           | 4.4123      | 3.1644      | 0.1694 | 5.6246      | 1.2211      | 5.4648 | 5.6561      | 0.5109      | 1.6096 | 3.7807      | 1.5365      | 2.3817 |
| IM 13           | 4.8829      | 1.641       | 0.8781 | 8.0134      | 1.4762      | 1.0656 | 5.2993      | 1.3644      | 0.5235 | 3.7134      | 1.1631      | 2.6632 |
| IM 14           | 6.0738      | 2.1599      | 1.0809 | 7.2224      | 2.4795      | 2.1333 | 6.0942      | 1.3044      | 0.9106 | 3.6364      | 0.7145      | 0      |
| IM 15           | 4.1335      | 1.6663      | 0.6394 | 7.8573      | 1.0353      | 1.397  | 5.1601      | 2.6366      | 2.7824 | 4.9877      | 0.7211      | 1.2175 |
| IM 16           | 4.7049      | 2.8785      | 0.8354 | 4.754       | 1.9003      | 2.3893 | 5.8987      | 3.4229      | 2.683  | 3.811       | 0.9693      | 2.5824 |
| TZ17            | 4.7263      | 2.4231      | 1.618  | 7.2734      | 1.358       | 0.053  | 5.1753      | 1.1334      | 2.2964 | 2.938       | 1.0363      | 0.9651 |
| TZ 18           | 2.802       | 3.145       | 0.7759 | 6.8537      | 3.0008      | 1.6321 | 7.8024      | 2.4086      | 2.4203 | 4.6169      | 1.5742      | 3.205  |
| TZ 19           | 5.2455      | 4.8167      | 3.4624 | 5.6781      | 2.5738      | 1.298  | 5.1226      | 2.2316      | 1.0413 | 3.4199      | 1.0615      | 2.0714 |
| TZ 20           | 4.2031      | 2.0537      | 1.495  | 6.1116      | 2.1732      | 3.8228 | 6.2266      | 0.6144      | 1.7861 | 2.938       | 1.0363      | 0.9651 |
| TZ 21           | 3.0014      | 4.7503      | 2.5662 | 6.8135      | 1.9569      | 0.1433 | 6.5063      | 2.1789      | 3.6709 | 5.7655      | 1.6648      | 2.5621 |
| TZ 22           | 3.7751      | 3.6506      | 1.0649 | 3.7896      | 0.9741      | 1.2645 | 6.1962      | 3.8971      | 2.3063 | 4.0152      | 1.5781      | 2.7668 |
| TZ 23           | 5.1601      | 2.6366      | 2.7824 | 8.5232      | 1.5576      | 1.447  | 5.1729      | 0.7908      | 0.0547 | 2.6522      | 1.3858      | 1.0325 |
| TZ 24           | 2.9866      | 4.5065      | 3.6118 | 3.7807      | 1.5325      | 1.1317 | 6.9491      | 1.9739      | 4.849  | 5.6246      | 1.2211      | 5.4648 |
| TZ 25           | 4.8039      | 2.7509      | 4.8277 | 7.5881      | 1.5654      | 2.7715 | 6.8022      | 1.7602      | 1.3582 | 4.6179      | 0.8504      | 3.0354 |
| TZ 26           | 4.6867      | 5.5789      | 4.0836 | 4.082       | 0.8257      | 1.2626 | 5.6376      | 1.0268      | 0.6945 | 6.1116      | 2.1732      | 3.8228 |
| TZ 27           | 5.0617      | 0.919       | 3.0108 | 8.2356      | 5.0255      | 2.733  | 6.9041      | 1.2875      | 1.3144 | 4.0538      | 2.6973      | 2.4686 |
| TZ 28           | 4.754       | 1.9003      | 2.3893 | 3.7807      | 1.5365      | 2.3817 | 6.2017      | 0.8992      | 2.0979 | 2.8957      | 2.2563      | 1.1849 |
| TZ 29           | 3.8498      | 3.1807      | 2.6601 | 8.0953      | 2.9258      | 0.0118 | 5.0893      | 1.1718      | 1.9465 | 4.0316      | 1.4654      | 2.5085 |
| TZ 30           | 2.1031      | 2.8504      | 0.4643 | 3.7644      | 2.6181      | 0.8861 | 4.971       | 3.1573      | 1.1485 | 2.8812      | 1.0498      | 0.0078 |
| TZ 31           | 3.5097      | 3.5835      | 1.0165 | 6.7706      | 0.5308      | 0.0066 | 4.9571      | 1.2321      | 1.1728 | 2.7919      | 2.5153      | 1.8636 |
| TZ 32           | 2.9901      | 3.3732      | 1.7976 | 2.041       | 4.6648      | 1.4029 | 6.2178      | 0.9615      | 1.6287 | 3.6108      | 1.261       | 2.2254 |

|       |        |        |        |         |        |        |        |        |        |        |        |        |
|-------|--------|--------|--------|---------|--------|--------|--------|--------|--------|--------|--------|--------|
| PU33  | 5.0124 | 2.6209 | 1.6596 | 8.3705  | 2.4455 | 1.8383 | 5.1058 | 2.8533 | 2.1314 | 4.082  | 0.8257 | 1.2626 |
| PU 34 | 1.8876 | 3.1575 | 1.8876 | 2.9186  | 1.7769 | 0.7803 | 6.2293 | 0.79   | 4.1623 | 5.7541 | 0.8169 | 2.2649 |
| PU 35 | 4.2415 | 0.9639 | 1.4337 | 8.5453  | 0.7988 | 0.3678 | 5.993  | 1.1302 | 1.6123 | 3.7896 | 0.9741 | 1.2645 |
| PU 36 | 3.7644 | 2.6181 | 0.8861 | 3.4946  | 1.6854 | 2.8474 | 5.5186 | 0.8034 | 1.7233 | 4.2415 | 0.9639 | 1.4337 |
| PU 37 | 2.2051 | 3.0552 | 1.6443 | 8.8008  | 1.667  | 3.5679 | 6.3895 | 1.7399 | 2.0389 | 5.0617 | 0.919  | 3.0108 |
| PU 38 | 5.2735 | 4.1465 | 2.4599 | 4.754   | 1.9003 | 2.3893 | 4.2415 | 0.9639 | 1.4337 | 3.4946 | 1.6854 | 2.8474 |
| PU 39 | 5.0617 | 0.919  | 3.0108 | 7.8157  | 1.3292 | 0.2824 | 5.0617 | 0.919  | 3.0108 | 4.2155 | 0.823  | 3.9682 |
| PU 40 | 4.8638 | 5.448  | 1.8878 | 4.2415  | 0.9639 | 1.4337 | 3.2316 | 1.6854 | 2.8474 | 4.7646 | 1.6643 | 4.7161 |
| PU 41 | 7.1661 | 3.1588 | 5.0991 | 10.3389 | 4.9022 | 4.0552 | 3.2121 | 0.823  | 3.9682 | 5.2192 | 1.3596 | 1.3065 |
| PU 42 | 5.278  | 1.1462 | 3.3261 | 4.754   | 1.9003 | 2.3893 | 5.4326 | 1.6643 | 4.7161 | 4.9542 | 3.6876 | 3.8272 |
| PU 43 | 5.2192 | 1.3596 | 1.3065 | 10.8916 | 2.8239 | 2.464  | 4.0152 | 1.5781 | 2.7668 | 3.9964 | 1.1219 | 0.8063 |
| PU 44 | 4.8815 | 3.9606 | 2.9386 | 6.5063  | 2.1789 | 3.6709 | 3.9964 | 1.1219 | 0.8063 | 4.3649 | 0.7553 | 3.4696 |
| PU 45 | 3.4541 | 3.3428 | 1.9008 | 8.3081  | 0.3422 | 2.9369 | 3.9597 | 1.1337 | 1.1388 | 4.2415 | 0.9639 | 1.4337 |
| PU 46 | 3.5097 | 3.5835 | 1.0165 | 6.0942  | 1.3044 | 0.9106 | 3.9556 | 1.1707 | 0.6484 | 5.0617 | 0.919  | 3.0108 |
| PU 47 | 3.7807 | 1.5365 | 2.3817 | 7.5477  | 2.2832 | 2.7503 | 4.0152 | 1.5781 | 2.7668 | 3.4946 | 1.6854 | 2.8474 |
| PU 48 | 3.6402 | 3.5929 | 1.2563 | 4.2415  | 0.9639 | 1.4337 | 3.9964 | 1.1219 | 0.8063 | 4.2155 | 0.823  | 3.9682 |


## Figures



**Fig. 1.** Volcano plot of differentially expressed genes. Genes with a significant change of more than two-fold were selected. Green dot represented up regulated significant genes and red dot represented down regulated significant genes.




**Fig. 2.** Heat map of differentially expressed genes. Legend on the top left indicate log fold change of genes. (A1 – A114 = normal control samples; B1 – B284 = PDAC samples)




**Fig. 3.** PPI network and the most significant modules of DEGs. (A) The PPI network of DEGs was constructed using Cytoscape (B) The most significant module was obtained from PPI network with 16 nodes and 44 edges for

up regulated genes (C) The most significant module was obtained from PPI network with 6 nodes and 20 edges for up regulated genes. Up regulated genes are marked in green; down regulated genes are marked in red




**Fig. 4.** (A) Target gene - miRNA regulatory network between target genes and miRNAs (B) Target gene - TF regulatory network between target genes and TFs. Up regulated genes are marked in green; down regulated genes are marked in red; The blue color diamond nodes represent the key miRNAs; the gray color triangle nodes represent the key TFs




**Fig. 5.** Overall survival analysis of hub genes. Overall survival analyses were performed using the UALCAN online platform. Red line denotes - high expression; Blue line denotes - low expression. A) CCNB1 B) FHL2 C) HLA-DPA1 D) TUBB1







**Fig. 6.** Box plots (expression analysis) hub genes were produced using the UALCAN platform. A) CCNB1 B) FHL2 C) HLA-DPA1 D) TUBB1




**Fig. 7.** Box plots (clinical stage analysis) hub genes were produced using the UALCAN platform. A) CCNB1 B) FHL2 C) HLA-DPA1 D) TUBB1




**Fig. 8.** Mutation analyses of hub genes were produced using the CbioPortal online platform. A) CCNB1 B) FHL2 C) HLA-DPA1 D) TUBB1




**Fig. 9.** Immunohisto chemical (IHC) analyses of hub genes were produced using the human protein atlas (HPA) online platform. A) CCNB1 B) FHL2 C) HLA-DPA1 D) TUBB1




**Fig. 10.** Scatter plot for immune infiltration for hub genes. A) CCNB1 B) FHL2 C) HLA-DPA1 D) TUBB1




**Fig. 11.** ROC curve validated the sensitivity, specificity of hub genes as a predictive biomarker for PDAC prognosis. A) CCNB1 B) FHL2 C) HLA-DPA1 D) TUBB1




**Fig. 12.** Validation of hub genes by RT-PCR. A) CCNB1 B) FHL2 C) HLA-DPA1 D) TUBB1



**Fig. 13.** Structures of Designed Molecules



**Fig.14.** 3D Binding of Molecule IM 8 with 1H0V



**Fig. 15.** 2D Binding of Molecule IM 8 with 1H0V

